



EXPRESS MAIL CERTIFICATE

Date _____ Label No. _____

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 by "Express Mail Post Office to Addressee" service.

Name (Print)

Signature

**PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR
CREDIT ANY EXCESS IN THE FEES DUE WITH THIS
DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100**

Customer No.: 29311

Docket No.: 02427/100G772-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Erich HOFFMANN

Serial No.: 09/844,517

Group Art Unit: 1648

Confirmation No.: 9063

Examiner: Myron G. Hill

Filed: April 27, 2001

For: DNA TRANSFECTION SYSTEM FOR THE GENERATION OF
INFECTIOUS INFLUENZA VIRUS**DECLARATION OF ROBERT G. WEBSTER UNDER 37 CFR § 1.132**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

I, ROBERT G. WEBSTER, do hereby declare and state the following:

{W:\02427\100G772000\00279971.DOC *02427100G772000* }

BEST AVAILABLE COPY

1. I am a Director of the World Health Organization (WHO) Collaborating Center for Studies on the Ecology of Influenza in Animals and Birds, Member of the Division of Virology, Department of Infectious Diseases and Rose Marie Thomas Chair at St. Jude Children's Research Hospital, Professor at the Department of Microbiology and Immunology at the University of Tennessee Center for the Health Sciences, Memphis, and Visiting Distinguished Professor of Excellence at the Department of Microbiology at the University of Hong Kong, Hong Kong SAR.

2. I was awarded a Ph.D. degree in Microbiology in 1962 from the Australian National University, Canberra. Upon completion of my doctorate, I worked as a Research Fellow (Fullbright Scholar) at the Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor and then as a Fellow at the Department of Microbiology, John Curtin Medical School, Australian National University, Canberra. In 1968, I joined the Laboratories of Virology and Immunology at St. Jude Children's Research Hospital and Department of Microbiology at University of Tennessee, Memphis as an Assistant Professor. After obtaining a Member position in 1969, I have been continuously affiliated with St. Jude Children's Research Hospital, where I currently hold the title of Member and Rose Marie Thomas Chair at the Division of Virology, Department of Infectious Diseases.

3. During my entire career I have been working in the field of virology, with a specific focus on influenza virus biology and production of recombinant vaccines. My contributions to the field of influenza virology have been acknowledged by numerous international awards and honorary titles, which include, among others, a title of the Director of the WHO Collaborating Center, as noted above, Member of the National Academy of Sciences

of the United States, Fellow of the Royal Society of London, Fellow of the Royal Society of New Zealand, and holder of the 12th Annual Bristol-Myers Squibb Award for Distinguished Achievement in Infectious Diseases 2002. A copy of my Curriculum Vitae is annexed as Exhibit 1.

4. My contributions to the field of influenza virology are disclosed in numerous patents and scientific and popular publications, which include, among others, U.S. Patents No. 6,344,354; 5,916,879; 5,824,536; 5,643,578; 4,552,758; 4,552,757 and published U.S. Application No. 2004/0142450. I have also authored a number of widely used textbooks on virology and, in particular, influenza virology, which include, among others, *Textbook of Influenza*, Karl G. Nicholson, Robert G. Webster, Alan J. Hay, Blackwell Publishers, 1998; *Encyclopedia of Virology*, Robert G. Webster, Allan Granoff, Academic Press, 1999, 1996 and 1994; *Origin and Evolution of Viruses*, Esteban Domingo, Robert G. Webster, John J. Holland, Academic Press, 1999.

5. My contributions to the area of influenza vaccine production include, among others, development of a mild detergent treatment of whole virus vaccines. This treatment reduces vaccine toxicity and this type of approach is currently used to produce all influenza vaccines used throughout the world.

6. Many leading world experts in the field of influenza virology have spent time in my laboratory at St. Jude Children's Research Hospital training as graduate students or postdoctoral fellows or obtaining various types of expertise as visiting scientists. The list of such

experts includes, among others, Dr. Yoshihiro Kawaoka¹ (who was a postdoctoral fellow in my laboratory 08/83-06/85 and then an Assistant and Associate Member 07/85-06/97), Dr. Gabriele Neumann² (who was a postdoctoral fellow in my laboratory 08/95-06/97), and Dr. Erich Hoffmann³ (who was a postdoctoral fellow in my laboratory 03/98-08/01).

7. I make this Declaration in support of the application identified above ("the '517 application"). I am not an inventor of the '517 application and I do not have any financial interest in this application. However, I have a firsthand knowledge of the work that lead to the present invention as this work was conducted in my laboratory at St. Jude Children's Research Hospital.

8. I have reviewed the entire disclosure of the '517 application, including the original claims and the drawings, as well as the prosecution history and claims, as amended in the accompanying amendment. I have also specifically reviewed the Final Office Action dated May 5, 2004, which was issued in connection with this application.

9. I understand that in the Final Office Action dated May 5, 2004, the United States Patent and Trademark Office has rejected claims 15-17, 19-30, 32, 39, and 44 of the '517 application under 35 U.S.C. § 103(a) on the grounds that the claims are allegedly obvious over Hoffmann dissertation (1997) and Neumann *et al.* (Proc. Natl. Acad. Sci., 1999, 96: 9345-50) and has rejected claim 45 as being allegedly obvious over Hoffmann and Neumann *et al.* and further in view of Pleshka *et al.* (J. Virol., 1996, 70: 4188-92).

¹ The senior author of the Neumann *et al.* article cited by the Examiner.

² The lead author of the Neumann *et al.* article cited by the Examiner.

³ The sole inventor of the above-identified patent application (the '517 application).

10. In the Office Action, the Examiner has stated that, knowing that Neumann *et al.* (i) generated infectious influenza virus using a plasmid-based system, and (ii) disclosed the benefit of adding more protein expressing plasmids to the transfection, and also knowing that multi-plasmid transfections are complex, one of ordinary skill in the art at the time of the invention would be motivated to come up with the present invention by using the plasmid described in the Hoffmann dissertation to reduce the number of plasmids for transfection and to save time in cloning. The Examiner seems to believe that there was an expectation of success, because the promoter elements used by Hoffmann are the same as used by Neumann *et al.*

11. Based on the materials I reviewed, my extensive experience in the field, and my firsthand knowledge of the work that lead to Neumann *et al.* publication and to the present invention⁴, it is my opinion that the Hoffmann dissertation and Neumann *et al.* article do not suggest or provide any leads for the creation of the dual pol I-pol II promoter plasmid system for the generation of infectious influenza viruses from cloned viral segments as disclosed in the '517 application and recited in the present claims. Much less do these cited references provide any expectation that the generation of an infectious influenza virus could be successfully accomplished using the 8-plasmid pol I-pol II system of the present invention. The detailed explanation is provided below.

12. First, I would like to describe the historical context in which the present invention came into existence. The antigenic variation of influenza A virus hemagglutinin (HA) and

⁴ As specified in Section 6, above, both Dr. Gabriele Neumann (the lead author of the Neumann *et al.* article cited by the Examiner) and Dr. Erich Hoffmann (the sole inventor of the '517 application) were postdoctoral fellows in my laboratory. Dr. Neumann was a postdoctoral fellow in my laboratory from August 1995 to June 1997, and Dr. Hoffmann was a postdoctoral fellow in my laboratory from March 1998 to August 2001.

neuraminidase (NA) surface glycoproteins requires very frequent changes in vaccine formulations. The classical method of creating influenza virus seed strains for vaccine production generates 6 + 2 reassortants that contain six genes from a high-yield laboratory-adapted avirulent virus, such as A/PR/8/34 (H1N1), and the HA and NA genes of the circulating strains. The resulting reassortant virus has the antigenic properties of the circulating strain and the safety and high-yield properties of the laboratory-adapted virus. Reassortants are currently generated by coinfecting the high-yield laboratory-adapted virus with the circulating virus. Coinfection with two influenza viruses containing 8 segments can theoretically result in the generation of $2^8 \cdot 2 = 254$ different progeny viruses. Clearly, this method is extremely time-consuming because of the selection process required to isolate the desired reassortant virus. Reverse genetics could significantly speed this process by generating a set of plasmids encoding the internal genes of a high-yield virus. Recent re-emergence of human infections caused by avian influenza viruses (*e.g.*, the avian H5N1 influenza virus, A/Hong Kong/213/03) which (i) have no antigenically similar avirulent viruses and (ii) kill embryonated chicken eggs (where the seed strains are normally propagated), have further increased the need for rapid and reproducible plasmid-based reverse genetic approaches to influenza vaccine development and production.

13. Neumann *et al.* (1999 publication cited by the Examiner) described a first reverse genetic system for influenza virus production (a very similar system was also developed by Fodor *et al.*, J. Virol., 1999, 73: 9679-82, attached as Exhibit 2). The system of Neumann *et al.* contains two types of plasmids: (i) pol I-only replication plasmids directing the synthesis of vRNAs from a pol I promoter and (ii) pol II-only protein expression plasmids encoding viral proteins (*i.e.*, at least plasmids encoding viral polymerase proteins PB1, PB2, PA, and NP). Accordingly, this reverse genetic system uses the total number of plasmids which exceeds the

{W:\02427\100G772000\00279971.DOC *02427100G772000* }

total number of gene segments from the source virus (*i.e.*, at least 12 plasmids for an 8-segmented influenza A virus). The separation of pol I and pol II promoters on different plasmids lies at the very core of the Neumann *et al.* system, as this system tries to recapitulate the life cycle of an influenza virus by allowing regulation of viral protein expression separately from viral genome segment replication. In fact, in its most efficient (high yield) versions, the system of Neumann *et al.* uses extra protein expression (pol II) plasmids encoding HA, NA, M1, M2, and NS2 viral proteins (making the total number of transfected plasmids 17 instead of 12; see, p. 9347 [~~¶~~ bridging left and right col.] and Table 1 at p. 9348 of the Neumann *et al.* article). The optimal use of Neumann *et al.* system also relies on the ability to provide specified amounts of each viral protein by transfecting different amounts of each of the protein expression (pol II) plasmids (see, *e.g.*, p. 9347 left col., ¶¶ 3-4 of the Neumann *et al.* article).

14. The 8-plasmid dual pol I-pol II promoter system of the present invention is an alternative plasmid-based system for generation of an infectious influenza virus entirely from cloned DNA. This system represents not a minor variant of the Neumann *et al.* system as suggested by the Examiner, but a different approach altogether, based on a totally different principle of coordination of viral replication and protein expression. As specified above, in the Neumann *et al.* system, viral segment replication and protein expression are regulated separately due to the use of pol I-only plasmids directing the synthesis of vRNAs from a pol I promoter and pol II-only plasmids directing the synthesis of mRNAs encoding viral proteins from a pol II promoter. In contrast, in the dual pol I-pol II promoter system of the present invention, the vRNA (or cRNA) and mRNA synthesis occur from the same plasmid. As specified above, the ability to separately regulate the amount of viral proteins produced was believed to lie at the very core of the success of the Neumann *et al.* system. Accordingly, when Dr. Hoffmann came up

{W:\02427\100G772000\00279971.DOC *02427100G772000* }

with the idea of the dual pol I-pol II promoter system, everyone in the laboratory, including myself, was very skeptical that such a system could produce an infectious virus.

15. At the time, we were fully aware of Dr. Hoffmann's prior Ph.D. thesis work on dual pol I-pol II promoter plasmids (the 1997 Hoffmann dissertation cited by the Examiner). However, this work gave no indication whatsoever that an infectious influenza virus could be produced in the absence of any helper virus using eight pol I-pol II plasmids, each encoding one viral segment. The Hoffmann dissertation merely describes single pol I-pol II plasmids carrying reporter genes such as CAT and GFP, which are capable of directing transcription of a single reporter mRNA and expression of a reporter protein using host cell transcription/translation machinery, and replication of a single reporter RNA in the presence of viral polymerase proteins supplied by a helper virus (*e.g.*, FPV). The Hoffmann dissertation does not even provide a suggestion of making a single pol I-pol II plasmid encoding a single viral gene segment, much less a full set of such plasmids to achieve generation of an infectious viral particle in the absence of any helper virus. Accordingly, Dr. Hoffmann's dissertation provided no support for his novel idea of the 8-plasmid dual pol I-pol II promoter system.

16. Although I was skeptical that the 8-plasmid dual pol I-pol II promoter system suggested by Dr. Hoffmann would ever generate an infectious virus, I admired his enthusiasm and believed in his skills as an excellent molecular biologist. I therefore supported his work. To everyone's great surprise and excitement, he succeeded in generating an infectious virus (as disclosed in the '517 application). In fact, the dual pol I-pol II promoter system of the present invention has rapidly become the reverse genetic system of choice in the field of influenza vaccine production. This system turned out to be not only much simpler and more reproducible

than the system of Neumann *et al.*, because it significantly decreased the number of plasmids for transfection and eliminated the need to adjust the relative amount of each plasmid, but efficient as well. Also, in contrast to the Neumann *et al.* system, which for a long time was capable of efficiently producing infectious virus only in 293T cells, the dual pol I-pol II promoter system of the present invention efficiently generated infectious viral particles in monkey Vero cells. This is not a trivial difference. 293T cells are transformed cells that are not approved by WHO for vaccine seed production. Vero cells are approved for vaccine seed production. Thus, at the time Dr. Hoffmann did the work leading to the present invention, the Neumann *et al.* system would have been regarded as not yet practical. Nothing in Hoffmann's thesis indicates this particular characteristic of the dual pol I-pol II promoter system.

17. More and more investigators around the world are using the dual pol I-pol II promoter reverse genetic system of the present invention and prefer it to the system of Neumann *et al.* (see, e.g., a report from the National Influenza Center of Netherlands by de Wit *et al.*, *Virus Res.*, 2004, 103: 155-161; attached as Exhibit 3).

18. We and others have demonstrated the unmatched usefulness of the 8-plasmid dual pol I-pol II promoter system of the present invention for the fast and easy generation of influenza vaccines. For example, in Hoffmann *et al.*, *Vaccine*, 2002, 20: 3165-3170 (attached as Exhibit 4), Dr. Hoffmann and I, with other researchers at St. Jude Children's Research Hospital, have demonstrated the direct application of the 8-plasmid dual pol I-pol II promoter system to rapid and reproducible generation of reassortant influenza A viruses having the antigenic determinants of the influenza virus strains A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), A/teal/HK/W312 (H6N1), and A/quail/HK/G1/97 (H9N2), and a growth phenotype in

{W:\02427\100G772000\00279971.DOC *02427100G772000* }

embryonated chicken eggs which was equivalent to that of the wild-type virus. Even more importantly, the use of the 8-plasmid dual pol I-pol II promoter system of the present invention allowed our team at St. Jude to produce a vaccine to the deadly avian H5N1 influenza virus A/Hong Kong/213/03 (which caused human infections and lead to a WHO pandemic alert on February 19, 2003). The vaccine was produced in Good Manufacturing Practice (GMP)-grade facilities *in less than 4 weeks* from the time of virus isolation (see Webby *et al.*, Lancet, 2004, 363: 1099-103; attached as Exhibit 5). The use of the 8-plasmid dual pol I-pol II promoter system allowed us to remove the polybasic amino acids from the HA cleavage site, which are associated with high virulence of the H5N1 virus, and produce a reference vaccine virus on an A/Puerto Rico/8/34 (PR8) backbone in WHO-approved Vero cells. Specifically, using a PCR-based mutagenesis approach, we replaced the cleavage site encoded by the HA gene of H5N1 virus with that of the avirulent A/teal/Hong Kong/W312/97 (H6N1) strain. This modified HA gene and the NA gene of H5N1 were cloned individually into pol I-pol II dual promoter vectors. The two resulting plasmids and the six plasmids encoding the remaining proteins of PR8 were transfected into Vero cells under GMP conditions to rescue the vaccine seed virus. 36–48 hours after transfection, isolated areas of cytopathic effect could be seen on the Vero monolayers. The candidate vaccine strain grew to high titers on subsequent amplification in eggs and did not cause embryo death. The rescued virus was fully sequenced and was identical to the plasmids used in its creation. This virus proved to be non-pathogenic in chickens and ferrets and was shown to be stable after multiple passages in embryonated chicken eggs. The ability to produce a candidate reference virus in such a short period of time has set a new standard for rapid response to emerging infectious disease threats and has clearly demonstrated the superior usefulness of the 8-plasmid dual pol I-pol II promoter reverse genetic system for influenza

{W:\02427\100G772000\00279971.DOC *02427100G772000* }

vaccine development. The same technologies and procedures are currently being used to create reference vaccine viruses against the 2004 H5N1 viruses circulating in Asia. In sum, the approach set out in the '517 application addresses a raging need for rapid influenza vaccine response, particularly with the expectation of a worldwide pandemic on the order of the 1918 flu pandemic in the near term.

19. In light of the above, it is my opinion that the present invention represents a significant breakthrough both in the field of basic virology of negative stranded RNA viruses and in the field of influenza vaccine production. I strongly disagree with the Examiner's conclusion that the present invention is obvious over the Hoffmann dissertation and Neumann *et al.* article. Perhaps viewed from the vantage of Dr. Hoffmann's success it seems obvious to introduce the viral gene segments into pol I-pol II dual promoter plasmids. However, none of us - including myself, one of the leading experts in influenza in the world, thought so at the time. As noted above, having a full knowledge of the Hoffmann dissertation and Neumann *et al.* article, I along with other colleagues familiar with Dr. Hoffmann's idea were highly skeptical that his invention would ever work and produce an infectious virus. Moreover, a close reading of the Hoffmann's thesis provides no basis to extrapolate his curious reporter gene dual promoter construct even to plasmid-based expression of a single viral mRNA and vRNA. That work led to a separate publication in a leading journal (Hoffmann *et al.*, Virology, 2000, 267: 310-7; attached as Exhibit 6). As noted above, the Neumann *et al.* publication describes an alternative approach, like the present invention based on plasmids to generate an infectious influenza virus, but otherwise having nothing in common with the system of the present invention. It took extraordinary vision to employ the dual pol I-pol II promoter system for all of the viral segments. In my view, such vision, and the results obtained, are the antithesis of obviousness.

{W:\02427\100G772000\00279971.DOC *02427100G772000* }

Serial No.: 09/844,517
Filed: 04/27/2001
Group Art Unit: 1648

20. I hereby declare that all statements made herein of my own knowledge are true and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

10-19-04



Date:

Robert G. Webster, Ph.D.

{W:\02427\100G772000\00279971.DOC *02427100G772000* }

CURRICULUM VITAE

NAME:

ROBERT GORDON WEBSTER

CITIZENSHIP:

American

OFFICE ADDRESS:

Department of Infectious Diseases
 Division of Virology
 St. Jude Children's Research Hospital
 332 North Lauderdale
 Memphis, Tennessee 38105-2794
 Telephone: (901) 495-3400

ACADEMIC DEGREES:

BSc	1955	Otago University, New Zealand (Microbiology)
MSc	1957	Otago University, New Zealand (Microbiology)
PhD	1962	Australian National University, Canberra (Microbiology)

PROFESSIONAL APPOINTMENTS:

1958-59	Virologist, New Zealand Department of Agriculture
1962-63	Postdoctoral Fellow, Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor (Fullbright Scholar)
1964-66	Research Fellow, Department of Microbiology, John Curtin Medical School, Australian National University, Canberra
1966-67	Fellow, Department of Microbiology, John Curtin Medical School, Australian National University, Canberra
1968-69	Associate Member, Laboratory of Immunology, St. Jude Children's Research Hospital, and Associate Professor, Department of Microbiology, University of Tennessee Medical Units, Memphis
1969-74	Member, Laboratories of Virology and Immunology, St. Jude Children's Research Hospital, and Associate Professor, Department of Microbiology, University of Tennessee Medical Units, Memphis
1974-75	Member, Laboratories of Virology and Immunology, St. Jude Children's Research Hospital, and Professor, Department of Microbiology, University of Tennessee Center for the Health Sciences, Memphis
1975-78	Member, Division of Virology, St. Jude Children's Research Hospital, and Professor, Department of Microbiology, University of Tennessee Center for the Health Sciences, Memphis
1978-79	Fogarty International Senior Fellow, National Institute for Medical Research, Medical Research Council, London, England
1978-85	Member, Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, and Professor, Department of Microbiology and Immunology, University of Tennessee Center for the Health Sciences, Memphis
1985 to 2001	Member, Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee
1988 to 2001	Rose Marie Thomas Chair, Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, Memphis, Tennessee
2001 to present	Member, Rose Marie Thomas Chair, Division of Virology, Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee

APPOINTMENTS:

1975 to Present	World Health Organization Designation as a WHO collaborating laboratory on the ecology of influenza viruses in lower animals and birds
-----------------	--

PROFESSIONAL SOCIETY MEMBERSHIPS:

American Society for Microbiology
 American Society for Virology
 Fellow of the Royal Society of Medicine
 American Association for the Advancement of Science

HONORS:

Fellow of the Royal Society, London, 1989
 Fellow of the Royal Society of New Zealand, 1990 (Honorary)
 National Academy of Sciences of the United States of America, 1998
 Twelfth Annual Bristol-Myers Squibb Award for Distinguished Achievement in Infectious Diseases, 2002

RESEARCH INTERESTS:

The emergence and control of influenza viruses
 Viral immunology

PUBLICATIONS:**Original Articles**

1. Webster RG, Miles JAR. The relations of contagious pustular dermatitis virus. Proc Univ Otago Med Sch 35:2-3, 1957.
2. Webster RG. The immunological relations of the contagious pustular dermatitis virus to the mammalian pox group. Aust J Exp Biol 36:267-274, 1958.
3. Webster RG. Studies on infectious laryngotracheitis in New Zealand. N Z Vet J 7:67-71, 1959.
4. Webster RG. The isolation of orphan viruses from pigs in New Zealand. Aust J Exp Biol 37:263-270, 1959.
5. Webster RG, Manktelow BW. Some observations on bovine rhinotracheitis in New Zealand. N Z Vet J 7:143-148, 1959.
6. Fazekas de St Groth S, Webster RG. Methods in immunochemistry of viruses. I. Equilibrium filtration. Aust J Exp Biol 39:549-562, 1961.
7. Webster RG, Laver WG, Fazekas de St Groth S. Methods in immunochemistry of viruses. III. Simple techniques for labeling antibodies with ^{131}I and ^{35}S . Aust J Exp Biol 40:321-328, 1962.
8. Fazekas de St Groth S, Webster RG. The neutralization of animal viruses. III. Equilibrium conditions in the influenza virus-antibody system. J Immunol 90:140-150, 1963.
9. Fazekas de St Groth S, Webster RG. The neutralization of animal viruses. IV. Parameters of the influenza virus-antibody system. J Immunol 90:151-164, 1963.
10. Fazekas de St Groth S, Webster RG, Datyner A. Two new staining procedures for quantitative estimation of proteins on electrophoresis strips. Biochim Biophys Acta 71:377-391, 1963.
11. Davenport FM, Hennessy AV, Brandon FM, Webster RG, Barrett DC, Lease, GO. Comparison of serologic and febrile responses in humans to vaccination with influenza A viruses of their hemagglutinins. J Lab Clin Med 63:5-13, 1964.

12. Webster RG. The immune response to influenza virus. I. Effect of the route and schedule of vaccinations on the time course of the immune response as measured by three serological methods. *Immunology* 9:501-519, 1965.
13. Webster RG, Laver WG. Influenza virus subunit vaccines. Immunogenicity and lack of toxicity for rabbits of ether and detergent-disrupted virus. *J Immunol* 96:596-605, 1966.
14. Fazekas de St Groth S, Webster RG. Disquisitions on original antigenic sin. I. Evidence in man. *J Exp Med* 124:331-345, 1966.
15. Fazekas de St Groth S, Webster RG. Disquisitions on original antigenic sin. II. Proof in lower creatures. *J Exp Med* 124:347-361, 1966.
16. Webster RG. Original antigenic sin in ferrets: The response to sequential infection with influenza viruses. *J Immunol* 97:177-183, 1966.
17. Laver WG, Webster RG. The structure of influenza viruses. IV. Chemical studies of the host antigen. *Virology* 30:104-115, 1966.
18. Webster RG, Laver WG. Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus. *J Immunol* 99:49-55, 1967.
19. Pereira HG, Tumova B, Webster RG. Antigenic relationship between influenza A viruses of human and avian origins. *Nature* 215:982-983, 1967.
20. Webster RG. The immune response to influenza virus. II. Effect of the route and schedule of vaccination on the quantity and avidity of antibodies. *Immunology* 14:29-38, 1968.
21. Webster RG. The immune response to influenza virus. III. Changes in the avidity and specificity of early IgM and IgG antibodies. *Immunology* 14:39-52, 1968.
22. Laver WG, Webster RG. Selection of antigenic mutants of influenza viruses. Isolation and peptide mapping of their hemagglutinin proteins. *Virology* 34:193-202, 1968.
23. Kilbourne ED, Laver WG, Schulman JL, Webster RG. Antiviral activity of antiserum specific for an influenza virus neuraminidase. *J Virol* 2: 281-288, 1968.
24. Webster RG, Pereira HG. A common surface antigen in influenza from human and avian sources. *J Gen Virol* 3:201-208, 1968.
25. Webster RG, Laver WG, Kilbourne ED. Reactions of antibodies with surface antigens of influenza virus. *J Gen Virol* 3:315-326, 1968.
26. Webster RG, Darlington RW. Disruption of myxoviruses with Tween 20 and isolation of biologically active hemagglutinin and neuraminidase subunits. *J Virol* 4:182-187, 1969.
27. Kingsbury DW, Webster RG. Some properties of influenza virus nucleocapsids. *J Virol* 4:219-225, 1969.
28. Fazekas de St Groth S, Webster RG, Davenport FM. The antigenic subunits of influenza viruses. I. The homologous antibody response. *J Immunol* 103:1099-1106, 1969.
29. Marine WM, Workman WM, Webster RG. Immunological interrelationships of Hong Kong, Asian and Equi-2 influenza viruses in man. *Bull WHO* 41:475-482, 1969.
30. Webster RG. Antigenic variation in influenza viruses, with special reference to Hong Kong influenza. *Bull WHO* 41:483-485, 1969.
31. Webster RG. Estimation of the molecular weights of the polypeptide chains from the isolated hemagglutinin and neuraminidase subunits of influenza viruses. *Virology* 40:643-654, 1970.

32. Webster RG. Antigenic hybrids of influenza A viruses with surface antigens to order. *Virology* 42:633-642, 1970.
33. Campbell CH, Webster RG, Breese SS. Fowl plague virus from man. *J Infect Dis* 122:513-516, 1970.
34. Webster RG, Laver WG. Antigenic variation in influenza virus. *Biology and Chemistry. Prog Med Virol* 13:271-338, 1971.
35. Morrison M, Bayse GS, Webster RG. Use of lactoperoxidase catalyzed iodination in immunochemical studies. *Immunochemistry* 8:289-297, 1971.
36. Borella L, Webster RG. The immunosuppressive effect of long term combination chemotherapy in children with acute leukemia in remission. *Cancer Res* 31:420-426, 1971.
37. Webster RG, Campbell CH, Granoff A. The *in vivo* production of "new" influenza viruses. I. Genetic recombination between avian and mammalian influenza viruses. *Virology* 44:317-328, 1971.
38. Webster RG. Immunological aspects of the preparation and application of virus vaccines. *Recent Adv Microbiol* 31:563-567, 1971.
39. Laver WG, Webster RG. Antibodies to human influenza virus neuraminidase (the A2/Asian/57 H2N2 strain) in sera from Australian pelagic birds. *Bull WHO* 47:535-541, 1972.
40. Borella L, Green A, Webster R. Immunological rebound after cessation of long-term chemotherapy in acute leukemia. *Blood* 40:42-51, 1972.
41. Webster RG, Laver WG. The origin of pandemic influenza. *Bull WHO* 47: 449-452, 1972.
42. Webster RG, Campbell CH. The *in vivo* production of "new" influenza A viruses. II. *In vivo* isolation of "new" viruses. *Virology* 48:528-536, 1972.
43. Webster RG, Laver WG. Studies on the origin of pandemic influenza. I. Antigenic analysis of A2 influenza viruses isolated before and after the appearance of Hong Kong influenza using antisera to the isolated hemagglutinin subunits. *Virology* 48:433-444, 1972.
44. Laver WG, Webster RG. Studies on the origin of pandemic influenza. II. Peptide maps of the light and heavy polypeptide chains from the hemagglutinin subunits of A2 influenza viruses isolated before and after the appearance of Hong Kong Influenza. *Virology* 48:445-455, 1972.
45. Fedson DS, Huber MA, Kasel JA, Webster RG. Presence of A/Equi-2 hemagglutinin and neuraminidase antibodies in man. *Proc Exp Biol Med* 139:825-826, 1972.
46. Webster RG, Campbell CH. An inhibition test for identifying the neuraminidase antigen on influenza viruses. *Avian Dis* 16:1057-1066, 1972.
47. Webster RG. On the origin of pandemic influenza viruses. *Curr Top Microbiol* 59:75-105, 1972.
48. Webster RG, Campbell CH, Granoff A. The *in vivo* production of "new" influenza viruses. III. Isolation of recombinant influenza viruses under simulated conditions of natural transmission. *Virology* 51:149-162, 1973.
49. Baker N, Stone HO, Webster RG. Serological cross reactions between the hemagglutinin subunits of H0N1 and H1N1 influenza viruses detected with "monospecific" antisera. *J Virol* 11:137-140, 1973.
50. Laver WG, Webster RG. Studies on the origin of pandemic influenza. III. Evidence implicating duck and equine influenza viruses as possible progenitors of the Hong Kong strain of human influenza. *Virology* 51:383-391, 1973.

51. Kingsbury DW, Webster RG. Cell-free translation of influenza virus messenger RNA. *Virology* 56:654-657, 1973.
52. Aymard-Henry M, Coleman MT, Dowdle WR, Laver WG, Schild GC, Webster RG. Influenza neuraminidase and neuraminidase-inhibition test procedures. *Bull WHO* 48:199-202, 1973.
53. Downie JC, Webster RG, Schild GC, Dowdle WR, Laver WG. Characterization and ecology of a type A influenza virus isolated from a Shearwater. *Bull WHO* 49:559-566, 1973.
54. Webster RG, Goorha R, Granoff A. Replication of influenza virus in chick embryo fibroblasts after inhibition of host cell macromolecular synthesis by frog virus 3. *Virology* 58:600-604, 1974.
55. Laver WG, Downie JC, Webster RG. Studies on antigenic variation in influenza virus. Evidence for multiple antigenic determinants on the hemagglutinin subunits of A/Hong Kong/68 [H3N2] virus and the A/England/72 strains. *Virology* 59:230-244, 1974.
56. Webster RG, Campbell CH. Studies on the origin of pandemic influenza. IV. Selection and transmission of "new" influenza viruses *in vivo*. *Virology* 62:404-413, 1974.
57. Webster RG, Isachenko V, Carter M. A new avian influenza virus from feral birds in the USSR. Recombination in nature? *Bull WHO* 51:325-332, 1974.
58. Webster RG, Laver WG, Tumova B. Studies on the origin of pandemic influenza viruses. V. Persistence of Asian influenza virus hemagglutinin (H2) antigen in nature? *Virology* 67:534-543, 1975.
59. Tumova B, Eisengarten HJ, Siebelist-Konstantinow I, Stumpa A, Webster, RG. A duck influenza virus with hemagglutinin related to that of A/Singapore/57 [H2N2] virus [Letter]. *Acta Virol* 19:26, 1975.
60. Dowdle WR, Davenport FM, Fukumi H, Schild GC, Tumova B, Webster RG, Zakstelskaja LY. Orthomyxoviridae. *Intervirology* 5:245-251, 1975.
61. Laver WG, Webster RG. Preparation and immunogenicity of an influenza virus hemagglutinin and neuraminidase subunit vaccine. *Virology* 69:511-522, 1976.
62. Laver WG, Downie JC, Webster RG. Diversity of the antibody response to the different antigenic determinants on the hemagglutinin subunits of influenza viruses. *J Immunol* 116:336-341, 1976.
63. Webster RG, Morita M, Pridgen C, Tumova B. Ortho- and paramyxoviruses from migrating feral ducks: Characterization of a new group of influenza A viruses. *J Gen Virol* 32:217-225, 1976.
64. Webster RG, Kasel JA, Couch RB, Laver WG. Influenza virus subunit vaccines. II. Immunogenicity and original antigenic sin in humans. *J Infect Dis* 134:48-58, 1976.
65. Laver WG, Webster RG. Preparation and immunogenicity of a purified influenza virus hemagglutinin and neuraminidase subunit vaccine. *Postgrad Med J* 52:373-378, 1976.
66. Green AA, Pratt C, Webster RG, Smith K. Immunotherapy of osteosarcoma patients with virus-modified tumor cells. *Ann N Y Acad Sci* 277:396-411, 1976.
67. Smith JW, Tannous R, Thompson E, Webster RG. Swine influenza in Hodgkin's Disease. *N Engl J Med* 295:732, 1976.
68. Webster RG, Tumova B, Hinshaw VS, Lang G. Characterization of avian influenza viruses. Designation of a newly recognized hemagglutinin. *Bull WHO* 54:555-560, 1977.
69. Feldman S, Webster RG, Sugg M. Influenza in children and young adults with cancer: 20 cases. *Cancer* 39:350-353, 1977.

70. Sazonov AA, Lvov DK, Webster RG, Sokolova TV, Braude NA, Portyanko NV. Isolation of an influenza virus similar to A/Port Chalmers/1/73 [H3N2] from a common murre at Sakhalin Island in USSR. (Strain A/common murre/Sakhalin/1/74). *Arch Virol* 53:1-7, 1977.
71. Campbell CH, Easterday BC, Webster RG. Strains of Hong Kong influenza virus in calves. *J Infect Dis* 135:678-680, 1977.
72. Shortridge KF, Butterfield WK, Webster RG, Campbell CH. Isolation and characterization of influenza A viruses from avian species in Hong Kong. *Bull WHO* 55:15-20, 1977.
73. Shortridge KF, Webster RG, Butterfield WK, Campbell CH. Persistence of Hong Kong influenza virus variants in pigs. *Science* 196:1454-1455, 1977.
74. Laver WG, Webster RG. Hemagglutinin molecules of Hong Kong, equine-2, and duck/Ukraine influenza viruses lack N-terminal aspartic acid. *Virology* 81:482-485, 1977.
75. Biddison WE, Doherty PC, Webster RG. Antibody to influenza virus matrix protein detects a common antigen on the surface of cells infected with type A influenza viruses. *J Exp Med* 146:690-697, 1977.
76. Webster RG, Hinshaw VS. Matrix protein from influenza A virus and its role in cross-protection in mice. *Infect Immun* 17:561-566, 1977.
77. Shablovskaya EA, Lvov DK, Sazonov AA, Webster RG, Vinograd IA, Braude NA, Stelmakh SG, Portyanko NV, Kovalchuk-Ivanyuk TV, Sololova NN. Isolation of strains identical with influenza A/England/42/72 virus from semi-synantropic species of birds in the Rovno region of the Ukrainian SSR [In Russian]. *Vopr Virusol (Prob Virol)* 4:414-417, 1977.
78. Kaplan MM, Webster RG. The epidemiology of influenza. *Sci Am* 237:88-106, 1977.
79. Webster RG, Glezen WP, Hannoun C, Laver WG. Potentiation of the immune response to influenza virus subunit vaccines. *J Immunol* 119:2073-2077, 1977.
80. Webster RG, Hinshaw VS, Bean WJ Jr. Antigenic shift in myxoviruses. *Med Microbiol Immunol* 164:57-68, 1977.
81. Allison JE, Glezen WP, Taber LH, Paredes A, Webster RG. Reactogenicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccines in high-risk children. *J Infect Dis* 136(Suppl):S672-S676, 1977.
82. Glezen WP, Kasel JA, Webster RG, Taber LH. Alternative approaches to immunization of children with inactivated influenza virus vaccines. *J Infect Dis* 136(Suppl):S677-S681, 1977.
83. Webster RG, Yakhno M, Hinshaw VS, Bean WJ, Murti KG. Intestinal influenza: Replication and characterization of influenza viruses in ducks. *Virology* 84:268-278, 1978.
84. Hinshaw VS, Bean WJ Jr, Webster RG, Easterday BC. The prevalence of influenza viruses in swine and the antigenic and genetic relatedness of influenza viruses from man and swine. *Virology* 84:51-62, 1978.
85. Gerhard W, Webster RG. Antigenic drift in influenza A viruses: I. Selection and characterization of antigenic variants of A/PR/8/34 (HON1) influenza virus with monoclonal antibodies. *J Exp Med* 148:383-392, 1978.
86. Nerome K, Nakayama M, Ishida M, Fukumi H, Butterfield WK, Webster RG, Campbell CH. Isolation and serological characterization of influenza A viruses from birds that were dead on arrival at Tokyo airport. *Acta Virol* 57:261-270, 1978.

87. Hinshaw VS, Webster RG, Turner B. Novel influenza A viruses isolated from Canadian feral ducks: Including strains antigenically related to swine influenza (Hsw1N1) viruses. *J Gen Virol* 41:115-127, 1978.

88. Butterfield WK, Campbell CH, Webster RG, Shortridge KF. Identification of a swine influenza virus (Hsw1N1) isolated from a duck in Hong Kong. *J Infect Dis* 138:686-689, 1978.

89. Webster RG, Bean WJ. Genetics of influenza virus. *Ann Rev Genet* 12:415-431, 1978.

90. Hinshaw VS, Webster RG, Turner B. Water-borne transmission of influenza A viruses? *Intervirology* 11:66-68, 1979.

91. Shortridge KF, Webster RG. Geographical distribution of swine (Hsw1N1) and Hong Kong (H3N2) influenza virus variants in pigs in Southeast Asia. *Intervirology* 11:9-15, 1979.

92. Laver WG, Webster RG. Ecology of influenza viruses in lower mammals and birds. *Br Med J* 35:29-33, 1979.

93. Laver WG, Gerhard W, Webster RG, Frankel ME, Air GM. Antigenic drift in influenza A viruses: Peptide mapping and antigenic analysis of A/PR/8/34 (H0N1) variants selected with monoclonal antibodies. *Proc Natl Acad Sci USA* 76:1425-1429, 1979.

94. Yewdell JW, Webster RG, Gerhard W. Antigenic variation in three distinct determinants of an influenza type A hemagglutinin molecule. *Nature* 279:246-248, 1979.

95. Webster RG, Kendal AP, Gerhard W. Analysis of antigenic drift in recently isolated influenza A (H1N1) viruses using monoclonal antibody preparations. *Virology* 96:258-264, 1979.

96. Laver WG, Air GM, Webster RG, Gerhard W, Ward CW, Dopheide TAA. Antigenic drift in type A influenza virus. Sequence changes in the hemagglutinin of Hong Kong (H3N2) variants selected with monoclonal hybridoma antibodies. *Virology* 98:226-237, 1979.

97. Shortridge KF, Butterfield W, Webster RG, Campbell CH. Diversity of influenza A virus subtypes isolated from domestic poultry in Hong Kong. *Bull WHO* 57:465-469, 1979.

98. Shortridge KF, Webster RG, Kam SL, Gardner JM. Reappearance of H1N1 influenza virus in man: Evidence for the persistence of the virus in domestic chickens. *Bull WHO* 57:475-477, 1979.

99. Hay AJ, Skehel JJ, Webster RG. Differentiation of the hemagglutinin genes of variant influenza viruses by RNA-RNA hybridization. *J Gen Virol* 45:245-248, 1979.

100. Couch RB, Webster RG, Kasel JA, Cate TR. The efficacy of purified influenza subunit vaccines and relationship to the major antigenic determinants on the hemagglutinin molecule. *J Infect Dis* 140:553-559, 1979.

101. Hinshaw VS, Webster RG. Characterization of a new avian influenza virus subtype and proposed designation of this hemagglutinin as Hav10. *J Gen Virol* 45:751-754, 1979.

102. Hinshaw VS, Webster RG, Rodriguez RJ. Influenza A viruses: Combinations of hemagglutinin and neuraminidase subtypes isolated from animals and other sources. *Arch Virol* 62:281-290, 1979.

103. Schild GC, Newman RW, Webster RG, Major D, Hinshaw VS. Antigenic analysis of influenza A virus surface antigens: Considerations for the nomenclature of influenza virus. *Arch Virol* 63:171-184, 1980.

104. Bean WJ, Sriram G, Webster RG. Electrophoretic analysis of iodine-labeled influenza virus RNA segments. *Anal Biochem* 102:228-232, 1980.

105. Askonas BA, Webster RG. Monoclonal antibodies to the hemagglutinin and to H-2 inhibit the cross-reactive cytotoxic T-cell population induced by influenza. *Eur J Immunol* 10:151-156, 1980.

106. Hinshaw VS, Bean WJ, Webster RG, Sriram G. Genetic reassortment of influenza A viruses in the intestinal tract of ducks. *Virology* 102:412-419, 1980.
107. Hackett CJ, Askonas BA, Webster RG, van Wyke K. Monoclonal antibodies to influenza matrix protein: Detection of low levels of matrix protein on abortively infected cells. *J Gen Virol* 47:497-501, 1980.
108. Hinshaw VS, Webster RG, Turner B. The perpetuation of orthomyxoviruses and paramyxoviruses in Canadian waterfowl. *Can J Microbiol* 26:622-629, 1980.
109. Webster RG, Laver WG. Determination of the number of non-overlapping antigenic areas on Hong Kong (H3N2) influenza virus hemagglutinin with monoclonal antibodies and the selection of variants with potential epidemiological significance. *Virology* 104:139-148, 1980.
110. Murti KG, Bean WJ Jr, Webster RG. Helical ribonucleoproteins of influenza virus: An electron microscopic analysis. *Virology* 104:224-229, 1980.
111. Portner A, Webster RG, Bean WJ. Similar frequencies of antigenic variants in Sendai, vesicular stomatitis, and influenza A viruses. *Virology* 104: 235-238, 1980.
112. van Wyke KL, Hinshaw VS, Bean WJ Jr, Webster RG. Antigenic variation of influenza A virus nucleoprotein detected with monoclonal antibodies. *J Virol* 35:24-30, 1980.
113. Hackett CJ, Askonas A, Webster RG, van Wyke K. Quantitation of influenza virus antigens on infected target cells and their recognition by cross-reactive cytotoxic T cells. *J Exp Med* 151:1014-1025, 1980.
114. Webster RG, Askonas BA. Cross-protection and cross-reactive cytotoxic T-cells induced by influenza virus vaccines in mice. *Eur J Immunol* 10:396-401, 1980.
115. Dimmock NJ, Carver AS, Webster RG. Categorization of nucleoproteins and matrix proteins from type A influenza viruses by peptide mapping. *Virology* 103:350-356, 1980.
116. Sriram G, Bean WJ Jr, Hinshaw VS, Webster RG. Genetic diversity among avian influenza viruses. *Virology* 105:592-599, 1980.
117. Phillips DJ, Kendal AP, Webster RG, Feorino PM, Reimer CB. Detection of monoclonal influenza antibodies synthesized in culture by hybridoma cells with a solid-phase indirect immunofluorometric assay. *J Virol Meth* 1:274-283, 1980.
118. Webster RG, Laver WG, Air GM, Ward C, van Wyke KL, Gerhard W. The mechanism of antigenic drift in influenza viruses: Analysis of Hong Kong (H3N2) variants with monoclonal antibodies to the hemagglutinin molecule. *Ann N Y Acad Sci* 354:142-161, 1980.
119. Webster RG, Hinshaw VS, Bean WJ, Sriram G. Influenza viruses: Transmission between species. *Philos Trans R Soc Lond [Biol]* 288:439-447, 1980.
120. Moore BW, Webster RG, Bean WJ, van Wyke KL, Laver WG, Evered MG, Downie JC. Reappearance in 1979 of a 1968 Hong Kong-like influenza virus. *Virology* 109:219-222, 1981.
121. Laver WG, Air GM, Webster RG. Mechanism of antigenic drift in influenza virus. Amino acid sequence changes in an antigenically active region of Hong Kong (H3N2) influenza virus hemagglutinin. *J Mol Biol* 145:339-361, 1981.
122. Hinshaw VS, Webster RG, Bean WJ, Sriram G. The ecology of influenza viruses in ducks and analysis of influenza viruses with monoclonal antibodies. *Comp Immunol Microbiol Infect Dis* 3:155-164, 1981.

123. Webster RG, Geraci J, Petursson G, Skirnisson K. Conjunctivitis in human beings caused by influenza A virus of seals. *N Engl J Med* 304:911, 1981.
124. Gerhard W, Yewdell J, Frankel M, Webster R. Antigenic structure of influenza virus hemagglutinin defined by hybridoma antibodies. *Nature* 290:713-717, 1981.
125. Ward CW, Webster RG, Inglis AS, Dopheide TA. Composition and sequence studies show A/Duck/Ukraine/63 hemagglutinin (Hav7) belongs to the Hong Kong (H3) subtype. *J Gen Virol* 53:163-168, 1981.
126. van Wyke KL, Bean WJ Jr, Webster RG. Monoclonal antibodies to the influenza A virus nucleoprotein affecting RNA transcription. *J Virol* 39:313-317, 1981.
127. Kendal AP, Phillips DJ, Webster RG, Galland GG, Reimer CB. Effect of test system on the ability of monoclonal antibodies to detect antigenic drift in influenza A (H1N1) virus hemagglutinins. *J Gen Virol* 54:253-261, 1981.
128. Laver WG, Air GM, Webster RG. Antigenicity of influenza virus hemagglutinin following chemical modification. *Virology* 111:538-548, 1981.
129. Hinshaw VS, Webster RG, Rodriguez RJ. Influenza A viruses: Combinations of hemagglutinin and neuraminidase subtypes isolated from animals and other sources. *Arch Virol* 67:191-201, 1981.
130. Frank AL, Webster RG, Glezen WP, Cate TR. Immunogenicity of influenza A/USSR (H1N1) subunit vaccine in unprimed young adults. *J Med Virol* 7:135-142, 1981.
131. Webster RG, Hinshaw VS, Bean WJ Jr, van Wyke KL, Geraci JR, St Aubin DJ, Petursson G. Characterization of an influenza A virus from seals. *Virology* 113:712-724, 1981.
132. Hinshaw VS, Webster RG, Easterday BC, Bean WJ. Replication of avian influenza A viruses in mammals. *Infect Immun* 34:354-361, 1981.
133. Colman PM, Gough KH, Lilley GG, Blagrove RJ, Webster RG, Laver WG. A crystalline monoclonal FAB fragment with specificity towards an influenza virus neuraminidase. *J Mol Biol* 152:609-614, 1981.
134. Webster RG, Berton MT. Analysis of antigenic drift in the hemagglutinin molecule of influenza B virus with monoclonal antibodies. *J Gen Virol* 54:243-251, 1981.
135. McMichael AJ, Gotch F, Cullen P, Askonas BA, Webster RG. The human cytotoxic T-cell response to influenza A vaccination. *Clin Exp Immunol* 43:276-284, 1981.
136. Webster RG, Hinshaw VS, Laver WG. Selection and analysis of antigenic variants of the neuraminidase of N2 influenza viruses with monoclonal antibodies. *Virology* 117:93-104, 1982.
137. Webster RG, Laver WG, Air GM, Schild GC. Molecular mechanisms of variation in influenza viruses. *Nature* 296:115-121, 1982.
138. Geraci JR, St Aubin DJ, Barker IK, Webster RG, Hinshaw VS, Bean WJ, Ruhnke HL, Prescott JH, Early G, Baker AS, Madoff S, Schooley RT. Mass mortality of harbor seals: Pneumonia associated with influenza A virus. *Science* 215:1129-1131, 1982.
139. Murphy BR, Hinshaw VS, Sly DL, London WT, Hosier NT, Wood FT, Webster RG, Chanock RM. Virulence of avian influenza A viruses for squirrel monkeys. *Infect Immun* 37:1119-1126, 1982.
140. Ottis K, Sidoli L, Bachmann PR, Webster RG, Kaplan MM. Human influenza A viruses in pigs: Isolation of a H3N2 strain antigenically related to A/England/42/72 and evidence for continuous circulation of human viruses in the pig population. *Arch Virol* 73:103-108, 1982.

141. Kida H, Brown LE, Webster RG. Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. *Virology* 122:38-47, 1982.
142. McMichael AJ, Askonas BA, Webster RG, Laver WG. Vaccination against influenza: B-cell or T-cell immunity? *Immunol Today* 3:256-260, 1982.
143. Jackson DC, Webster RG. A topographical map of the enzyme active center and antigenic sites on the neuraminidase of influenza virus A/Tokyo/3/67 (H2N2). *Virology* 123:69-77, 1982.
144. Laver WG, Air GM, Webster RG, Markoff LJ. Amino acid sequence changes in antigenic variants of type A influenza virus N2 neuraminidase. *Virology* 122:450-460, 1982.
145. Lu BL, Webster RG, Hinshaw VS. Failure to detect hemagglutination-inhibiting antibodies with intact avian influenza virions. *Infect Immun* 38:530-535, 1982.
146. Murphy BR, Sly DL, Tierney EL, Hosier NT, Massicot JG, London WT, Chanock RM, Webster RG, Hinshaw VS. Reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys. *Science* 218:1330-1332, 1982.
147. Atassi MZ, Webster RG. Localization, synthesis, and activity of an antigenic site on influenza virus hemagglutinin. *Proc Natl Acad Sci USA* 80:840-844, 1983.
148. Hinshaw VS, Webster RG, Bean WJ, Downie J, Senne DA. Swine influenza-like viruses in turkeys: Potential source of virus for humans? *Science* 220:206-208, 1983.
149. Hinshaw VS, Naeve CW, Webster RG, Douglas A, Skehel JJ, Bryans J. Analysis of antigenic variation in equine 2 influenza A viruses. *Bull WHO* 61:153-158, 1983.
150. Jackson DC, Howlett GJ, Nestorowicz A, Webster RG. The equilibrium constant for the interaction between a monoclonal Fab fragment and an influenza virus neuraminidase. *J Immunol* 130:1313-1316, 1983.
151. Hinshaw VS, Webster RG, Naeve CW, Murphy BR. Altered tissue tropism of human-avian reassortant influenza viruses. *Virology* 128:260-263, 1983.
152. Kida H, Webster RG, Yanagawa R. Inhibition of virus-induced hemolysis with monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. *Arch Virol* 76:91-99, 1983.
153. Newton SE, Air GM, Webster RG, Laver WG. Sequence of the hemagglutinin gene of influenza virus A/Memphis/1/71 and previously uncharacterized monoclonal antibody derived variants. *Virology* 128:495-501, 1983.
154. Naeve CW, Webster RG, Hinshaw VS. Phenotypic variation in influenza virus reassortants with identical gene constellations. *Virology* 128:331-340, 1983.
155. Lu BL, Webster RG, Brown LE, Nerome K. Heterogeneity of influenza B viruses. *Bull WHO* 61:681-687, 1983.
156. Webster RG, Brown LE, Jackson DC. Changes in the antigenicity of the hemagglutinin molecule of H3 influenza virus at acidic pH. *Virology* 126:587-599, 1983.
157. Brown LE, Hinshaw VS, Webster RG. Antigenic variation in the influenza A virus nonstructural protein, NS1. *Virology* 130:134-143, 1983.

158. Oxford JS, Abbo H, Corcoran T, Webster RG, Smith J, Grilli EA, Schild GC. Antigenic and biochemical analysis of field isolates of influenza B virus: Evidence for intra- and inter-epidemic variation. *J Gen Virol* 64:2367-2377, 1983.
159. Schild GC, Oxford JS, de Jong J, Webster RG. Evidence for host-cell selection of influenza virus antigenic variants. *Nature* 303:706-709, 1983.
160. Murphy BR, Harper J, Sly DL, London WT, Miller NT, Webster RG. Evaluation of the A/Seal/Mass/1/80 virus in squirrel monkeys. *Infect Immun* 42: 424-426, 1983.
161. Naeve CW, Webster RG. The sequence of the hemagglutinin gene from influenza virus A/Seal/Mass/1/80. *Virology* 129:298-308, 1983.
162. Six HR, Webster RG, Kendal AP, Glezen WP, Griffis C, Couch RB. Antigenic analysis of H1N1 viruses isolated in the Houston metropolitan area during four successive seasons. *Infect Immun* 42:453-458, 1983.
163. Nerome K, Sakamoto S, Yano N, Yamamoto T, Kobayashi S, Webster RG, Oya A. Antigenic characteristics and genome composition of a naturally occurring recombinant influenza virus isolated from a pig in Japan. *J Gen Virol* 64:2611-2620, 1983.
164. Laver WG, Webster RG, Chu CM. Summary of a meeting on the origin of pandemic influenza viruses. *J Infect Dis* 149:108-115, 1984.
165. Webster RG, Brown LE, Laver, WG. Antigenic and biological characterization of influenza virus neuraminidase (N2) with monoclonal antibodies. *Virology* 135:30-42, 1984.
166. Nerome K, Yoskioka Y, Torres CA, Oya A, Bachmann P, Ottis K, Webster RG. Persistence of Q strains of H2N2 influenza virus in avian species. *Arch Virol* 81:239-250, 1984.
167. Zakstelskaya LY, Isachenko VA, Oskerkova TA, Shenderovich SF, Webster RG, Zhdanov VM. Changes in the antigenic composition of hemagglutinin of (H1N1) viruses in 1977-1982 revealed by means of monoclonal antibodies. *Vopr Virusol* 1:66, 1984.
168. Yamada A, Brown LE, Webster RG. Characterization of H2 influenza virus hemagglutinin with monoclonal antibodies: Influence of receptor specificity. *Virology* 138:276-286, 1984.
169. Daniels RS, Douglas AR, Skehel JJ, Wiley DC, Naeve CW, Webster RG, Rogers GN, Paulson JC. Antigenic analyses of influenza virus hemagglutinins with different receptor binding specificities. *Virology* 138:174-177, 1984.
170. Hinshaw VS, Bean WJ, Webster RG, Rehg JE, Fiorelli P, Early G, Geraci JR, St Aubin DJ. Are seals frequently infected with avian influenza viruses? *J Virol* 51:863-865, 1984.
171. Naeve CW, Hinshaw VS, Webster RG. Mutations in the hemagglutinin receptor-binding site can change the biological properties of an influenza virus. *J Virol* 51:567-569, 1984.
172. Wabuke-Bunoti MAN, Taku A, Fan DP, Kent S, Webster RG. Cytolytic T lymphocyte and antibody responses to synthetic peptide of influenza virus hemagglutinin. *J Immunol* 133:2194, 1984.
173. Lentz MR, Air GM, Laver WG, Webster RG. Sequence of the neuraminidase gene of influenza virus A/Tokyo/3/67 and previously uncharacterized monoclonal variants. *Virology* 135:257-265, 1984.
174. Geraci JR, St Aubin DJ, Barker IK, Hinshaw VS, Webster RG, Ruhnke HL. Susceptibility of grey (*Halichoerus grypus*) and harp (*Phoca groenlandica*) seals to the influenza virus and mycoplasma of epizootic pneumonia of harbor seals (*Phoca vitulina*). *Can J Fish Aquatic Sci* 41:151-156, 1984.

175. Kawaoka Y, Naeve CW, Webster RG. Is virulence of H5N2 influenza viruses in chickens associated with loss of carbohydrate from the hemagglutinin? *Virology* 139:303-316, 1984.
176. Laver WG, Colman PM, Webster RG, Hinshaw VS, Air GM. Influenza virus neuraminidase with hemagglutinin activity. *Virology* 137:314-323, 1984.
177. Berton MT, Naeve CW, Webster RG. Antigenic structure of the influenza B virus hemagglutinin: Nucleotide sequence analysis of antigenic variants selected with monoclonal antibodies. *J Virol* 52:919-927, 1984.
178. Hinshaw VS, Alexander DJ, Aymard M, Bachmann PA, Easterday BC, Hannoun C, Kida H, Lipkind M, MacKenzie JS, Nerome K, Schild GC, Scholtissek C, Senne DA, Shortridge KF, Skehel JJ, Webster RG. Antigenic comparisons of swine-influenza-like H1N1 isolates from pigs, birds, and humans: An international collaborative study. *Bull WHO* 62:871-878, 1984.
179. Els MC, Air GM, Murti KG, Webster RG, Laver WG. An 18 amino acid deletion in an influenza neuraminidase. *Virology* 142:241-247, 1985.
180. Wood JM, Webster RG, Nettles VF. Host range of A/Chicken/Pennsylvania/83 (H5N2) influenza virus. *Avian Dis* 29:198-207, 1985.
181. Bean WJ, Kawaoka Y, Wood JM, Pearson JE, Webster RG. Characterization of virulent and avirulent A/Chicken/Pennsylvania/83 influenza A viruses: Potential role of defective interfering RNAs in nature. *J Virol* 54:151-160, 1985.
182. Robertson JS, Naeve CW, Webster RG, Bootman JS, Newman R, Schild G. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. *Virology* 143:166-174, 1985.
183. Wood JM, Kawaoka Y, Newberry LA, Bordwell E, Webster RG. Standardization of inactivated H5N2 influenza vaccine and efficacy against lethal A/chicken/Pennsylvania/1370/83 infection. *Avian Dis* 29:867-872, 1985.
184. Kawaoka Y, Webster RG. Evolution of the A/chicken/Pennsylvania/83 (H5N2) influenza virus. *Virology* 146:130-137, 1985.
185. Webster RG, Kawaoka Y, Bean WJ, Beard CW, Brugh M. Chemotherapy and vaccination: A possible strategy for the control of highly virulent influenza virus. *J Virol* 55:173-176, 1985.
186. Nettles VF, Wood JM, Webster RG. Wildlife surveillance associated with an outbreak of lethal H5N2 avian influenza in domestic poultry. *Avian Dis* 29:733-741, 1985.
187. Pereira MS, Chakraverty P, Cunningham P, Webster RG. The use of monoclonal antibodies for the antigenic analysis of influenza A viruses. *Bull WHO* 63:265-271, 1985.
188. Hinshaw VS, Wood JM, Webster RG, Deibel R, Turner B. Circulation of influenza viruses and paramyxoviruses in waterfowl originating from two different areas of North America. *Bull WHO* 63:711-719, 1985.
189. Deshpande KL, Naeve CW, Webster RG. The neuraminidases of the virulent and avirulent A/chicken/Pennsylvania/83 (H5N2) influenza A viruses: sequence and antigenic analyses. *Virology* 147:49-60, 1985.
190. Air GM, Els MC, Brown LE, Laver WG, Webster RG. Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase. *Virology* 145:237-248, 1985.
191. Berton MT, Webster RG. The antigenic structure of the influenza B virus hemagglutinin: Operational and topological mapping with monoclonal antibodies. *Virology* 143:583-594, 1985.

192. Feldman S, Wright PF, Webster RG, Roberson PK, Mahoney J, Thompson J, Doolittle M, Lott L, Johnson P, Christoph RC. Use of influenza A virus vaccines in seronegative children: Live coldadapted versus inactivated whole virus. *J Infect Dis* 152:1212-1218, 1985.

193. Webster RG, Kawaoka Y, Bean WJ Jr. Molecular changes in A/Chicken/Pennsylvania/83 (H5N2) influenza virus associated with acquisition of virulence. *Virology* 149:165-173, 1986.

194. Murti KG, Webster RG. Distribution of hemagglutinin and neuraminidase on influenza virions as revealed by immunoelectron microscopy. *Virology* 149:36-43, 1986.

195. Hinshaw VS, Bean WJ, Geraci J, Fiorelli P, Early G, Webster RG. Characterization of two influenza A viruses from a pilot whale. *J Virol* 58:655-656, 1986.

196. Hinshaw VS, Nettles VF, Schorr LF, Wood JM, Webster RG. Influenza virus surveillance in waterfowl in Pennsylvania after the H5N2 avian outbreak. *Avian Dis* 30:207-212, 1986.

197. Tulloch PA, Colman PM, Davis PC, Laver WG, Webster RG, Air GM. Electron and X-ray diffraction studies of influenza neuraminidase complexed with monoclonal antibodies. *J Mol Biol* 190:215-225, 1986.

198. Yoden S, Kida H, Kuwabara M, Yanagawa R, Webster RG. Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody. *Virus Res* 4:251-261, 1986.

199. Webster RG, Kawaoka Y, Bean WJ. Vaccinations as a strategy to reduce the emergence of amantadine- and rimantadine-resistant strains of A/Chick/ Pennsylvania/83 (H5N2) influenza virus. *J Antimicrob Chemother* 18:157-164, 1986.

200. Austin FJ, Webster RG. Antigenic mapping of an avian H1 influenza virus haemagglutinin and interrelationships of H1 viruses from humans, pigs and birds. *J Gen Virol* 67:983-992, 1986.

201. Oxford JS, Corcoran T, Knott R, Bates J, Bartolomei O, Major D, Newman RW, Robertson J, Webster RG, Schild GC. Serological studies with influenza A (H1N1) viruses cultivated in eggs or in mammalian cells. *Bull WHO* 65:181-187, 1987.

202. Copeland CS, Doms RW, Bolzan EM, Webster RG, Helenius A. Assembly of influenza hemagglutinin trimers and its role in intracellular transport. *J Cell Biol* 103:1179-1191, 1987.

203. Katz JM, Naeve CW, Webster RG. Host cell-mediated variation in H3N2 influenza viruses. *Virology* 156:386-395, 1987.

204. Shortridge KF, King AP, Webster RG. Monoclonal antibodies for characterizing H3N2 influenza viruses that persist in pigs in China. *J Infect Dis* 155:577-581, 1987.

205. Kawaoka Y, Bordwell E, Webster RG. Intestinal replication of influenza A viruses in two mammalian species. *Arch Virol* 93:303-308, 1987.

206. Deshpande K, Fried VA, Ando M, Webster RG. Glycosylation affects cleavage of an H5N2 influenza virus hemagglutinin and regulates virulence. *Proc Natl Acad Sci USA* 84:36-40, 1987.

207. Laver WG, Webster RG, Colman PM. Crystals of antibodies complexed with influenza virus neuraminidase show isosteric binding of antibody to wild-type and variant antigens. *Virology* 156: 181-184, 1987.

208. Kawaoka Y, Nestorowicz A, Alexander DJ, Webster RG. Molecular analysis of the hemagglutinin genes of H5 influenza viruses: Origin of a virulent turkey strain. *Virology* 158:218-227, 1987.

209. Kida H, Kawaoka Y, Neave CW, Webster RG. Antigenic and genetic conservation of H3 influenza virus in wild ducks. *Virology* 159:109-119, 1987.

210. Colman PM, Laver WG, Varghese JN, Baker AT, Tulloch PA, Air GM, Webster RG. Three-dimensional structure of a complex of antibody with influenza virus neuraminidase. *Nature* 326:358-363, 1987.

211. Webster RG, Air GM, Metzger DW, Colman PM, Varghese JN, Baker AT, Laver WG. Antigenic structure and variation in an influenza virus N9 neuraminidase. *J Virol* 61:2910-2916, 1987.

212. Ritchie LR, Webster RG, Laver WG, Air GM. Heterogeneity of neuraminidase genetic information in an H1N2 reassortant influenza virus [X-7(F1)]. *Arch Virol* 96:303-308, 1987.

213. Nestorowicz A, Kawaoka Y, Bean WJ, Webster RG. Molecular analysis of the hemagglutinin genes of Australian H7N7 influenza viruses: Role of Passerine birds in maintenance or transmission? *Virology* 160:411-418, 1987.

214. Chambers TM, Webster RG. Defective interfering virus associated with A/Chicken/Pennsylvania/83 influenza virus. *J Virol* 61:1517-1523, 1987.

215. Beard CW, Brugh M, Webster RG. Emergence of amantadine-resistant H5N2 avian influenza virus during a simulated layer flock treatment program. *Avian Dis* 31:533-537, 1987.

216. Webster RG, Rott R. Influenza virus A pathogenicity: The pivotal role of hemagglutinin. *Cell* 50:665-666, 1987.

217. Lentz MR, Webster RG, Air GM. Site-directed mutation of the active site of influenza neuraminidase and implications for the catalytic mechanism. *Biochemistry* 26:5351, 1987.

218. Robertson JS, Bootman JS, Newman R, Oxford JS, Daniels RS, Webster RG, Schild GC. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. *Virology* 160:31-37, 1987.

219. Air GM, Webster RG, Colman PM, Laver WG. Distribution of sequence differences in influenza N9 neuraminidase of tern and whale viruses and crystallization of the whale neuraminidase complexed with antibodies. *Virology* 160:346-354, 1987.

220. Webster RG, Reay PA, Laver WG. Protection against lethal influenza with neuraminidase. *Virology* 164:230-237, 1988.

221. Boulay F, Doms RW, Webster RG, Helenius A. Post-translational oligomerization and cooperative acid-activation of mixed influenza hemagglutinin trimers. *J Cell Biol* 106:629-639, 1988.

222. Varghese JN, Webster RG, Laver WG, Colman PM. Structure of an escape mutant of glycoprotein N2 neuraminidase of influenza virus A/Tokyo/3/67 at 3 Å. *J Mol Biol* 200:201-203, 1988.

223. Murti KG, Webster RG, Jones IM. Localization of RNA polymerases on influenza viral ribonucleoproteins by immunogold labeling. *Virology* 164:562-566, 1988.

224. Hunt LA, Brown DW, Robinson HL, Naeve CW, Webster RG. Retrovirus-expressed hemagglutinin protects against lethal influenza virus infections. *J Virol* 62:3014-3019, 1988.

225. Katz JM, Webster RG. Antigenic and structural characterization of multiple subpopulations of H3N2 influenza virus from an individual. *Virology* 165:446-456, 1988.

226. Kawaoka Y, Webster RG. Sequence requirements for cleavage activation of influenza virus hemagglutinin expressed in mammalian cells. *Proc Natl Acad Sci USA* 85:324-328, 1988.

227. Kida H, Shortridge KF, Webster RG. Origin of the hemagglutinin gene of H3N2 influenza viruses from pigs in China. *Virology* 1988 162:160-166, 1988.

228. Kawaoka Y, Chambers TM, Sladen WL, Webster RG. Is the gene pool of influenza viruses in shorebirds and gulls different from that in wild ducks? *Virology* 163:247-250, 1988.

229. Kawaoka Y, Webster RG. Molecular mechanism of acquisition of virulence in influenza virus in nature. *Microb Pathog* 5:311-318, 1988.

230. Chambers TM, Kawaoka Y, Webster RG. Protection of chickens from lethal influenza infection by vaccinia-expressed hemagglutinin. *Virology* 167:414-421, 1988.

231. Taylor J, Weinberg R, Kawaoka Y, Webster RG, Paoletti E. Protective immunity against avian influenza induced by a fowlpox virus recombinant. *Vaccine* 6:504-508, 1988.

232. Podchernyaeva RJ, Webster RG, Skvorodka VV, Klimov AI, Zhdanov VM. Molecular and biological properties of a variant of avian influenza A/Seal-Massachusetts/1/80 (H7N7) virus that is pathogenic for mice. *Acta Virol* 33:38-42, 1989.

233. Laing P, Knight JG, Hill JM, Harris AG, Oxford JS, Webster RG, Markwell MAK, Paul SM, Pert CB. Influenza viruses induce autoantibodies to a brain-specific 37-kDa protein in rabbit. *Proc Natl Acad Sci USA* 86:1998-2002, 1989.

234. Donis RO, Bean WJ, Kawaoka Y, Webster RG. Distinct lineages of influenza virus H4 hemagglutinin genes in different regions of the world. *Virology* 169:408-417, 1989.

235. Kawaoka Y, Bean WJ, Webster RG. Evolution of the hemagglutinin of Equine H3 influenza viruses. *Virology* 169:283-292, 1989.

236. Bean WJ, Threlkeld SC, Webster RG. Biologic potential of amantadine-resistant influenza A virus in an avian model. *J Infect Dis* 259:1050-1056, 1989.

237. Katz JM, Webster RG. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. *J Infect Dis* 160:191-198, 1989.

238. Webster RG, Kawaoka Y, Bean WJ. What is the potential of avirulent influenza viruses to complement a cleavable hemagglutinin and generate virulent strains? *Virology* 171:484-492, 1989.

239. Suzuki Y, Kato H, Naeve CW, Webster RG. Single-amino-acid substitution in an antigenic site of influenza virus hemagglutinin can alter the specificity of binding to cell membrane-associated gangliosides. *J Virol* 63:4298-4302, 1989.

240. Kawaoka Y, Krauss S, Webster RG. Avian-to-human transmission of the PB1 gene of influenza A virus in the 1957 and 1968 pandemics. *J Virol* 63: 4603-4608, 1989.

241. Okazaki K, Kawaoka Y, Webster RG. Evolutionary pathways of the PA genes of influenza A viruses. *Virology* 172:601-608, 1989.

242. Treanor J, Kawaoka Y, Miller R, Webster RG, Murphy B. Nucleotide sequence of the avian influenza A/Mallard/NY/6750/78 virus polymerase genes. *Virus Res* 14:257-270, 1989.

243. Chambers TM, Yamnikova S, Kawaoka Y, Lvov DK, Webster RG. Antigenic and molecular characterization of subtype H13 hemagglutinin of influenza virus. *Virology* 172:180-188, 1989.

244. Yamnikova SS, Kovtun TO, Dmitriev GA, Shemyakin IG, Semenova NP, Lvov DK, Chambers T, Webster RG. Antigenic variability of avian influenza A/H13 viruses isolated in the USSR. *Problems in Virology* 5:568-572, 1989.

245. Air GM, Laver WG, Webster RG, Els MC, Luo M. Antibody recognition of the influenza virus neuraminidase. *Cold Spring Harb Symp Quant Biol* 54:247-255, 1989.

246. Kawaoka Y, Webster RG. Origin of the hemagglutinin on A/Equine/Johannesburg/86 (H3N8): The first known equine influenza outbreak in South Africa. *Arch Virol* 106:159-164, 1989.

247. Kawaoka Y, Webster RG. Interplay between carbohydrate in the stalk and the length of the connecting peptide determines the cleavability of influenza virus hemagglutinin. *J Virol* 63:3296-3300, 1989.

248. Colman PM, Tulip WR, Varghese JN, Tulloch PA, Baker AT, Laver WG, Air GM, Webster RG. Three-dimensional structures of influenza virus neuraminidase-antibody complexes. *Phil Trans R Soc Lond [Biol]* 323:511-518, 1989.

249. Tulip WR, Varghese JN, Webster RG, Air GM, Laver WG, Colman PM. Crystal structures of neuraminidase-antibody complexes. *Cold Spring Harb Symp Quant Biol* 54:257-264, 1989.

250. Yamnikova SS, Chambers TM, Dmitriev GA, Chemyakin IG, Semenova NP, Webster RG, Lvov DK. Antigenic variability of avian influenza viruses A/H13 isolated in the USSR. *Voprosii Virologii* 5:568-572, 1989.

250a. Wang M, Katz JM, Webster R. Extensive heterogeneity in the hemagglutinin of egg-grown influenza viruses from different patients. *Virology* 171:275-279, 1989.

251. Mandler J, Gorman OT, Ludwig S, Schroeder E, Fitch WM, Webster RG, Scholtissek C. Derivation of the nucleoproteins (NP) of influenza A viruses isolated from murine mammals. *Virology* 176:255-261, 1990.

252. Gorman OT, Bean WJ, Kawaoka Y, Webster RG. Evolution of the nucleoprotein gene of influenza A virus. *J Virol* 64:1487-1497, 1990.

253. Katz JM, Wang M, Webster RG. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. *J Virol* 64:1808-1811, 1990.

254. Air GM, Gibbs AJ, Laver WG, Webster RG. Evolutionary changes in influenza B are not primarily governed by antibody selection. *Proc Natl Acad Sci* 87:3884-3888, 1990.

255. Laver WG, Air GM, Webster RG, Smith-Gill SJ. Epitopes on protein antigens: Misconceptions and realities. *Cell* 61:553-556, 1990.

256. Air GM, Laver WG, Luo M, Stray SJ, Legrone G, Webster RG. Antigenic, sequence and crystal variation in influenza B neuraminidase. *Virology* 177:578-587, 1990.

257. Wang M, Webster RG. Lack of persistence of influenza virus genetic information in ducks. *Arch Virol* 111:263-268, 1990.

258. Austin FJ, Kawaoka Y, Webster RG. Molecular analysis of the haemagglutinin gene of an avian H1N1 influenza virus. *J Gen Virol* 71:2471-2474, 1990.

259. Lambré CR, Terzidis H, Creffard A, Webster RG. Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. *J Immunol Methods* 135:49-57, 1990.

260. Lin Y, Luo M, Laver WG, Air GM, Smith CD, Webster RG. New crystalline forms of neuraminidase of type B human influenza virus. *J Mol Biol* 214:639-640, 1990.

261. Chambers TM, Essani K, Webster RG. Conditional expression of foreign genes by temperature-sensitive mutants of vaccinia virus. *Gene* 95:275-278, 1990.

262. Gorman OT, Donis RO, Kawaoka Y, Webster RG. Evolution of influenza A virus PB2 genes: Implications for evolution of the ribonucleoprotein complex and origin of human influenza A virus. *J Virol* 64:4893-4902, 1990.

263. Kawaoka Y, Yamnikova S, Chambers TM, Lvov DK, Webster RG. Molecular characterization of a new hemagglutinin, subtype H14, of influenza A virus. *Virology* 179:759-767, 1990.

264. Air GM, Laver WG, Webster RG. Mechanism of antigenic variation in an individual epitope on influenza virus N9 neuraminidase. *J Virol* 64:5797-5803, 1990.

265. Tamura M, Webster RG, Ennis FA. Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry. *Virology* 182:211-219, 1991.

266. Webster RG, Kawaoka Y, Taylor J, Weinberg R, Paoletti E. Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. *Vaccine* 9:303-306, 1991.

267. Webster RG, Yuanji G. New influenza virus in horses. *Nature* 351:527, 1991.

268. Chambers TM, Hinshaw VS, Kawaoka Y, Easterday BC, Webster RG. Influenza viral infection of swine in the United States 1988-1989. *Arch Virol* 116: 261-265, 1991.

269. Chambers TM, Webster RG. Protection of chickens from lethal influenza virus infection by influenza A/Chicken/Pennsylvania/1/83 Virus: Characterization of the protective effect. *Virology* 183:427-432, 1991.

270. Gorman OT, Bean WJ, Kawaoka Y, Donatelli I, Guo Y, Webster RG. Evolution of influenza A virus nucleoprotein genes: Implications for the origins of H1N1 human and classical swine viruses. *J Virol* 65: 3704-3714, 1991.

271. Banbara MW, Kawaoka Y, Thomas TL, Webster RG. Reassortants with Equine 1 (H7N7) influenza virus hemagglutinin in an Avian influenza virus genetic background are pathogenic in chickens. *Virology* 184: 469-471, 1991.

272. Eichelberger MC, Wang M, Allan W, Webster RG, Doherty PC. Influenza virus RNA in the lung and lymphoid tissue of immunologically intact and CD4-depleted mice. *J Gen Virol* 72:1695-1698, 1991.

273. Jackson DC, Tang H-L, Murti KG, Webster RG, Tregear GW, Bean WJ. Electron microscopic evidence for the association of M2 protein with the influenza virus. *Arch Virol* 118:199-207, 1991.

274. Beare AS, Webster RG. Replication of avian influenza virus in humans {occurs with types H4N8, H6N1 and H10N7, but not with H1N1 or H3N2. Infection results in mild symptoms, without detectable antibody response}. *Arch Virol* 119(1/2):37-42, 1991.

275. Tulip WR, Varghese JN, Baker AT, van Donkelaar A, Laver WG, Webster RG, Colman PM. The refined atomic structures of N9 subtype influenza virus neuraminidase and escape mutants. *J Mol Biol* 221(2): 487-497, 1991.

276. Ito T, Gorman OT, Kawaoka Y, Bean WJ, Webster RG. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. *J Virol* 65:5491-5498, 1991.

277. Yuanji G, Webster RG, Min W, Hongyong Z. Further study on origin of H3N8 subtype of influenza A virus in horses in China. *Chin J Exp Clin Virol* 5:263-270, 1991.

278. Banbara M, Webster RG, Cooper M, Doherty PC. Size and frequency characteristics of $\square\Box$ and $\Box\Box$ T cells in the spleens of normal and cyclophosphamide-suppressed virus-infected chickens. *Cell Immunol* 136:242-250, 1991.

279. Marx PA, Li Y, Lerche NW, Sutjipto S, Gettie A, Yee JA, Brotman BH, Prince AM, Hanson A, Webster R, Desrosiers RC. Simian immunodeficiency virus related to human immunodeficiency virus Type 2 from a West African Pet Sooty Mangabey. *J Virol* 65:4480-4485, 1991.

280. Murti KG, Brown PS, Bean WJ Jr, Webster RG. Composition of the helical internal components of influenza virus as revealed by immunogold labeling-electron microscopy. *Virology* 186:294-299, 1992.

281. Bean WJ, Schell M, Katz J, Kawaoka Y, Naeve C, Gorman O, Webster RG. Evolution of the H3 influenza virus hemagglutinin from human and nonhuman hosts. *J Virol* 66:1129-1138, 1992.

282. Ryan-Poirer KA, Katz JM, Webster RJ, Kawaoka Y. Application of directigen FLU-A for the detection of influenza A virus in human and nonhuman specimens. *J Clin Microbiol* 30:1072-1075, 1992.

283. Guo Y, Wang M, Kawaoka Y, Gorman O, Ito T, Saito T, Webster RG. Characterization of a new avian-like influenza A virus from horses in China. *Virology* 188:245-255, 1992.

284. Herlocher ML, Bucher D, Webster RG. Host range determination and functional mapping of the nucleoprotein and matrix genes of influenza viruses using monoclonal antibodies. *Virus Res* 22:281-293, 1992.

285. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses (review). *Microbiol Rev* 56(1):152-179, 1992.

286. Klimov AI, Markushin SG, Prosch S, Ginzburg VP, Heider H, Heider AM, Schroeder C, Webster RG. Relation between drug resistance and antigenicity among norakine-resistant mutants of influenza A (fowl plague) virus. *Arch Virol* 124(1/2):147-156, 1992.

287. Katz JM, Webster RG. Amino acid sequence identity between the HA1 of influenza A (H3N2) viruses grown in mammalian and primary chick kidney cells. *J Gen Virol* 73(5):1159-1165, 1992.

288. Gorman OT, Bean WJ, Webster RG. Evolutionary processes in influenza viruses: Divergence, rapid evolution, and stasis. *Curr Top Microbiol Immunol* 176:75-97, 1992.

289. Guo Y, Webster RG, Min W, Hongyong S, Zhongmin G, Rigetai Z. Genetic studies on influenza viruses isolated from horses in China. *Chin J Exp Clin Virol* 6:119-124, 1992.

290. Wright SM, Kawaoka Y, Sharp GV, Senne DA, Webster RG. Interspecies transmission and reassortment of influenza A viruses in pigs and turkeys in the United States. *Am J Epidemiol* 136:488-497, 1992.

291. Brown DW, Kawaoka Y, Webster RG, Robinson HL. Assessment of retrovirus-expressed nucleoprotein as a vaccine against lethal influenza virus infections of chickens. *Avian Dis* 36:515-520, 1992.

292. Tulip WR, Varghese JN, Laver WG, Webster RG, Colman PM. Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex. *J Mol Biol* 227:122-148, 1992.

293. Tulip WR, Varghese JN, Webster RG, Laver WG, Colman PM. Crystal structures of two mutant neuraminidase-antibody complexes with amino acid substitutions in the interface. *J Mol Biol* 227:149-159, 1992.

294. Castrucci MR, Donatelli I, Sidoli L, Barigazzi G, Kawaoka Y, Webster RG. Genetic reassortment between avian and human influenza A viruses in Italian pigs. *Virology* 193:503-506, 1993.

295. Malby RL, Caldwell JB, Gruen LC, Harley VR, Ivancic N, Kortt AA, Lilley GC, Power BE, Webster RG, Colman PM, Hudson PJ. Recombinant antineuraminidase single chain antibody: Expression, characterization, and crystallization in complex with antigen. *Proteins: Structure, Function and Genetics* 16:57-63, 1993.

296. Sharp GB, Kawaoka Y, Wright SM, Turner B, Hinshaw V, Webster RG. Wild ducks are the reservoir for only a limited number of influenza A subtypes. *Epidemiol Infect* 110:161-176, 1993.

297. Saito T, Kawaoka Y, Webster RG. Phylogenetic analysis of the N8 neuraminidase gene of influenza A viruses. *Virology* 193:868-876, 1993.

298. Alstad AD, Sahu SP, Pedersen DD, Saari DA, Kawaoka Y, Webster RG. Pathogenic studies and antigenic and sequence comparison of A/equine/Alaska/1/91 (H3N8) influenza virus. *J Vet Diagn Invest* 5:8-11, 1993.

299. Taylor G, Garman E, Webster R, Saito T, Laver G. Crystallization and preliminary X-ray studies of influenza A virus neuraminidase of subtypes N5, N6, N8 and N9. *J Mol Biol* 230:345-348, 1993.

300. Shu LL, Bean WJ, Webster RG. Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990. *J Virol* 67:2723-2729, 1993.

301. Webster RG, Wright SM, Castrucci MR, Bean WJ, Kawaoka Y. Influenza - a model of an emerging virus disease. *Intervirology* 35:16-25, 1993.

302. Herlocher ML, Maassab HF, Webster RG. Molecular and biological changes in the cold-adapted "master strain" A/AA/6/60 (H2N2) influenza virus. *Proc Natl Acad Sci USA* 90:6032-6036, 1993.

303. Webster RG, Thomas TL. Efficacy of equine influenza vaccines for protection against A/Equine/Jilin/89 (H3N8) - a new equine influenza virus. *Vaccine* 11:987-993, 1993.

304. Schäfer JR, Kawaoka Y, Bean WJ, Süss J, Senne D, Webster RG. Origin of the pandemic 1957 H2 influenza A virus and the persistence of its possible progenitors in the avian reservoir. *Virology* 194:781-788, 1993.

305. Laudert E, Sivanandan V, Halvorson D, Shaw D, Webster RG. Biological and molecular characterization of H13N2 influenza type A viruses isolated from turkeys and surface water. *Avian Dis* 37:793-799, 1993.

306. Webster R. Are equine 1 influenza viruses still present in horses? *Equine Vet J* 25:537-538, 1993.

307. Meyer WJ, Wood JM, Major D, Robertson JS, Webster RG, Katz JM. Influence of host cell-mediated variation on the international surveillance of influenza A (H3N2) viruses. *Virology* 196:130-137, 1993.

308. Austin FJ, Webster RG. Evidence of ortho- and paramyxoviruses in fauna from Antarctica. *J Wildlife Dis* 29:568-571, 1993.

309. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. *Proc Natl Acad Sci USA* 90:11478-11482, 1993.

310. Webster RG. Influenza: A constantly emerging disease. *Karger Gazette* 57:1-3, 1993.

311. Robinson HL, Hunt LA, Webster RG. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. *Vaccine* 11:957-960, 1993.

312. Brown IH, Manvell RJ, Alexander DJ, Chakraverty P, Hinshaw VS, Webster RG. Swine influenza outbreaks in England due to a new H1N1 virus. *Vet Rec* 132:461-462, 1993.

313. Lin YP, Shu LL, Wright S, Bean WJ, Sharp GB, Shortridge KF, Webster RG. Analysis of the influenza virus gene pool of avian species from Southern China. *Virology* 198:557-566, 1994.

314. Arnold GF, Resnick DA, Yuling L, Zhang A, Smith AD, Geisler SC, Jacobo-Molina A, Lee W-M, Webster RG, Arnold E. Design and construction of rhinovirus chimeras incorporating immunogens from polio, influenza, and human immunodeficiency viruses. *Virology* 198:703-708, 1994.

315. Saito T, Taylor G, Laver WG, Kawaoka Y, Webster RG. Antigenicity of the N8 influenza A virus neuraminidase: Existence of an epitope at the subunit interface of the neuraminidase. *J Virol* 68:1790-1796, 1994.

316. Gubareva LV, Wood JM, Meyer WJ, Katz JM, Robertson JS, Major D, Webster RG. Codominant mixtures of viruses in reference strains of influenza virus due to host cell variation. *Virology* 199:89-97, 1994.

317. Süss J, Schäfer J, Sinnecker H, Webster RG. Influenza virus subtypes in aquatic birds of Eastern Germany. *Arch Virol* 135:101-114, 1994.

318. Saito T, Horimoto T, Kawaoka Y, Senne DA, Webster RG. Emergence of a potentially pathogenic H5N2 influenza virus in chickens. *Virology* 201:277-284, 1994.

319. Shu LL, Lin YP, Wright SM, Shortridge KF, Webster RG. Evidence for interspecies transmission and reassortment of influenza A viruses in pigs in Southern China. *Virology* 202:825-833, 1994.

320. Webster R, Chambers TM. China 'Flu'. *Equine Disease Quarterly* 2:1, 1994.

321. Kortt AA, Malby RL, Caldwell JB, Gruen LC, Ivancic N, Lawrence MC, Howlett GJ, Webster RG, Hudson PJ, Colman PM. Recombinant anti-sialidase single-chain variable fragment antibody characterization. Formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex. *Eur J Biochem* 221:151-157, 1994.

322. Tulip WR, Harley VR, Webster RG, Novotny J. N9 neuraminidase complexes with antibodies NC41 and NC10: empirical free-energy calculations capture specificity trends observed with mutant binding data. *Biochemistry* 33:7986-7997, 1994.

323. Malby RL, Tulip WR, Harley VR, McKimm-Breschkin JL, Laver WG, Webster RG, Colman PM. The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody. *Structure* 2:733-746, 1994.

324. Lai ACK, Lin YP, Powell DG, Shortridge KF, Webster RG, Daly J, Chambers TM. Genetic and antigenic analysis of the influenza virus responsible for the 1992 Hong Kong equine influenza epizootic. *Virology* 204:673-679, 1994.

325. Claas ECJ, Kawaoka Y, de Jong JC, Masurel N, Webster RG. Infection of children with avian-human influenza virus from pigs in Europe. *Virology* 204:453-457, 1994.

326. Webster RG, Fynan EF, Santoro JC, Robinson HL. Protection of ferrets against influenza challenge with a DNA vaccine to the haemagglutinin. *Vaccine* 12:1495-1498, 1994.

327. Kida H, Ito T, Yasuda J, Shimizu Y, Itakura C, Shortridge KF, Kawaoka Y, Webster RG. Potential for transmission of avian influenza viruses to pigs. *J Gen Virol* 75:2183-2188, 1994.

328. Connor RJ, Kawaoka Y, Webster RG, Paulson JC. Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates. *Virology* 205:17-23, 1994.

328a. Webster, R. While awaiting the next pandemic of influenza A. *BMJ* 309:1179-1180, 1994.

329. Toth LA, Rehg JE, Webster RG. Strain differences in sleep and other pathophysiological sequelae of influenza virus infection in naive and immunized mice. *J Neuroimmunol* 58:89-99, 1995.

330. Kaverin NV, Webster RG. Impairment of multicycle influenza virus growth in vero (WHO) cells by loss of trypsin activity. *J Virol* 69:2700-2703, 1995.

331. Govorkova EA, Kaverin NV, Gubareva LV, Meignier B, Webster RG. Replication of influenza A viruses in a green monkey kidney continuous cell line (Vero). *J Infect Dis* 172:250-253, 1995.

332. Röhm C, Horimoto T, Kawaoka Y, Süss J, Webster RG. Do hemagglutinin genes of highly pathogenic avian influenza viruses constitute unique phylogenetic lineages? *Virology* 209:664-670, 1995.

333. Saito T, Taylor G, Webster RG. Steps in maturation of influenza A virus neuraminidase. *J Virol* 69:5011-5017, 1995.

334. Ito T, Okazaki K, Kawaoka Y, Takada A, Webster RG, Kida H. Perpetuation of influenza A viruses in Alaskan waterfowl reservoirs. *Arch Virol* 140:1163-1172, 1995.

335. Hardy CT, Young SA, Webster RG, Naeve CW, Owens RJ. Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses. [Short communication]. *Virology* 211:302-306, 1995.

336. Kodihalli S, Justewicz DM, Gubareva LV, Webster RG. Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective. *J Virol* 69:4888-4897, 1995.

337. Guo Y, Wang M, Zheng G-S, Li W-K, Kawaoka Y, Webster RG. Seroepidemiological and molecular evidence for the presence of two H3N8 equine influenza viruses in China in 1993-94. *J Gen Virol* 76:2009-2014, 1995.

338. Justewicz DM, Doherty PC, Webster RG. The B-cell response in lymphoid tissue of mice immunized with various antigenic forms of the influenza virus hemagglutinin. *J Virol* 69:5414-5421, 1995.

339. Horimoto T, Rivera E, Pearson J, Senne D, Krauss S, Kawaoka Y, Webster RG. Origin and molecular changes associated with emergence of a highly pathogenic H5N2 influenza virus in Mexico. *Virology* 213:223-230, 1995.

340. Gubareva LV, Penn CR, Webster RG. Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneurameric acid. *Virology* 212:323-330, 1995.

341. Justewicz DM, Morin MJ, Robinson HL, Webster RG. Antibody-forming cell response to virus challenge in mice immunized with DNA encoding the influenza virus hemagglutinin. *J Virol* 69:7712-7717, 1995.

342. Webster RG, Sharp GB, Claas ECJ. Interspecies transmission of influenza viruses. *Am J Respir Crit Care Med* 152:S25-S30, 1995.

343. Abbasi S, Gruber W, Edwards K, Gubareva L, Webster RG, Kawaoka Y. The HA1 of cold-adapted influenza B vaccine is not altered during replication human vaccines. *Virus Res* 39:377-383, 1995.

344. Rohm C, Zhou N, Suss J, Mackenzie J, Webster RG. Characterization of a novel influenza hemagglutinin, H15: Criteria for determination of influenza A subtypes. *Virology* 217:508-516, 1996.

345. Robinson HL, Lu S, Feltquate DM, Torres CT, Richmond J, Boyle CM, Morin MJ, Santoro JC, Webster RG, Montefiori D, Yasutomi Y, Letvin NL, Manson K, Wyand M, Haynes JR. DNA Vaccines. *AIDS Res Hum Retroviruses* 12:455-457, 1996.

346. Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-Guanidino-Neu5Ac2en. *J Virol* 70:1818-1827, 1996.

347. Röhm C, Süss J, Pohle V, Webster RG. Different hemagglutinin cleavage site variants of H7N7 in an influenza outbreak in chickens in Leipzig, Germany. *Virology* 218:253-257, 1996.

348. Zhou N, He S, Zhang T, Zou W, Shu L, Sharp GB, Webster RG. Influenza infection in humans and pigs in southeastern China. *Arch Virol* 141:649-661, 1996.

349. Webster RG, Taylor J, Pearson J, Rivera E, Paoletti E. Immunity to Mexican H5N2 avian influenza viruses induced by a fowl pox-H5 recombinant. *Avian Dis* 40:461-465, 1996.

350. Senne DA, Panigrahy B, Kawaoka Y, Pearson JE, Süss, Lipkind M, Kida H, Webster RG. Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential. *Avian Dis* 40:425-437, 1996.

351. Govorkova EA, Murti G, Meignier B, de Taisne C, Webster RG. African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. *J Virol* 70:5519-5524, 1996.

352. Shu LL, Sharp GB, Lin YP, Claas ECJ, Krauss SL, Shortridge KF, Webster RG. Genetic reassortment in pandemic and interpandemic influenza viruses. A study of 122 viruses infecting humans. *Eur J Epidemiol* 12:63-70, 1996.

353. Boyle CM, Morin M, Webster RG, Robinson HL. Role of different lymphoid tissues in the initiation and maintenance of DNA-raised antibody responses to the influenza virus H1 glycoprotein. *J Virol* 70:9074-9078, 1996.

354. Shu LL, Zhou NN, Sharp GB, He SQ, Zhang TJ, Zou WW, Webster RG. An epidemiological study of influenza viruses among Chinese farm families with household ducks and pigs. *Epidemiol Infect* 117:179-188, 1996.

355. Justewicz DM, Webster RG. Long-term maintenance of B cell immunity to influenza virus hemagglutinin in mice following DNA-based immunization. *Virology* 224:10-17, 1996.

356. Guan Y, Shortridge KF, Krauss S, Li PH, Kawaoka Y, Webster RG. Emergence of avian H1N1 influenza viruses in pigs in China. *J Virol* 70:8041-8046, 1996.

357. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-Guanidino-Neu5Ac2en. *J Virol* 71:3385-3390, 1997.

358. Kodihalli S, Haynes JR, Robinson HL, Webster RL. Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin. *J Virol* 71:3391-3396, 1997.

359. Feltquate DM, Heaney S, Webster RG, Robinson HT. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. *J Immunol* 158:2278-2284, 1997.

360. Campitelli L, Donatelli I, Foni E, Castrucci MR, Fabiani C, Kawaoka Y, Krauss S, Webster RG. Continued evolution of H1N1 and H3N2 influenza viruses in pigs in Italy. *Virology* 232:210-218, 1997.

361. Webster R. Predictions for future human influenza pandemics. *J Infect Dis* 176(Suppl 1):S14-19, 1997.

362. Sharp G, Kawaoka Y, Jones DJ, Bean WJ, Pryor SP, Hinshaw V, Webster RG. Coinfection of wild ducks by influenza A viruses: Distribution patterns and biological significance. *J Virol* 71(8): 6128-6135, 1997.

363. Robinson HL, Boyle CA, Feltquate DM, Morin MJ, Santoro JC, Webster RG. DNA immunization for influenza virus: Studies using hemagglutinin- and nucleoprotein-expressing DNAs. *J Infect Dis* 176(Suppl 1):S50-5, 1997.

364. Webster RG, Robinson HL. DNA vaccines. *BioDrugs* 8(4):273-292, 1997.

365. Webster RG, Shortridge KF, Kawaoka Y. Influenza: interspecies transmission and emergence of new pandemics. *FEMS Immunol Med Microbiol* 18:275-279, 1997.

366. Webster RG. Influenza virus: transmission between species and relevance to emergence of the next human pandemic. *Arch Virol (Suppl)* 13:105-113, 1997.

367. DeJong JC, Claas ECJ, Osterhaus ADME, Webster RG, Lim WL. A pandemic warning? *Nature* 389:554, 1997.

368. Claas ECJ, Osterhaus ADME, van Beek R, DeJong JC, Rimmelzwaan GF, Senne DA, Krauss S, Shortridge KF, Webster RG. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. *Lancet* 351:472-477, 1998.

369. Scholtissek C, Quack G, Klenk HD, Webster RG. How to overcome resistance of influenza A viruses against adamantane derivatives. *Antiviral Res* 32:83-95, 1998.

370. Scholtissek C, Webster RG. Long-term stability of the anti-influenza A compounds -- amantadine and rimantadine. *Antiviral Res* 213-215, 1998.

371. Garica A, Johnson H, Srivastava DK, Jayawardene DA, Wehr DR, Webster RG. Efficacy of inactivated H5N2 influenza vaccines against lethal A/Chicken/Queretarol/19/95 infection. *Avian Dis* 42:248-256, 1998.

372. Chen Y, Webster RG, Woodland DL. Induction of CD8⁺ T cell responses to dominant and subdominant epitopes and protective immunity to Sendai virus infection by DNA vaccination. *J Immunol* 160:2425-2432, 1998.

373. Ito T, Nelson J, Couceiro SS, Kelm S, Baum LG, Krauss S, Castrucci MR, Donatelli I, Kida H, Paulson JC, Webster RG, Kawaoka Y. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. *J Virol* 72:7367-7373, 1998.

374. Webster, R. Influenza: An emerging disease. *Emerging Infectious Diseases* 4:436-441, 1998.

375. Alymova IV, Kodihalli S, Govorkova EA, Fanget B, Gerdil C, Webster RG. Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs. *J Virol* 72:4472-4477, 1998.

376. Kawaoka Y, Gorman OT, Ito T, Wells K, Donis RO, Castrucci MR, Donatelli I, Webster RG. Influence of host species on the evolution of the nonstructural (NS) gene of influenza A viruses. *Virus Res* 55:143-156, 1998.

377. Gubareva LV, McCullers JA, Bethell RC, Webster RG. Characterization of influenza A/Hong Kong/156/97 (H5N1) in a mouse model and protective effect of zanamivir on H5N1 infection in mice. *J Infect Dis* 178:1592-1596, 1998.

378. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. *J Infect Dis* 178:1257-1262, 1998.

379. Shortridge KF, Zhou NN, Guan Y, Gao P, Ito T, Kawaoka Y, Kodihalli S, Krauss S, Markwell D, Murti KG, Norwood M, Senne D, Sims L, Takada A, Webster RG. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. *Virology* 252:331-342, 1998.

380. Riberdy JM, Flynn KJ, Stech J, Webster RG, Altman JD, Doherty, PC. Protection against a lethal avian influenza A virus in a mammalian system. *J Virol* 73:1453-1459, 1999.

381. Matrosovich M, Zhou N, Kawaoka Y, Webster R. The surface glycoproteins of H5 influenza viruses isolated from humans, chickens and wild aquatic birds have distinguishable properties. *J Virol* 73:1146-1155, 1999.

382. Stech J, Xiong X, Scholtissek C, Webster RG. Independence of evolutionary and mutational rates after transmission of avian influenza viruses to swine. *J Virol* 73:1878-1884, 1999.

383. Kodihalli S, Goto H, Kobasa DL, Krauss S, Kawaoka Y, Webster RG. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. *J Virol* 73:2094-2098, 1999.

384. Webster RG. 1918 Spanish influenza: the secrets remain elusive. *Proc Natl Acad Sci USA* 96:1164-1166, 1999.

385. Zhou NN, Shortridge KF, Claas, ECJ, Krauss SL, Webster RG. Rapid evolution of H5N1 influenza viruses in chickens in Hong Kong. *J Virol* 73:3366-3374, 1999.

386. Webster RG. Potential advantages of DNA immunization for influenza epidemic and pandemic planning. *Clin Infect Dis* 28:225-229, 1999.

387. Caver TE, Lockey TD, Srinivas RV, Webster RG, Hurwitz JL. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation. *Vaccine* 17:1567-1572, 1999.

388. Gubareva LV, Webster RG. Neuraminidase inhibitors: new candidate drugs for influenza. *Infections in Medicine* 16:345-355, 1999.

389. McCullers JA, Facchini S, Chesney PJ, Webster RG. Influenza B Virus Encephalitis. *Clin Infect Dis*. 28:898-900, 1999.

390. Guan Y, Shortridge KF, Krauss S, Webster RG. Molecular characterization of H9N2 influenza viruses: were they the donors of the "internal" genes of H5N1 viruses in Hong Kong? *Proc Natl Acad Sci USA* 96:9363-9367, 1999.

391. McCullers JA, Wang GC, He S, Webster RG. Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in nature. *J Virol*. 73:7343-7348, 1999.

392. Gorvokova EA, Matrosovich MN, Tuzikov AB, Bovin NV, Gerdil C, Fanget B, Webster RG. Selection of receptor-binding variants of human influenza A and B viruses in baby hamster kidney cells. *Virology*. 262:31-38, 1999.

393. Zhou NN, Senne DA, Landgraf JS, Swenson SL, Erickson G, Rossow K, Liu L, Yoon KJ, Krauss S, Webster RG. Genetic reassortment of avian, swine, and human influenza A viruses in American pigs. *J Virol*. 73:8851-8856, 1999.

394. Makarova NA, Kaverin NV, Krauss S, Senne D, Webster RG. Transmission of Eurasian avian H2 influenza virus to shorebirds in North America. *J Gen Virol*. 80:3167-3171, 1999.

395. Govorkova EA, Kodihalli S, Alymova IV, Fanget B., Webster RG. Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs. *Dev Biol Stand*. 98:39-51, 1999.

396. Guo YJ, Krauss S, Senne DA, Mo IP, Lo KS, Xiong XP, Norwood M, Shortridge KF, Webster RG, Guan Y. Characterization of the pathogenicity of members of the newly established H9N2 influenza virus lineages in Asia. *Virology* 267:279-288, 2000.

397. Hoffmann E, Neumann G, Hobom G, Webster RG, Kawaoka Y. "Ambisense" approach for the generation of influenza A virus: vRNA and mRNA synthesis from one template. *Virology*. 267:310-317, 2000.

398. Laver WG, Bischofberger N, Webster, RG. The origin and control of pandemic influenza. *Perspect Biol Med*. 43:173-192, 2000.

399. Webster RG. Immunity to influenza in the elderly. *Vaccine* 18:1686-1689, 2000.

400. Shortridge KF, Gao P, Guan Y, Ito T, Kawaoka Y., Markwell D, Takada A, Webster RG. Interspecies transmission of influenza viruses: H5N1 virus and a Hong Kong SAR perspective. *Vet Microbio* 74:141-147, 2000.

401. Kodihalli S, Kobasa DL, Webster RG. Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines. *Vaccine* 18: 2592-2599, 2000.

402. Hoffmann E, Neumann N, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. *Proc Natl Acad Sci USA* 97:6108-6113, 2000.

403. Hoffmann E, Stech J, Leneva I, Krauss S, Scholtissek C, Chin PS, Peiris M, Shortridge KF, Webster RG. Characterization of the influenza A virus gene pool in avian species in Southern China: Was H6N1 a derivative or a precursor of H5N1? *J Virol.* 74:6309-6315, 2000.

404. Kaverin NV, Smirnov YA, Govorkova EA, Rudneva IA, Gitelman AK, Lipatov AS, Varich NL, Yamnikova SS, Makarova NV, Webster RG, Lvov DK. Cross-protection and reassortment studies with avian H2 influenza viruses. *Arch Virol* 145:1059-1066, 2000.

405. Lin YP, Shaw M, Gregory V, Cameron K, Lim W, Klimov A, Subbarao K, Guan Y, Krauss S, Shortridge K, Webster R, Cox N, Hay A. Avian-to-human transmission of H9N2 subtype influenza A viruses: Relationship between H9N2 and H5N1 human isolates. *Proc Natl Acad Sci USA* 97: 9654-9658, 2000.

406. Webby RJ, Swenson SL, Krauss SL, Gerrish PJ, Goyal SM, Webster RG. Evolution of swine H3N2 influenza viruses in the United States. *J. Virol.* 74:8243-8251, 2000.

407. O'Neill E, Krauss SL, Riberdy JM, Webster RG, Woodland DL. Heterologous protection against lethal A/HongKong/156/97(H5N1) infection in C57BL/6 mice. *J. Gen Virol.* 81:2689-2696, 2000.

408. Guan Y, Shortridge KF, Krauss S, Chin PS, Dyrting KC, Ellis TM, Webster RG, Peiris M. H9N2 influenza viruses possessing H5N1-like internal genomes continue to circulate in poultry in southeastern China. *J. Virol.* 74:9372-9380, 2000.

409. Leneva IA, Roberts N, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. *Antiviral Res. Antiviral Res.* 48:101-115, 2000.

410. Hoffmann E and Webster RG. Unidirectional RNA polymerase I-polymerase II transcription system for the generation of influenza A virus from eight plasmids. *J Gen. Virol.* 81:2843-2847, 2000.

411. Seo HS and Webster RG. Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. *J Virol* 75:2516-2525, 2001.

412. Leneva IA, Goloubeva O, Fenton RJ, Tisdale M and Webster RG. Efficacy of Zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. *Antimicrob Agents Chemother* 45:1216-1224, 2001.

413. Matrosovich M, Krauss S and Webster RG. H9N2 Influenza A Viruses from poultry in Asia have human virus-like receptor specificity. *Virology* 281:156-162, 2001.

414. Donatelli I, Campitelli L, Di Trani L, Puzelli S, Sell L, Fioretti A, Alexander D, Tollis M, Krauss S and Webster RG. Characterization of H5N2 influenza viruses from Italian poultry. *J Gen Virol* 82:623-630, 2001.

415. D'Costa S, Slobod KS, Webster RG, White SW and Hurwitz JL. Structural features of HIV envelope defined by antibody escape mutant analysis. *Aids Res Hum Retroviruses* 17:1205-1209, 2001.

416. Seo SH, Goloubeva O, Webby R and Webster RG. Characterization of a porcine lung epithelial cell line suitable for influenza virus studies. *J Virol* 75:9517-9525, 2001.

417. Govorkova EA, Leneva IA, Goloubeva OG, Bush K and Webster RG. Comparison of Efficacies of RWJ-270201, Zanamivir, and Oseltamivir against H5N1, H9N2, and Other Avian Influenza Viruses. *Antimicrob Agents Chemother* 45:2723-2732, 2001.

418. Webster, RG. Influenza – Challenges at the beginning of the new millennium. *Influenza* 2:5-18, 2001.
{W:\02427\100G772000\00263838.DOC *02427100G772000* }

419. Webster RG. Virology. A molecular whodunit. *Science* 293:1773-1775, 2001.

420. Peiris JS, Guan Y, Markwell D, Ghose P, Webster RG, Shortridge KF. Cocirculation of avian H9N2 and contemporary "human" H3N2 influenza A viruses in pigs in southeastern China: potential for genetic reassortment? *J Virol* 75:9679-9686, 2001.

421. Gubareva LV, Webster RG and Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor resistant variants. *Antimicrob Agents and Chemother*. 45:3403-3408, 2001.

422. Webby RJ, Swenson SL, Krauss SL, Goyal SM, Rossow KD, Webster RG. Evolving H3N2 and emerging H1N2 swine influenza viruses in the United States. *International Congress Series* 1219:241-249, 2001.

423. O'Neill E, Seo SH, Woodland DL, Shortridge KF, Webster RG. Infection with H9N2 viruses confers immunity against lethal H5N1 infection. *International Congress Series* 1219:775-781, 2001.

424. Hoffmann E, Zhou NN, Webster RG. Eight-Plasmid rescue system for influenza A virus. *International Congress Series* 1219:1007-1013, 2001.

425. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. Universal primer set for the full-length amplification of all influenza A viruses. *Arch of Virol* 146:2275-2289, 2001.

426. Smirnov YA, Kaverin NV, Govorkova EA, Lipatov AS, Claas ECJ, Makarova NV, Gitelman AK, Webster RG, Lvov DK. Cross-protection studies with H5 influenza viruses. *International Congress Series* 1219:767-773, 2001.

427. Webby RJ, Webster RG. Emergence of influenza A viruses. *Philos Trans R Soc Lond B Biol Sci* 356:1817-1828, 2001.

428. Webster RG, Guan Y, Peiris M, Walker D, Krauss S, Zhou NN, Govorkova EA, Ellis, TM, Dyrting KC, Sit T, Perez DR, Shortridge KF. Characterization of H5N1 Influenza Viruses that Continue to Circulate in Geese in Southeastern China. *J Virol* 76:118-126, 2002.

429. Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidases inhibitors by an enzyme inhibition assay. *Antiviral Res* 53:47-61, 2002.

430. Seo SH, Webster RG. Tumor Necrosis Factor Alpha Exerts Powerful Anti-Influenza Virus Effects in Lung Epithelial Cells. *J Virol* 76:1071-1076, 2002.

431. Scholtissek C, Stech, J, Krauss S, Webster RG. Cooperation between Hemagglutinin of Avian Viruses and the Matrix Protein of Human Influenza A Viruses. *J Virol* 76:1781-1786, 2002.

432. Chin PS, Hoffmann E, Webby R, Webster RG, Guan Y, Peiris M, Shortridge KF. Molecular Evolution of H6 Influenza Viruses from Poultry in Southeastern China: Prevalence of H6N1 Influenza Viruses Possessing Seven A/HongKong/156/97 (H5N1)-like Genes in Poultry. *J Virol* 76:507-516, 2002.

433. Nedyalkova MS, Hayden FG, Webster RG, Gubareva LV. Accumulation of Defective Neuraminidase (NA) Genes by Influenza A Viruses in the Presence of NA Inhibitors as a Marker of Reduced Dependence on NA. *J Infect Dis* 185:581-598, 2002 (Epub 2002 Feb. 14).

434. Campitelli L, Fabiani C, Puzelli S, Fioretti A, Foni E, De Marco A, Krauss, S, Webster RG, Donatelli I. H3N2 influenza viruses from domestic chickens in Italy: an increasing role for chickens in the ecology of influenza? *J Gen Virol* 83:413-420, 2002.

435. Seo SH, Peiris M, Webster RG. Protective cross-reactive cellular immunity to lethal A/Goose/Guangdong/1/96-like H5N1 influenza virus is correlated with the proportion of pulmonary CD8⁺ T cells expressing gamma interferon. *J Virol* 76:4886-4890, 2002.

436. Webby RJ, Woolcock PR, Krauss SL, Webster RG. Reassortment and interspecies transmission of North American H6N2 influenza viruses. *Virology* 295:44-53, 2002.

437. Gambarian AS, Iamnikova SS, L'vov DK, Robertson JS, Webster RG, Matrosovich MN. Differences in receptor specificity between the influenza A viruses isolated from the duck, chicken and human. *Mol Biol* 36:542-549, 2002.

438. Guan Y, Peiris JS, Lipatov AS, Ellis TM, Dyrting KC, Krauss S, Zhang LJ, Webster RG, Shortridge KF. Emergence of multiple genotypes of H5N1 avian influenza viruses in Hong Kong SAR. *Proc Natl Acad Sci USA* 99:8950-8955, 2002.

439. Hoffmann E, Krauss S, Perez D, Webby R, Webster RG. Eight-plasmid system for rapid generation of influenza virus vaccines. *Vaccine* 20:3165-3170, 2002.

440. Webster RG. The importance of animal influenza for human disease. *Vaccine* 20:S16-S20, 2002.

441. Kaverin NV, Rudneva IA, Ilyushina NA, Varich NL, Lipatov AS, Smirnov YA, Govorkova EA, Gitelman AK, Lvov DK, Webster RG. Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. *J Gen Virol* 83:2497-2505, 2002.

442. Seo SH, Hoffmann E, Webster RG. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. *Nature Med* 8:950-954, 2002.

443. Hoffmann E, Mahmood K, Yang CF, Webster RG, Greenberg HB, Kemble G. Rescue of influenza viruses escape host anti-viral cytokine responses. *Nat. Med.* 8:950-954, 2002.

444. Liu M, He S, Walker D, Zhou NN, Perez DR, Mo B, Li F, Huang X, Webster RG, Webby RJ. The Influenza Virus Gene Pool in a Poultry Market in South Central China. *Virology* 305:267-275, 2003.

445. Perez DR, Lim W, Seiler JP, Yi G, Peiris M, Shortridge KF, Webster RG. Role of quail in the interspecies transmission of H9 influenza A viruses molecular changes on ha that correspond to adaptation from ducks to chickens. *J. Virol.* 77:3148-3156, 2003.

446. Lipatov AS, Krauss SK, Guan Y, Peiris M, Rehg JE, Perez DR, Webster, RG. Neurovirulence in Mice of H5N1 Influenza Virus Genotypes Isolated from Hong Kong Poultry in 2001. *J Virol.* 77:3816-3823, 2003.

447. Perez DR, Webby RJ, Hoffmann E, Webster RG. Land based birds as potential disseminators of avian mammalian reassortants influenza A viruses. *Avian Dis.* 47(3 Suppl):1154-1160, 2003.

448. Guan Y, Peiris JS, Poon LL, Dyrting KC, Ellis TM, Sims L, Webster RG, Shortridge KF. Reassortants of H5N1 influenza viruses recently isolated from aquatic poultry in Hong Kong SAR. *Avian Dis.* 47(3 Suppl):911-913, 2003.

449. Webby RJ, Woolcock PR, Krauss SL, Walker DB, Chin PS, Shortridge KF, Webster, RG. Multiple genotypes of nonpathogenic H6N2 influenza viruses isolated from chickens in California. *Avian Dis.* 47(3 Suppl):905-910, 2003.

450. Webby RJ, Webster RG. Are we ready for pandemic influenza? *Science* 302:1519-1522, 2003.

451. Gambaryan AS, Tuzikov AB, Bovin NV, Yamnikova SS, Lvov DK, Webster RG, Matrosovich MN. Difference between influenza virus receptors on target cells of duck and chicken and receptor specificity of the 1997 H5N1 chicken and human influenza viruses from Hong Kong. *Avian Dis.* 47(3 Suppl):1154-1160. 2003.

452. Liu M, Guan Y, Peiris M, He S, Webby RJ, Perez D, and Webster RG. The quest of influenza A viruses for new hosts. *Avian Dis.* 47(3 Suppl):849-856, 2003.

453. Liu M, Wood JM, Ellis T, Krauss S, Seiler P, Johnson C, Hoffmann E, Humberd J, Hulse D, Zhang Y, Webster RG, and Perez DR. Preparation of a Standardized, Efficacious Agricultural H5N3 Vaccine by Reverse Genetics. *Virology* 314:580-590, 2003.

454. Richt JA, Lager KM, Janke BH, Woods RD, Webster RG, Webby RJ. Pathogenic and antigenic properties of phylogenetically distinct reassortants H3N2 swine influenza viruses cocirculating in the United States. *J Clin Microbiol* 41:3198-3205, 2003.

455. Webby RJ, Andreansky S, Stambas J, Rehg JE, Webster RG, Doherty PC, Turner SJ. Protection and compensation in the influenza virus-specific CD8+ T Cell response. *Proc Natl Acad Sci USA* 100:7235-7240, 2003.

456. Li KS, Xu KM, Peiris JS, Poon LL, Yu KZ, Yuen KY, Shortridge KF, Webster RG, Guan Y. Characterization of H9 subtype influenza viruses from the ducks of southern China: a candidate for the next influenza pandemic in humans? *J Virol* 77:6988-6994, 2003.

457. Il'yushina NA, Rudneva IA, Varich NL, Lipatov AS, Webster RG, Kaverin NV. Antigenic structure of influenza A virus subtype H5 hemagglutinin: mechanism of acquiring stability to monoclonal antibodies in escape mutants. *Mol Gen Mikrobiol Virusol* 1:40-45, 2003.

458. Webster RG and Webby RJ. Both H5 and H7 Bird Flus Are on the Wing!! National Campaign for Influenza Newsletter (In Press).

459. Makarova NV, Ozaki H, Kida, H, Webster RG, and Perez DR. Replication and transmission of influenza viruses in Japanese quail. *Virology* 310:8-15, 2003.

460. Sturm-Ramirez KM, Ellis T, Bousfield B, Bissett L, Dyrting K, Rehg JE, Poon L, Guan Y, Peiris M, Webster RG. Reemerging H5N1 influenza viruses in Hong Kong in 2002 are highly pathogenic to ducks. *J Virol* 78:4892-4901, 2004.

461. Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova EA, McClain-Moss LR, Peiris JS, Rehg JE, Tuomanen EI, Webster RG. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. *Lancet* 363:1099-1103, 2004.

462. Ozaki H, Govorkova EA, Li C, Xiong X, Webster RG, Webby RJ. Generation of high-yielding influenza A viruses in Africa green monkey kidney (Vero) cells by reverse genetics. *J Virol* 78:1851-1857, 2004.

463. Webster RG. Wet markets – a continuing source of severe acute respiratory syndrome and influenza? *Lancet* 363:234-236, 2004.

464. Kaverin NV, Rudneva IA, Il'yushina NA, Lipatov AS, Krauss S, Webster RG. Structural differences among hemagglutinins of influenza A virus subtypes are reflected in their antigenic architecture: analysis of H9 escape mutants. *J Virol* 78:240-249, 2004.

465. Guan Y, Poon LLM, Cheung CY, Ellis TM, Lim W, Lipatov AS, Chan KH, Sturm-Ramirez KM, Cheung CL, Leung YHC, Yuen KY, Webster RG, Peiris JSM. H5N1 influenza: a protean pandemic threat. *Proc Natl Acad Sci USA* 101(21):8156-61, 2004. Epub 2004 May 17.

466. Chen H, Deng G, Li Z, Tian G, Li Y, Jiao P, Zhang L, Liu Z, Webster RG, Yu K. The evolution of H5N1 influenza viruses in ducks in southern China. *Proc Natl Acad Sci USA* 101:10452-10457, 2004.

467. Campitelli L, Mogavero E, DeMarco MA, Delogu M, Puzelli S, Frezza F, Dacchini M, Chiapponi C, Toni E, Cordioli P, Webby R, Barigazzi G, Webster RG, Donatelli I. Interspecies transmission of an H7N3 influenza virus from wild birds to intensively reared domestic poultry in Italy. *Virology* 323:24-36, 2004.

468. Seo SH, Hoffmann E, Webster RG. The NS1 gene of H5N1 influenza virus circumvents the host antiviral cytokine responses. *Virus Res* 103:107-113, 2004.

469. Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova EA, McClain-Moss LR, Peiris JS, Rehg JE, Tuomanen EI, Webster, RG. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. *Lancet* 363:1099-1103, 2004.

470. Li KS, Guan Y, Wang J, Smith GJD, Xu KM, Rahaedjo AP, Puthavathana P, Buranhai C, Nguyen TD, Estoepangeste ATS, Chaiseng A, Auewarakul P, Poon LLM, Ellis TM, Lim W, Webby RJ, Chen H, Shortridge KF, Yuen KY, Webster RG, Peiris JSM. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. *Nature* 430:209-213, 2004.

471. Krauss S, Walker D, Pryor SP, Niles L, Chenghong L, Hinshaw VS, Webster RG. Influenza A viruses of migrating wild aquatic birds in North America. *Vector Borne and Zoonotic Diseases* (in press) 2004.

472. Widjaja L, Krauss SL, Webby RJ, Xie T, Webster RG. The matrix gene of influenza A viruses isolated from wild aquatic birds: an illustration of the properties of the ecology and emergence of influenza A viruses. *J Virol.* (in press) 2004.

473. Lipatov AS, Govorkova EL, Webby RJ, Ozaki H, Peiris M, Guan Y, Webster RG. Influenza: emergence and control. *J Virol* (in press) 2004.

474. Webster RG, Guan Y, Poon L, Krauss S, Webby R, Govorkova E, Peiris M. The spread of the H5N1 bird flu epidemic in Asia in 2004. *Archives Virol* (in press) 2004.

475. Hulse DJ, Webster RG, Russell RJ, Perez DR. Molecular determinants within the surface proteins involved in the pathogenicity of H5N1 influenza viruses in Chickens. *J Virol* (in press) 2004.

Books, Book Chapters and Reviews

1. Davenport FM, Hennessy AV, Drescher J, Webster RG. Analytical, serologic and clinical experiences with the hemagglutinating subunits of influenza A virus. *Ciba symposium on cellular aspects of myxovirus infection*, pp 272-287, 1964.
2. Fazekas de St Groth S, Webster RG. The antibody response. *Ciba symposium on cellular aspects of myxovirus infection*, pp 247-271, 1964.
3. Webster RG. The structure and function of the hemagglutinin and neuraminidase of influenza virus. In: Barry RD, Mahy BWJ, eds. *The biology of large RNA viruses*. London/New York: Academic Press, pp 53-74, 1970.
4. Webster RG, Laver WG, Granoff A. Genetic reassortment with orthomyxoviruses. In: Fox CF, ed. *Virus research, Proceedings of the 1973 ICN-UCLA symposium on molecular biology*. London/New York: Academic Press, pp 513-524, 1973.
5. Webster RG, Granoff A. Evolution of orthomyxoviruses. In: Maramorosch K, Kurstak E, eds. *Viruses, evolution and cancer*. New York: Academic Press, pp 626-649, 1974.
6. Webster RG, Laver WG. Antigenic variation of influenza viruses. In: Kilbourne ED, ed. *The influenza viruses and influenza*. New York: Academic Press, pp 269-314, 1975.
7. Webster RG. Strain surveillance in animals and birds. In: Selby P, ed. *Influenza: Virus, vaccines, and strategy*. London/ New York: Academic Press, pp 33-43, 1976.
8. Webster RG. Immunological basis for selection of vaccine strains. In: Selby P, ed. *Influenza: Virus, vaccines, and strategy*. London/New York: Academic Press, pp 199-214, 1976.

9. Webster RG, Hinshaw VS, Bean WJ Jr, Turner B, Shortridge KF. Influenza viruses from avian and porcine sources and their possible role in the origin of human pandemic strains. International Symposium on Influenza Immunization (II), Geneva. In: *Dev Biol Stand* 39:461-468, 1977.
10. Hay AJ, Bellamy AR, Abraham G, Skehel JJ, Brand CM, Webster RG. Procedures for characterization of the genetic material of candidate vaccine strains. International symposium on influenza immunization (II), Geneva. In: *Dev Biol Stand* 39:15-24, 1977.
11. Webster RG, Glenzen WP, Kasel JA, Laver WG. Potentiation of the immune response to influenza virus subunit vaccines. International symposium on influenza immunization (II), Geneva. In: *Dev Biol Stand* 39:243-248, 1977.
12. Webster RG, Laver WG. Antigenic determinants on the hemagglutinin subunits of influenza A viruses and their role in immunity. In: Laver WG, Bachmayer H, Weil R, eds. *The influenza virus hemagglutinin: Topics in infectious diseases*. Vol 3. New York: Springer-Verlag, pp 1-14, 1977.
13. Laver WG, Webster RG. 'N-Terminal amino acid analysis of hemagglutinin molecules from duck and equine influenza viruses previously implicated as progenitors of the Hong Kong strain of human influenza. In: Laver WG, Bachmayer B, Weil R, eds. *The influenza virus hemagglutinin: Topics in infectious diseases*. Vol 3. New York: Springer-Verlag, pp 139-166, 1977.
14. Bean WJ Jr, Webster RG. Phenotypic properties associated with influenza genome segments. In: Mahy BWJ, Barry RD, eds. *Negative strand viruses and the host cell*. London: Academic Press, pp 685-692, 1978.
15. Webster RG. The evolution of epidemic influenza viruses. In: Bryans JT, Gerber H, eds. *Equine infectious diseases IV*. Proceedings of the 4th international conference on equine infectious diseases. Princeton, New Jersey: Veterinary Publications, pp 305-313, 1978.
16. Webster RG, Bean WJ Jr. Genetics of influenza virus. In: Roman HL, ed. *Annual review of genetics*. Vol 12. Palo Alto, California: Annual Reviews, pp 415-431, 1978.
17. Webster RG, Bean WJ Jr, Hinshaw VS. The ecology of influenza viruses. In: Loutit MW, Miles JAR, eds. *Microbial ecology*. Berlin: Springer-Verlag, pp 188-193, 1978.
18. Laver WG, Air GM, Webster RG, Gerhard W, Ward CW, Dopheide TA. The mechanism of antigenic drift in influenza virus sequence changes in the hemagglutinin of variants selected with monoclonal hybridoma antibodies. *Philos Trans R Soc Lond [Biol]* 288:313-326, 1980.
19. Webster RG, Hinshaw VS, Bean WJ, Sriram G. Influenza viruses. Transmission between species. *Philos Trans R Soc Lond [Biol]* 288:439-447, 1980.
20. Webster RG, Laver WG. Antigenic drift in Hong Kong (H3N2) influenza viruses: Selection of variants with potential epidemiological significance using monoclonal antibodies. *Proceedings of the international workshop of structure and function in influenza viruses*, Thredbo, Australia. New York: Elsevier/North-Holland, pp 283-293, 1980.
21. Laver WG, Air GM, Webster RG, Gerhard W, Ward CW, Dopheide TA. The antigenic sites of influenza virus hemagglutinin. Studies on their structure and variation. *Proceedings of the international workshop of structure and function in influenza viruses*, Thredbo, Australia. New York: Elsevier/North-Holland, pp 295-307, 1980.
22. Schild GC, Newman RW, Webster RG, Major D, Hinshaw VS. Antigenic analysis of the hemagglutinin, neuraminidase and nucleoprotein antigens of influenza A viruses. *Proceedings of the international workshop of structure and function of influenza viruses*, Thredbo, Australia. New York: Elsevier/North-Holland, pp 373-384, 1980.
23. Air GM, Laver WG, Webster RG. Towards a universal influenza vaccine. In: *New developments with human and veterinary vaccines*. New York: Alan R Liss, pp 193-215, 1980.
24. Webster RG, Hinshaw VS, Henkel TJ, Stalmach MA, Coleman PM, Laver WG. Monoclonal antibodies as tools for characterization of viral antigens. In: Bachmann PA, ed. *Munich symposium on microbiology*, WHO

Collaborative Center for the Collection and Evaluation of Data on Comprehensive Virology, Munich, Germany, 1981.

25. Bean WJ Jr, Hinshaw VS, Webster RG. Genetic characterization of an influenza virus from seals. In: Bishop DHL, Compans RW, eds. *The replication of negative strand viruses*. New York: Elsevier/North-Holland, pp 363-367, 1981.
26. Laver WG, Air GM, Webster RG. Towards a universal influenza vaccine. In: Bishop DHL, Compans RW, eds. *The replication of negative strand viruses*. New York: Elsevier/North-Holland, pp 421-425, 1981.
27. Laver WG, Air GM, Webster RG. Structure and variation of antigenic sites on influenza virus hemagglutinin. In: Nayak DP, Fox CF, eds. *Genetic variation among influenza viruses: ICN-UCLA symposia on molecular and cellular biology*. Vol 22. New York: Academic Press, pp 283-296, 1981.
28. Webster RG, Hinshaw VS, Berton MT, Laver WG, Air G. Antigenic drift in influenza viruses and association of biological activity with the topography of the hemagglutinin molecule. In: Nayak DP, Fox CF, eds. *Genetic variation among influenza viruses: ICN-UCLA symposia on molecular and cellular biology*. Vol 22. New York: Academic Press, pp 309-322, 1981.
29. van Wyke KL, Bean WJ Jr, Webster RG. Antigenic characterization of influenza A virus nucleoprotein. In: Nayak DP, Fox CF, eds. *Genetic variation among influenza viruses: ICN-UCLA symposia on molecular and cellular biology*. Vol 22. New York: Academic Press, New York, pp 373-385, 1981.
30. Kendal A, Cox N, Nakajima S, Webster RG, Bean WJ Jr, Beare P. Natural and unnatural variation in influenza A (H1N1) viruses since 1977. In: Nayak DP, Fox CF, eds. *Genetic variation among influenza viruses: ICN-UCLA symposia on molecular and cellular biology*. Vol 22. New York: Academic Press, pp 489-504, 1981.
31. Six HR, Glenzen WP, Kasel JA, Couch RG, Griffis C, Webster RG. Heterogeneity of influenza viruses isolated from the Houston community during defined epidemic periods. In: Nayak DP, Fox CF, eds. *Genetic variation among influenza viruses: ICN-UCLA symposia on molecular and cellular biology*. Vol 22. New York: Academic Press, pp 505-513, 1981.
32. Hinshaw VS, Bean WJ Jr, Webster RG. Biologic and genetic characterization of an influenza A virus associated with epizootic pneumonia in seals. In: Nayak DP, Fox CF, eds. *Genetic variation among influenza viruses: ICN-UCLA symposia on molecular and cellular biology*. Vol 22. New York: Academic Press, pp 515-524, 1981.
33. Hinshaw VS, Webster RG, Bean WJ. Application of recently developed techniques to determine the origin of influenza A viruses appearing in avian and mammalian species and to develop potent avian influenza vaccines. In: Bankowski RA, ed. *Proceedings of the first international symposium on avian influenza*. Richmond, Virginia: Carter, pp 134-147, 1981.
34. Hinshaw VS, Webster RG. The natural history of influenza A viruses. In: Beare AS, ed. *Basic and applied influenza research*. Boca Raton, Florida: CRC Press, pp 79-104, 1982.
35. Askonas BA, McMichael A, Webster RG. The immune response to influenza viruses and the problem of protection against infection. In: Beare AS, ed. *Basic and applied influenza research*. Boca Raton, Florida: CRC Press, pp 159-188, 1982.
36. Webster RG, Hinshaw VS, Berton MT, Stalmach MA, Newton KL. Monoclonal antibodies to influenza viruses. In: Diagnostic and therapeutic applications of hybridoma technology. Toronto, Canada: Ortho, pp 35-44, 1982.
37. Webster RG, Gong XC, Brown LE, Jackson DC. Changes in antigenicity of H3 influenza virus hemagglutinin at low pH and in field strains since 1979. In: Laver WG, ed. *The origin of pandemic influenza viruses*. New York: Elsevier, pp 19-28, 1983.
38. Jackson RC, Murray JM, Anders EM, White DO, Webster RG, Brown LE. Expression of a unique antigenic determinant of influenza virus hemagglutinin at pH 5. In: Laver WG, ed. *The origin of pandemic influenza viruses*. New York: Elsevier, pp 29-38, 1983.

39. Jackson DC, Nestorowicz A, Webster RG. Spatial arrangement of the enzymic and antigenic sites of influenza virus neuraminidase. In: Laver WG, ed. *The origin of pandemic influenza viruses*. New York: Elsevier, pp 87-96, 1983.
40. Air GM, Blok J, Laver WG, Webster RG. Sequence changes associated with antigenic changes in the influenza A virus neuraminidase. In: Laver WG, ed. *The origin of pandemic influenza viruses*. New York: Elsevier, pp 97-102, 1983.
41. Laver WG, Webster RG, Air GM. Effect of chemical modification on the antigenic properties of A/Tokyo/67 neuraminidase effect of a single sequence change on the thermal stability of A/Tokyo/67 neuraminidase. In: Laver WG, ed. *The origin of pandemic influenza viruses*. New York: Elsevier, pp 113-120, 1983.
42. Hinshaw VS, Webster RG, Bean WJ. Swine influenza viruses in turkeys: A potential source of virus for humans? In: Laver WG, ed. *The origin of pandemic influenza viruses*. New York: Elsevier, pp 181-190, 1983.
43. Nerome K, Ishida M, Sakamoto S, Sako M, Nonaka S, Webster RG, Oya A. The possible origin of swine (H1N1) influenza virus in the swine population of Japan and genome composition of a recombinant (H1N2) virus. In: Laver WG, ed. *The origin of pandemic influenza viruses*. New York: Elsevier, pp 201-210, 1983.
44. Webster RG, Hinshaw VS, Naeve CW, Bean WJ, Murphy BR, Bigelow MA. Host range of influenza A viruses and potential new vaccines. In: Torres AR, ed. *Current topics and prospects in influenza*. Valladolid, Spain: Spanish Society for Microbiology, pp 123-131, 1983.
45. Webster RG, Hinshaw VS, Naeve CW, Bean WJ. Pandemics and Animal Influenza Viruses. In: Stuart-Harris C, Potter S, eds. *The molecular virology and epidemiology of influenza*. London: Academic Press, pp 39-59, 1984.
46. Webster RG. Confronting the highly pathogenic H5N2 avian influenza virus. *Broiler Industry* 47:14-22, 1984.
47. Webster RG, Kawaoka Y, Bean WJ, Naeve CW. Molecular characterization of the A/Chicken/Pennsylvania/83 (H5N2) influenza viruses. In: *Proceedings of 88th United States Animal Health Association Meeting*, Fort Worth, Texas, 1984.
48. Webster RG, Kawaoka Y, Bean WJ, Naeve CW, Wood JM. An outbreak of "fowl plague" in Pennsylvania. In: *Proceedings of Newcastle disease and fowl plague*, Sydney, Australia, pp 77-96, 1984.
49. Laver WG, Coleman PM, Ward CW, Varghese JM, Air GM, Webster RG. In: Bishop DHL, Compans RJ, eds. *Segmented negative strand viruses*. Orlando, Florida: Academic Press, pp 225-232, 1984.
50. Naeve CW, Hinshaw VS, Webster RG. Sequence changes in the hemagglutinin of an enterotropic H3 influenza virus. In: Bishop DHL, Compans RJ, eds. *Segmented negative strand viruses*. Orlando, Florida: Academic Press, pp 267-272, 1984.
51. Wood JM, Webster RG, Kawaoka Y, Bean WJ, Nettles VF. A lethal outbreak of H5N2 influenza in poultry in the USA: Virus characterization and host range. In: *Proceedings of acute viral infections of poultry*. European Economic Community, Brussels, June, 1985.
52. Murphy BR, Webster RG. Influenza viruses. In: Fields BN, Kneipe DN, Chanock RM, Melnick JL, Goizman B, Shope RE, eds. *Virology*. New York: Raven Press, pp 1179-1239, 1985.
53. Webster RG, Kawaoka Y, Bean WJ, Naeve CW, Wood JM, Laver WG. Lethal avian influenza (H5N2) in the USA: Is a similar outbreak in Australia or New Zealand possible? In: Gibbs AJ, Meischke HRC, eds. *Pests and parasites as migrants: An Australian perspective*. Canberra: Australian Academy of Science, pp 140-146, 1985.
54. Scholtissek C, Webster RG. Workshop summary: Molecular approaches to understanding the biology of influenza viruses. In: *Options for the control of influenza*. New York: Alan R Liss, pp 497-500, 1986.

55. Kawaoka Y, Bean WJ, Webster RG. Molecular characterization of the A/chicken/Pennsylvania/83 (H5N2) influenza viruses. In: Proceedings of the second international symposium on avian influenza. Athens, Georgia: Georgia Center for Continuing Education, pp 197-206, 1986.
56. Senne DA, Pearson JE, Kawaoka Y, Carbrey EA, Webster RG. Alternative methods for evaluation of pathogenicity of chicken Pennsylvania H5N2 viruses. In: Proceedings of the second international symposium on avian influenza. Athens, Georgia: Georgia Center for Continuing Education, pp 246-257, 1986.
57. Webster RG, Bean WJ Jr. Antiviral compounds for treatment of highly pathogenic avian influenza. In: Proceedings of the second international symposium on avian influenza. Athens, Georgia: Georgia Center for Continuing Education, pp 293-301, 1986.
58. Webster RG. Avian influenza update. Foreign Animal Dis Rep 13-3:2-5, 1986.
59. Webster RG, Bean WJ, Kawaoka Y, Senne D. Characterization of H5N2 influenza viruses from birds in live mutants in USA. Proceedings of the 19th annual meeting of Usahr, Kentucky, pp 278-286, 1986.
60. Bean WJ, Kawaoka Y, Webster RG. Genetic characterization of H5N2 influenza viruses isolated from poultry in 1986. In: Proceedings of the second international symposium on avian influenza. Athens, Georgia: Georgia Center for Continuing Education, pp 207-221, 1987.
61. Colman PM, Webster RG. The structure of an antineuraminidase monoclonal fab fragment and its interaction with the antigen. In: Burnett RM, Vogel HJ, eds. Biological organization: Macromolecular interactions at high resolution. New York: Academic Press, pp 125-133, 1987.
62. Air GM, Laver WG, Webster RG. Antigenic variation in influenza viruses. In: Cruse JM, Lewis RE Jr, eds. Contr Microbiol Immunol. Basel: S. Karger, pp 20-59, 1987.
63. Webster RG, Kawaoka Y, Bean WJ. A single change in the hemagglutinin of H5N2 influenza virus is associated with high virulence. In: Vaccines 87. New York: Cold Spring Harbor Laboratory, pp 283-289, 1987.
64. Colman PM, Varghese JN, Laver WG, Webster RG. The 3-dimensional structures of influenza virus neuraminidase and an antineuraminidase Fab fragment. In: Moras D, Drenth J, Strandberg B, Suck D, Wilson K, eds. Crystallography in molecular biology. Plenum, p 373, 1987.
65. Wood JM, Schild GC, Minor PD, Magrath DI, Mumford J, Webster RG. Potency assay of inactivated influenza and poliovaccine: Applications of single-radial immunodiffusion. In: Kurstak E, Marusyk RG, Murphy FA, eds. Applied virology research. Plenum, p 173, 1988.
66. Webster RG, Kawaoka Y. Avian influenza. In: Critical reviews in poultry biology. Vol 1. CRC Press, pp 211-246, 1988.
67. Laver WG, Webster RG, Bossart PJ, Luo M, Air GM. Recognition of protein antigens by antibodies: crystal structure of antibody *fab* fragments complexed with influenza virus neuraminidase. In: Smith-Gill S, Sercarz E, eds. The immune response to structurally defined proteins: The lysozyme model. Adenine Press, pp 141-149, 1989.
68. Metzger DW, Air GM, Laver WG, Webster RG. Epitope mapping and idiotypic of the antibody response to influenza neuraminidase. In: Use of X-ray crystallography in the design of antiviral agents. New York: Academic Press, pp 13-18, 1990.
69. Metzger DW, Webster RG. Induction of antibody responses to influenza virus neuraminidase by syngeneic anti-idiotypes. Osterhaus ADME, UytdeHaag FGCM, eds. Idiotype networks in biology and medicine. Amsterdam: Excerpta Medica, pp 257-261, 1990.
70. Laver WG, Air GM, Luo M, Portner A, Thompson SD, Webster RG. Crystal structures of influenza virus neuraminidase complexed with monoclonal antibody fab fragments. In: Use of X-ray crystallography in the design of antiviral agents. New York: Academic Press, p 49-60, 1990.

71. Laver WG, Colman PM, Air GM, Webster RG, Varghese JN, Baker AT, Tulloch PA and Tulip WR. Recognition of protein antigens by antibodies: Crystal structure of antibody *fab* fragments complexed with influenza virus neuraminidase. In: Van Der Ploeg LHT, Cantor CR, Vogel HJ, eds. Immune recognition and evasion: Molecular aspects of host-parasite interaction. San Diego, California: Academic Press, p 77, 1990.
72. Webster RG, Sharp G, Hinshaw V, Turner B, Kawaoka Y. The progenitors of avian influenza viruses in domestic poultry. Proceeding of the 3rd International Symposium - Avian influenza, pp 112-122, The University of Wisconsin, Madison, May 27-29, 1992.
73. Kawaoka Y, Walker JA, Webster RG. Origin and molecular marker of avian influenza viruses. Proceeding of the 3rd International Symposium on Avian Influenza, pp 112-122, The University of Wisconsin, Madison, May 27-29, 1992.
74. Chambers TM, Webster RG. Modulation of highly pathogenic avian influenza with defective interfering particles. Proceeding of the 3rd International Symposium - Avian Influenza, pp 218-226, The University of Wisconsin, Madison, May 27-29, 1992.
75. Klimov AI, Markushin SG, Prosch S, Sokolov NI, Heider H, Heider AM, Ginzburg VP, Gorodkova NV, Gambaryan AS, Matrosovich MN, Cox NJ, Webster RG. Some aspects of using antiviral compounds in the treatment and control of influenza virus infection. Proceeding of the 3rd International Symposium on Avian Influenza, pp 354-367, May 27-29, 1992.
76. Webster RG, Schafer JR, Süss J, Bean WJ, Kawaoka Y. Evolution and ecology of influenza viruses. In: Hannoun C, et al, eds. Options for the control of influenza II. Elsevier Science Publishers B.V., pp 177-185, 1993.
77. Kawaoka Y, Bean WJ, Gorman OT, Sharp GB, Hinshaw VS, Wright SM, Castrucci MR, Donatelli I, Webster RG. The roles of birds and pigs in the generation of pandemic strains of human influenza. In: Hannoun C, et al. eds. Options for the control of influenza II. Elsevier Science Publishers B.V., pp 187-191, 1993.
78. Webster RG. Influenza. In: Morse SS, ed. Emerging Viruses. Oxford University Press, pp 37-45, 1993.
79. Webster RG. Influenza Viruses. In: Webster RG, et al., eds. Encyclopedia of Virology. London: Academic Press, pp 709-713, 1994.
80. Webster RG, Granoff A. In: Webster R, Granoff A, eds. Encyclopedia of Virology. Vol 1, Vol 2, Vol 3. London: Academic Press, Harcourt Brace & Company, 1994.
81. Murphy BR, Webster RG. Orthomyxoviruses. In: Fields BN, Kaipe DM, Howley PM, et al, eds. New York: Raven Press, Ltd, Chapter 46, 1397-1445, 1995.
82. Webster RG. Influenza: In: Krause R, ed. An emerging microbial pathogen. In: Webster RG, eds. Emerging Infections. Academic Press, pp 275-300, 1998.
83. Webster RG, Doherty PC, Tripp RA. Influenza virus (orthomyxovirus) infection and immunity. In: Delves PJ, ed. Encyclopedia of Immunology, 2nd Edition, Vol. 3, San Diego, CA: Academic Press, Publisher, pp 1385-1387, 1998.
83. Laver WG, Bischofberger N, Webster RG. Disarming flu viruses. Scientific American 280:78-87, 1999
84. Nicholson KG, Webster, RG, Hay, AJ. Textbook of Influenza. Blackwell Science, 1999
85. Govorkova EA, Kodihalli S, Alymova IV, Fanget B, Webster RG. Growth and immunogenicity of influenza viruses cultivated in vero or MDCK cells and in embryonated chicken eggs. In: Brown F, Robertson JS, Schild GC, Wood JM, eds. Inactivated influenza vaccines prepared in cell culture. Dev Biol. Stand, Basel, Karger, vol 98, pp 39-51, 1999.
86. Webster RG. Antigenic variation in influenza viruses. In: Origin and Evolution of Viruses, Academic Press pp 377-390, 1999.

87. Webster RG. Influenza viruses. In: Webster RG, et al., eds. Encyclopedia of Virology. 2nd ed. London: Academic Press, pp 824-829, 1999.
88. Webster RG, Granoff A. In: Webster R, Granoff A, eds. Encyclopedia of Virology, 2nd ed.. Vol 1, Vol 2, Vol 3. London: Academic Press, Harcourt Brace & Company, 1999.
89. Kaiser L, Couch RB, Galasso GJ, Glezen WP, Webster RG, Wright PF, Hayden FG. First international symposium on influenza and other respiratory viruses: summary and overview – Kapalua, Maui, Hawaii, Dec. 4-6, 1998. Antiviral Res 42:149-175, 1999.
90. Webby RJ, Webster RG. Are we ready for pandemic influenza? In Learning from SARS Preparing for the Next Disease Outbreak, Workshop Summary, Institute of Medicine, The National Academies Press, Knobler S, Mahmoud A, Lemon S, Mack A, Sivitz L, Oberholtzer K eds, pp. 208-
91. Webster RG, Fedson DS. Lessons for the future: Pandemic influenza. In Severe Acute Respiratory Syndrome, In press, 2004.

OTHER PROFESSIONAL ACTIVITIES:

Editorial Board Member: Infection and Immunity, Experimental Cell Biology
 Editorial Board Member: Problems of Virology

NATIONAL COMMITTEES:

Associate Coordinator, US-USSR Joint Committee for Health Cooperation on "The Ecology of Human Influenza and Animal Influenza Related to Human Infection"

Collaborator, World Health Organization, Study of Influenza Viruses in Animals

INSTITUTIONAL COMMITTEES:

1974	Credentials-Tenure Committee
1975-78	Ad Hoc Committee on Containment Facilities (Chairman)
1980	Sabbatical Leave Committee
1981	Animal Facilities Care Committee
1984-85	Credentials-Tenure Committee (Chairman 1985)
1988 to present	Executive Committee

INVITED PRESENTATIONS:

1969	International Conference of Hong Kong Influenza, Atlanta, Georgia
1969	Symposium on the Biology of Large RNA Viruses, Cambridge, England
1970	International Congress for Microbiology, Mexico City, Mexico
1971	International Congress for Virology, Budapest, Hungary
1971	American Society for Microbiology, Kentucky-Tennessee Branch, Bowling Green, Kentucky
1971	Workshop on Influenza: Immunologic Methodology and Surveillance, Atlanta, Georgia
1971	Workshop on Influenza Virus Polypeptides and Antigens, Madison, Wisconsin
1972	World Health Organization Symposium on Ecology of Influenza Viruses, Moscow, USSR
1972	Workshop on Epidemiology of Influenza, Washington, DC
1972	Workshop on Influenza Vaccines for Men and Horses, London, England
1973	ICN-UCLA Molecular Biology Conference: Symposium on Virus Research, Squaw Valley, California
1973	International Symposium on Comparative Immunodiagnosis of Viral Infections, Mont Gabriel, Canada

1973 Symposium on Acute Respiratory Diseases, Walter Reed Army Institute of Research, Washington, DC

1973 Workshop VI. Animal Influenza: Its Significance to Human Infection (sponsored by NIAID), Madison, Wisconsin

1973 World Health Organization Meeting On Animal Influenza, Geneva, Switzerland

1974 Symposium on Virus Antibody Interaction, Leeds, England

1975 Pacific Science Congress (13th), Vancouver, Canada

1976 International Conference on Equine Infectious Diseases, Lyon, France

1976 Working Group on Pandemic Influenza, Rougemont, Switzerland

1977 American Society for Microbiology, Conference on Myxoviruses, Tampa, Florida

1977 Conference on Hemagglutinin Subunits, Sandoz Institute, Vienna, Austria

1977 GO Broun Symposium on Influenza Viruses, St. Louis, Missouri

1977 International Association of Biological Standardization, Symposium on Influenza Immunization, Geneva, Switzerland

1977 International Symposium on Microbial Ecology, Otago University, Dunedin, New Zealand

1977 World Health Organization, Consultation on the Ecology of Influenza, Geneva, Switzerland

1978 Fogarty International Center and World Health Organization, International Meeting on the Ecology of Influenza, Bethesda, Maryland

1978 Influenza Workshop, Australian National University, Canberra, Australia

1978 International Congress for Virology (IV), The Hague, The Netherlands

1979 American Society for Microbiology, Kentucky-Tennessee Branch Meeting, Memphis, Tennessee

1979 International Workshop on Structure and Variation in Influenza Virus, Australian National University, Canberra, Australia

1979 National Institute of Health, Influenza B Meeting, Bethesda, Maryland

1979 New York Academy of Science, Conference on Genetic Variation of Viruses, New York, New York

1979 Pacific Science Congress (XIV) (Sponsored by US-USSR Science Exchange Program), Khabarovsk, USSR

1979 Royal Society of the United Kingdom, London, England

1979 World Health Organization Meeting on the Ecology of Influenza Viruses, London, England

1979 Workshop on the Structure of the Influenza Virus Hemagglutinin, Australian National University, Canberra, Australia

1980 Conference on Ecology of Influenza Viruses, Boston, Massachusetts

1980 Conference on New and Useful Techniques in Rapid Viral Diagnosis, National Institutes of Health, Bethesda, Maryland

1980 US-USSR Symposium on Influenza and Acute Respiratory Disease, Alma-Ata, USSR

1980 World Health Organization Consultation on Influenza A Virus Nomenclature, Geneva, Switzerland

1980 World Health Organization Consultation on the Ecology of Influenza Viruses, Munich, West Germany

1981 American Throacic Association Meeting, Detroit, Michigan

1981 Australian National University International Plant Virology Meeting, Kialoa Field Laboratory, Kialoa, New South Wales, Australia

1981 Australian National University, School of Biological Sciences, Canberra, Australia

1981 ICN-UCLA Symposium on Genetic Variation Among Influenza Viruses, Salt Lake City, Utah

1981 Ortho Pharmaceutical, Ltd. and Ortho Diagnostics Symposium on Diagnostic and Therapeutic Applications of Monoclonal Antibodies in Infectious Diseases, Don Mills, Ontario, Canada

1981 Symposia on Microbiology, Munich, Germany

1982 Conference on Influenza: B-cell or T-cell Immunity, Oxford University, Oxford, England

1982 Workshop on the Origin of Pandemic Influenza Viruses, Beijing, Peoples' Republic of China

1982 World Health and Organization Meeting on Ecology of Influenza Viruses, London, England

1983 Pacific Science Congress (XV), Dunedin, New Zealand

1983 Annual Conference on Protein Structure and Function (VIII), Lorne, Australia

1983 American Society for Virology Annual Meeting, East Lansing, Michigan

1983 Beecham Colloquium on the Molecular Virology and Epidemiology of Influenza, London, England

1983 National Congress of Microbiology (IX), Valladolid, Spain
 1984 USDA Meeting on Avian Influenza Virus, Hyattsville, Maryland
 1984 USDA Meeting on H5N2 Influenza Virus in Chickens, Hyattsville, Maryland
 1984 Experimental Virology Study Section, Bethesda, Maryland
 1984 USDA Meeting on Avian Influenza Virus, Lancaster, Pennsylvania
 1984 Seminar at University of Mississippi, Oxford, Mississippi
 1984 Australia and New Zealand Association for the Academy of Science Meeting, seminar in Sydney, Australia, and consultation in Canberra, Australia
 1984 USDA Meeting on Avian Influenza Viruses in Chickens, Hyattsville, Maryland
 1984 NIH Study Section, Bethesda, Maryland
 1984 North Central Avian Disease Conference, Sioux Falls, South Dakota
 1984 Avian Influenza Symposium, University Park, Pennsylvania
 1984 Workshop on Cell Substrates for Influenza Virus, Bethesda, Maryland
 1984 Third Annual ASV Meeting, Madison, Wisconsin Visited Influenza Labs, Hong Kong, Japan
 1984 International Symposium of Influenza Virus Hemagglutinin, Osaka, Japan
 1984 Sixth International Congress of Virology, Sendai, Japan
 1984 Technical Consultants for Avian Influenza Meeting, Hyattsville, Maryland
 1984 Seminar at University of Tennessee, Knoxville, Tennessee
 1984 Lecture to Wildlife Committee at US Animal Health Association Meeting, Fort Worth, Texas
 1984 Workshop entitled "Status of Attenuated Influenza Vaccines," Bethesda, Maryland
 1985 Seminar on Influenza, Vanderbilt University, Nashville, Tennessee
 1985 Consultation on Human and Animal Influenza Viruses with World Health Organization Officials, Geneva, Switzerland
 1985 Seminar at George Washington University, St. Louis, Missouri
 1985 Thirty-Sixth Annual Southern Conference on Avian Diseases at the University of Georgia Center for Continued Education, Athens, Georgia
 1985 Cold Spring Harbor Meeting on Influenza as Antigens, Cold Spring Harbor, New York
 1985 "Law Lecture" at Cornell University, Ithaca, New York
 1985 Seminar on Influenza, Lancaster, Pennsylvania
 1985 Immunology Symposium, Kalamazoo, Michigan
 1985 NIH Contract Review, Bethesda, Maryland
 1985 Seminar to Becton-Dickinson Company, Raleigh-Durham, North Carolina
 1985 Seminar on H5N2 Avian Flu, Lafayette, Indiana
 1985 UCLA Symposia on Options for the Control of Influenza, Keystone, Colorado
 1985 International Conference on Antivirals, Bath, England, Joint Study on Host Range Variants of Influenza, London, England
 1985 Lecture and Ph.D. Committee Meeting at University of Alabama, Birmingham, Alabama
 1985 Scientific Meeting at DI Ivanovsky Institute, Moscow, USSR
 1985 Biology of Negative Strand Viruses Meeting, Cambridge, England
 1985 Lecture to Delmarva Poultry Conference, Ocean City, Maryland
 1986 Antarctic Research Program on Influenza, Antarctica
 1986 Study on Influenza in Live Poultry Market, New York, New York
 1986 US Animal Health Meeting, Louisville, Kentucky
 1986 World Health Organization, Consultation on Influenza in Lower Animals, Geneva, Switzerland
 1986 Modern Approaches to New Vaccines Meeting, Cold Spring Harbor, New York
 1986 Second International Symposium on Avian Influenza, Athens, Georgia
 1986 International Meeting on Virology, Giessen, West Germany
 1986 Subcommittee on Reevaluation or Nomenclature of Avian Influenza, St. Louis, Missouri
 1987 USA/USSR Influenza Virus Exchange Program, Leningrad and Moscow, USSR
 1987 Sixth Annual Meeting of American Society for Virology, Chapel Hill, North Carolina
 1987 NIH Meeting on Influenza Viruses, Bethesda, Maryland
 1987 VII International Congress of Virology, Edmonton, Alberta, Canada
 1987 National Task Force on Influenza in Wildlife and Their Impact on Domestic Poultry, Madison, Wisconsin
 1987 U.S. Animal Health Meeting, Salt Lake City, Utah
 1987 Guest Lecturer, University of Minnesota, Minneapolis, Minnesota
 1987 National Academy of Sciences Meeting on Vaccines to AIDS, Washington, DC

1988 Seventh International Conference on Negative Strand Viruses Meeting, Dinard, France
 1988 First Asia-Pacific Congress of Medical Virology, Singapore
 1989 101st Meeting of the National Advisory Allergy and Infectious Diseases Council, Bethesda, Maryland
 1989 International Workshop on the Use of X-Ray Crystallography in the Design of Antiviral Agents, Kona, Hawaii
 1989 Seminar at Wayne State University, Detroit, Michigan
 1989 Seminar at Ohio State University, Columbus, Ohio
 1989 Seminar at East Carolina State University, Kinston, North Carolina
 1989 Anti-Infective Conference, Scottsdale, Arizona
 1989 Conference on Emerging Viruses: Evolution of Viruses and Viral Diseases, New York, New York
 1989 Seminar at Louisiana State University, Shreveport, Louisiana
 1989 Seminar at National Institutes of Health, Tokyo, Japan
 1989 Southern Association for Clinical Microbiology, Memphis, Tennessee
 1989 Scientific Basis of Medicine Seminar Series, Worcester, Massachusetts
 1989 Live Attenuated Influenza Virus Vaccine Meeting, Alexandria, Virginia
 1990 Society for General Microbiology at the University of Swansea, South Wales, United Kingdom
 1990 Seminar at University of Alabama-Birmingham, Birmingham, Alabama
 1990 UCLA Symposium, Keystone, Colorado
 1990 Seminar at University of Michigan, Ann Arbor, Michigan
 1990 SmithKline Beecham Pharmaceuticals Anti-infective Conference, Palm Springs, California
 1990 Virology Symposium at the Annual Meeting of the Canadian Society for Microbiology, Calgary, Canada
 1990 VIIIth International Congress of Virology, Berlin, Germany
 1990 Seminar at University of Nebraska-Lincoln, Lincoln, Nebraska
 1991 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut
 1991 WHO/OIE Meeting: Host Cell Selection of Influenza Virus Variants, England
 1991 Workshop on Acute Respiratory Infections, New Delhi, India
 1991 Second Asia-Pacific Congress of Medical Virology, Bangkok, Thailand
 1991 Fundacion Juan March, Madrid, Spain
 1992 WHO/OIE Influenza Meeting, Newmarket, England
 1992 Third International Symposium on Avian Influenza, Madison, Wisconsin
 1992 SmithKline Beecham Pharmaceuticals Anti-infective Conference, Tucson, Arizona
 1992 100 Years of Virology, Leningrad, Russia
 1992 Options for the Control of Influenza II, Courchevel, France
 1992 Merck Sharp & Dohme Research Laboratories, Westpoint, Pennsylvania
 1992 Burroughs Wellcome Symposium, Research Triangle Park, North Carolina
 1993 First International Workshop on Viral and Bacterial Diseases, Memphis, Tennessee
 1993 Seminar at University of Pittsburgh, Pittsburgh, Pennsylvania
 1993 2nd International Karger Symposium, Basel, Switzerland
 1993 The Thirteenth Sir Henry Dale Lecture, Hertfordshire, England
 1993 International Conference on Zoonoses, Piestany, Czechoslovakia
 1994 Seminar at Vanderbilt University Medical Center, Nashville, Tennessee
 1994 Seminar at Aviron, Burlingame, California
 1994 Seminar at University of Florida, Gainesville, Florida
 1994 Second International Workshop on Viral and Bacterial Diseases, Rigi Kaltbad, Switzerland
 1994 Seminar at Lilly Research Laboratories, Indianapolis, Indiana
 1994 Seminar in Tepatitlan, Mexico
 1994 Third Asia-Pacific Congress of Medical Virology, Interlaken, Switzerland
 1994 National Institutes of Health International Meeting, Rockville, Maryland
 1994 Ninth International Conference on Negative Strand Viruses, Estoril, Portugal
 1994 Avian Influenza Meeting, Mexico City, Mexico
 1995 Transatlantic Airway Conference, Key Biscayne, Florida
 1995 University of North Carolina at Chapel Hill, North Carolina
 1995 Symposium on Ecology and Molecular Biology of Influenza Viruses in Sapporo '95, Sapporo, Japan

1995	WHO Informal Consultation on Tissue Culture as a Substrate for the Production of Influenza Vaccines, Geneva, Switzerland
1995	Global Molecular Epidemiology of HIV-1, Rockville, Maryland
1995	Avian Influenza Meeting, Tepatitlan, Mexico
1995	7th International Symposium on Microbial Ecology, Santos, Brazil
1995	The 46th North Central Avian Disease Conference and Symposium on New Vaccines and Delivery System, Minneapolis/St. Paul, Minnesota
1995	IXth European Meeting on Influenza and Its Prevention, Czechoslovakia
2002	Institute of Medicine – Immunization Safety Review Committee, Washington DC
2002	Evolution and Ecology of Influenza Viruses, Hokkaido University Graduate School of Veterinary Medicine, Hokkaido, Japan
2002	50 th Annual Meeting of the Japanese Society for Virology, Sapporo, Japan
2002	Past 50 years of influenza virus research and its future, Sapporo, Japan
2002	1 st European Influenza Conference, Malta
2002	United States-Japan Cooperative Medical Sciences Program's 7 th International Conference on Emerging Infections in the Pacific Rim, Shanghai, China
2002	Seminar at Universiti Putra Malaysia, Malaysia
2002	Seminar Speaker at State University of New York Stony Brook Health Sciences Center, Stony Brook, NY
2002	Biosecurity 2002, Las Vegas, Nevada
2002	Bristol Myers Squibb Award, New York City, New York
2002	V International Symposium on Respiratory Viral Infections, Casa de Campo, La Romana, Dominican Republic
2002	Seminar at the University of Maryland, College Park, Maryland
2003	7 th Annual Meeting, Acute Respiratory Infections (ARI) Panel, Yokohama, Japan
2003	St. Jude-PIDS Pediatric Microbial Research Conference, Memphis, TN
2003	Corona Viruses and SARS: National Security Implications, McLean, VA
2003	AVECAO Annual Meeting, Guadalajara, Mexico
2003	The Environmental Determinants of Diabetes in the Young (TEDDY) Workshop, Reston, VA
2003	43 rd Annual ICAAC, Chicago, IL
	NIAID Pandemic Planning Workshop, Bethesda, MD
2003	4 th International Congress on Emerging Zoonosis, Keynote Speaker, Ames, Iowa
2003	Institute of Medicine, SARS Forum Meeting, Washington, DC
2003	Options for the Control of Influenza V, Okinawa, Japan
2003	University of Texas, BL4 Laboratory Dedication, Houston, TX
2004	Infectious Diseases from Nature, Galveston, TX
2004	US/Japan Cooperative Medical Sciences Program Meeting, San Francisco, CA
2004	Environmental Health impacts of CAFOs Anticipating Hazards – Search for Solutions, Ames, IA

GRADUATE STUDENTS SUPERVISED:

1981-1985	Michael T. Berton
1989-1989	Marja Korsman
1991-9292	Bruno Garulli
1992-1992	Rachel Aston
1993-1993	Mark Powell
1994-1994	Angus Cameron
1993-1994	Carolin Röhm
1995-1995	Matthew Robinson
1995-1996	Guan Yi
2001-present	Yun Zhang
2002-present	Linda Widjaja
2003-present	Hui-Ling Yen

POSTDOCTORAL TRAINEES SUPERVISED:

1977-1979	G. Sriram, PhD
1978-1980	Kathleen van Wyke, PhD
1981-1982	Lorena E. Brown, PhD
1982-1983	Akira Yamada, PhD
1983-1985	Mary E. Owens, PhD
1983-1985	Yoshihiro Kawaoka, DVM, PhD
1985-1987	Ann Nestorowicz, PhD
1985-1988	Jacqueline M. Katz, PhD
1986-1989	Ruben Donis, DVM, PhD
1987-1989	Katsunori Okazaki, DVM, PhD
1987-1989	Maoliang Wang, MD
1988-1991	Owen Gorman, PhD
1988-1990	Martin Banbura, PhD
1990-1992	William Meyer, PhD
1990-1992	Stephen Wright, PhD
1990-1993	Louise Herlocher, PhD
1992-1993	Yi Pu Lin, MD, PhD
1991-1994	Li Li Shu, MD, PhD
1991-1994	Takehiko Saito, DVM
1992-1998	Larisa Gubareva, PhD
1993-1996	Dominic Justewicz, PhD
1994-1999	Shantha Kodihalli, PhD
1993-1995	Charles Hardy, PhD
1994-1995	Carolin Röhm, DVM
1996-1999	Juergen Stech, PhD
1998-2001	Erich Hoffmann PhD
1996-2000	Mikhail Matrosovich PhD
1997-2000	Yi Guan PhD
1999-2003	Richard Webby PhD
1999-2002	Sang Seo DVM PhD
1999-2000	Eduardo O'Neill PhD
2000-2002	Natalia Makarova, PhD
2001-present	Aleksandr Lipatov Pharm D, PhD
2001-2003	Ming Liu PhD
2001-present	Hiroichi Ozaki, PhD
2002-2003	Todd Hatchette, MD
2002-present	Katharine Sturm-Ramirez, PhD
2002-present	Diane Hulse, PhD
2003-present	Young-Ki Choi, DVM, PhD
2004-present	Matthew Sandbult, PhD

VISITING OVERSEAS FELLOWS SUPERVISED:

1980-1981	Hiroshi Kida, DVM, PhD (Japan)
1981-1982	Xin-Chang Gong, MD (China)
1981-1982	Yin-Mei Zhang, MD (China)
1981-1982	Bao-Lan Lu, MD (China)
1982-1982	Vadim Yuferov, PhD (Russia)
1983-1984	John Wood, PhD (England)
1986-1987	Hiroshi Kida, DVM, PhD (Japan)
1987-1988	Svetralana Yamnikova, MD (Russia)
1989-1989	Claude Lambre, PhD (France)
1991-1991	Yuanji Guo, MD (China)
1993-1993	Eric Claas, PhD (The Netherlands)
1994-1994	Shiqin He, MD (China)

1992-1996	Elena Govorkova, PhD (Russia)
1995-1995	Laura Campitelli, PhD (Italy)
1998-2000	Irina Leneva PhD (Russia)
1997-1999	Nan-Nan Zhou (China)

VISITING PROFESSORSHIPS (SABBATICAL):

Christoph Scholtissek, PhD (Germany)

Rescue of Influenza A Virus from Recombinant DNA

ERVIN FODOR,^{1,2} LOUISE DEVENISH,¹ OTHMAR G. ENGELHARDT,^{2†} PETER PALESE,²
GEORGE G. BROWNLEE,^{1*} AND ADOLFO GARCÍA-SASTRE²

Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom,¹ and
Department of Microbiology, Mount Sinai School of Medicine, New York, New York 10029²

Received 13 July 1999/Accepted 5 August 1999

We have rescued influenza A virus by transfection of 12 plasmids into Vero cells. The eight individual negative-sense genomic viral RNAs were transcribed from plasmids containing human RNA polymerase I promoter and hepatitis delta virus ribozyme sequences. The three influenza virus polymerase proteins and the nucleoprotein were expressed from protein expression plasmids. This plasmid-based reverse genetics technique facilitates the generation of recombinant influenza viruses containing specific mutations in their genes.

Reverse genetics for negative-strand RNA viruses, first developed for influenza virus (8, 22), has dramatically changed our understanding of the replication cycles of these viruses. In addition, this methodology has allowed genetic manipulation of viral genomes in order to generate new viruses, which can be used as live, attenuated vaccines or vectors to express heterologous proteins (12). The past 5 years have witnessed the rescue of most of the important nonsegmented, negative-strand RNA viruses from recombinant DNA. First, Schnell et al. (30) succeeded in the recovery of rabies virus from cloned DNA. Shortly after, rescue systems were developed for vesicular stomatitis virus (21, 32), respiratory syncytial virus (5, 18a), measles virus (29), Sendai virus (14, 20), and more recently for human parainfluenza type 3 (7, 17), rinderpest virus (1), simian virus 5 (16), bovine respiratory syncytial virus (4), and Newcastle disease virus (27). Bridgen and Elliott (3) succeeded in rescuing a segmented, negative-strand RNA virus, a bunyavirus, from cDNA. In general, all these methods rely on intracellular reconstitution of ribonucleoprotein (RNP) complexes from RNA and viral proteins, i.e., nucleoprotein and RNA-dependent RNA polymerase, which are introduced into cells by a variety of techniques. Generally, a recombinant vaccinia virus expressing T7 RNA polymerase is used to drive transcription of antigenomic positive-sense RNA as the template in order to initiate the replication cycle. Alternatively, transcription is driven by a T7 RNA polymerase, which is constitutively expressed in specific cell lines. Successful recoveries have also been reported by directly transfecting naked RNA (plus sense or minus sense) into cells expressing the essential proteins for encapsidation, transcription, and replication (20). Although reverse genetics techniques allowing genetic manipulation of negative-strand RNA viruses were established for influenza A virus before other negative-strand RNA viruses (8, 22, 31), full recovery of infectious influenza virus from cDNA without the use of helper virus has proved to be technically more difficult.

The genome of influenza A virus consists of eight segments of single-stranded, negative-sense RNA (25). The minimal set of viral proteins required for encapsidation, transcription, and replication of the viral genome are the three subunits of the

viral RNA-dependent RNA polymerase complex (PB1, PB2, and PA) and the nucleoprotein (NP) (18). Initially, in order to manipulate the genome of influenza virus, RNPs were reconstituted in vitro from RNA transcribed from plasmid DNA in the presence of polymerase proteins and NP isolated from purified influenza virus (8, 9). The in vitro-reconstituted RNPs were transfected into cells infected with a helper influenza virus, which provided the remaining viral proteins and RNA segments, resulting in the generation of transfectant viruses. This technique has been extremely useful in advancing our understanding of the molecular biology and pathogenicity of influenza viruses. However, it relies on highly specialized selection methods to isolate the transfectant viruses from the helper virus, which restricts its use to certain RNA segments of a limited number of viral strains.

More recently, alternative methods for introducing influenza virus RNPs into cells have been developed, based on intracellular reconstitution of RNPs from in vivo-transcribed RNA and intracellularly expressed viral proteins (23, 24, 28, 33). We showed that the three polymerase proteins (PB1, PB2, and PA) and the nucleoprotein (NP) expressed from recombinant plasmids could encapsidate, transcribe, and replicate an influenza virus viral RNA (vRNA)-like RNA containing a chloramphenicol acetyltransferase (CAT) reporter gene in transfected human 293 cells (28). This vRNA-like reporter gene was introduced into the cells by transfection of a plasmid DNA (pPOLI-CAT-RT) with a truncated human RNA polymerase I (Pol I) promoter (nucleotides [nt] –250 to –1) positioned upstream of the vRNA-coding region. The sequence of the hepatitis delta virus genomic ribozyme was positioned downstream of the vRNA-coding region in order to ensure that RNA processing gave the correct 3' end of the vRNA. It has also been demonstrated that, by replacing the plasmid coding for the CAT reporter gene with a plasmid encoding an authentic influenza vRNA segment, intracellularly reconstituted RNP complexes could be rescued into transfectant viruses upon infection of the transfected cells with an influenza helper virus. Thus, helper virus-based rescue systems using the RNA Pol I promoter-driven reverse genetics technique have been established for the segments encoding the neuraminidase (NA), the hemagglutinin (HA), the NS1 and NEP proteins, and the polymerase 2 basic protein (PB2) (11, 13, 26, 28). These results suggested that coexpression of the eight vRNA segments of influenza virus with the three polymerase proteins and the NP might allow rescue of infectious influenza virus from plasmid DNA.

In this report we describe the rescue of influenza A virus

* Corresponding author. Mailing address: Chemical Pathology Unit, Sir William Dunn School of Pathology, University of Oxford, South Parks Rd., Oxford OX1 3RE, United Kingdom. Phone: 44 (01865) 275559. Fax: 44 (1865) 275556. E-mail: George.Brownlee@path.ox.ac.uk.

† Present address: Department of Virology, University of Freiburg, D-79008 Freiburg, Germany.




FIG. 1. Schematic representation of the plasmid-based rescue system for influenza A virus. The pGT-h set of protein expression plasmids was constructed by inserting the open reading frames of PB1, PB2, PA, and NP proteins into the *BclI* cloning site of the pGT-h plasmid (2). The PB1 and PA genes were derived from influenza A/WSN/33 virus. The viral genomic sequences of influenza A/WSN/33 virus were cloned into pUC18- or pUC19-based plasmids between a truncated human RNA Pol I promoter ($\text{nt} -250$ to -1) (19) and sequences of the hepatitis delta virus ribozyme in an analogous way as described for pPOLI-CAT-RT (28). Genetic tags were inserted into the HA- and NA-encoding plasmids by using conventional mutagenic techniques. For viral rescue, 5 μg of each of the polymerase protein expression plasmids (pGT-h-PB1, pGT-h-PB2, and pGT-h-PA), 10 μg of the NP-expressing pGT-h-NP, and 3 μg of each of the eight vRNA-coding transcription plasmids (pPOLI-PB2-RT, pPOLI-PB1-RT, pPOLI-PA-RT, pPOLI-HA-RT, pPOLI-NP-RT, pPOLI-NA-RT, pPOLI-M-RT, and pPOLI-NS-RT) were diluted to a concentration of 0.1 $\mu\text{g}/\mu\text{l}$ in 20 mM HEPES buffer (pH 7.5). The DNA solution was added to diluted DOTAP liposomal transfection reagent (Boehringer) containing 240 μl of DOTAP and 720 μl of 20 mM HEPES buffer (pH 7.5). The transfection mixture was incubated at room temperature for 15 min, mixed with 6.5 ml of MEM containing 0.5% fetal calf serum, 0.3% bovine serum albumin, penicillin, and streptomycin and added to near-confluent Vero cells washed with phosphate-buffered saline in 8.5-cm dishes (about 10^7 cells). At 24 h after transfection, the transfection mixture was removed and the cells were incubated with 8 ml of fresh medium, which was replaced daily for 4 days. The harvested medium from transfected dishes was screened for rescued influenza virus by plaquing and amplification on MDBK cells. POL I, truncated human RNA polymerase I promoter; R, genomic hepatitis virus ribozyme; MLP, adenovirus type 2 major late promoter; pA, polyadenylation sequence from SV40.

from recombinant DNA. The system is entirely plasmid driven and does not involve the use of any helper or heterologous virus (Fig. 1). In order to recover infectious influenza virus from cloned cDNA, we used a mixture of eight plasmids expressing the individual vRNA segments of influenza A/WSN/33 virus from a truncated human Pol I promoter. We also replaced the previously used four protein expression plasmids, which expressed PB1, PB2, PA, and NP under the con-

trol of a mouse hydroxymethylglutaryl-coenzyme A reductase (HMG) promoter (28), with plasmids expressing the same proteins under the control of the adenovirus type 2 major late promoter (pGT-h-PB1, pGT-h-PB2, pGT-h-PA, and pGT-h-NP) (2). Cotransfection of these four plasmids with pPOLI-CAT-RT into 293 or Vero cells resulted in CAT expression (results not shown). We decided to use Vero cells for the virus rescue, since they support the growth of influenza A/WSN/33 virus better than 293 cells (about 1 log difference in maximum viral titers) (results not shown).

For virus rescue, near-confluent Vero cells in 8.5-cm-diameter dishes, were cotransfected with the four protein expression plasmids and the eight vRNA transcription plasmids (pPOLI-PB2-RT, pPOLI-PB1-RT, pPOLI-PA-RT, pPOLI-HA-RT, pPOLI-NP-RT, pPOLI-NA-RT, pPOLI-M-RT, and pPOLI-NS-RT). After 24 h, the transfection medium was removed from the cells and it was replaced with 8 ml of fresh medium (MEM) containing 0.5% fetal calf serum, 0.3% bovine serum albumin, penicillin, and streptomycin. The transfected cells were maintained for at least 4 days after transfection. Every day, the medium from the transfected cells was collected and assayed for the presence of influenza virus by plaquing a 0.5-ml aliquot on MDBK cells by standard methods. The rest of the medium was transferred into 75-cm² flasks of subconfluent MDBK cells for amplification of any rescued virus. This procedure resulted in the recovery of infectious influenza virus on day 4 posttransfection. We obtained about 10 to 20 PFU of virus from an 8.5-cm dish containing approximately 10^7 cells. The rescued virus showed a specific property which is characteristic of influenza A/WSN/33 virus, i.e., it formed plaques on MDBK cells in the absence of trypsin. The plaques formed by the rescued virus were comparable in size to those formed by an authentic wild-type influenza A/WSN/33 virus grown on the same MDBK cells (results not shown).

To formally prove that the viral plaques observed on MDBK cells were formed by virus derived from the cloned cDNA, we analyzed two of the eight vRNA segments into which genetic tags were introduced. The HA segment contained a mutation of 6 nucleotides near the 3' end of the vRNA (26). Nucleotides 31 to 35 from the 3' end (3'-UUUG-5') were replaced with 3'-AAAAC-5', resulting in an amino acid substitution at amino acid 4 (K→F) and at amino acid 5 (L→V) near the N terminus of HA within the signal peptide. In addition, a silent C→U mutation was created at nucleotide 40. These changes introduced several new restriction sites, including an *SpeI* site. The NA segment contained two silent mutations at nucleotides 1358 and 1360, introducing a novel *SacI* restriction site (28). Medium from MDBK cells infected with the rescued transfectant virus was used to isolate vRNA. Short regions of the HA and NA vRNA containing the genetic tags were amplified by reverse transcription-PCR (RT-PCR) and then analyzed by digestion with *SpeI* and *SacI* restriction enzymes, respectively. As a control, the same regions of the HA and NA segments were amplified from vRNA isolated from authentic A/WSN/33 virus using the same RT-PCR primers. As expected, the PCR products obtained from both viruses had identical sizes (Fig. 2, compare lanes 2 and 5 and lanes 7 and 10). Those originating from the HA and the NA segments of the rescued transfectant virus could be digested with *SpeI* and *SacI*, respectively (lanes 3 and 8). However, the PCR products from the authentic A/WSN/33 virus were, as expected, not digested (lanes 6 and 11). The omission of reverse transcriptase in control RT-PCR reactions resulted in no visible PCR products (lanes 4 and 9).

It should be pointed out that we have succeeded in recovering influenza virus from plasmids expressing negative-sense vRNA. This seems to contradict some earlier studies, which




FIG. 2. Demonstration of the presence of genetic tags in the HA and NA vRNA segments of the rescued virus by RT-PCR and restriction enzyme analysis. vRNA of the rescued virus was isolated from medium of infected MDBK cells. One hundred microliters of the medium was treated with 5 U of RNase-free DNase to remove any residual plasmid DNA carried over. After 15 min at 37°C, vRNA was isolated by using the RNeasy Mini Kit (Qiagen), following the manufacturer's instructions. vRNA from authentic wild-type A/WSN/33 virus was isolated from purified virus as described previously (10). The first 149 nt at the 3' end of the HA vRNA were amplified by RT-PCR using oligonucleotide primers 5'-GCGCTCTAGAGCAAAAGCAGGGAAAATAA-3' (corresponding to nt 1 to 21) and 5'-CGCGAAGCT TCTCGAATATTGTGTCAAC-3' (corresponding to nt 129 to 149), resulting in a 165-nt-long PCR product. To amplify the sequence containing the genetic tag from the NA segment, primers 5'-TGGACTAGTGGGAGCATCAT-3' (corresponding to nt 1280 to 1309) and 5'-GAACAAACTTGTCAATGGT-3' (corresponding to nt 1367 to 1388) were used in RT-PCR to produce a 108-nt PCR product. The HA- and NA-specific PCR products were incubated for 2 h at 37°C in the presence (+) or absence (-) of 10 U of *SpeI* and *SacI* restriction enzymes, respectively. Samples were analyzed on 16% polyacrylamide gels and stained with ethidium bromide. Lanes: 1, DNA size markers (sizes in nucleotides are indicated); 2, 3, 7, and 8, PCR products from the rescued virus; 4 and 9, control reactions omitting reverse transcriptase; 5, 6, 10, and 11, PCR products from the authentic wild-type A/WSN virus.

emphasized the importance of using positive-strand RNA for rescuing negative-strand RNA viruses (3, 29a, 30). However, more recent successful recoveries of negative-strand RNA viruses from negative-sense RNA have been also reported (7, 20). Since at early stages posttransfection, positive-sense mRNA from the four protein expression plasmids coexists with naked negative-sense genomic vRNA transcribed from the transcription plasmids, inevitably double-stranded RNA can form. Formation of double-stranded RNA could lead to the induction of interferon-mediated antiviral responses and consequently to suppression of the growth of any rescued virus. Therefore the use of a cell line, such as Vero, which is known to be deficient in interferon expression (6), might be an important factor for successful virus rescue. Further work, however, is needed to prove this.

At present, we are able to rescue 1 to 2 infectious viral particles from about 10^6 transfected cells, which corresponds with the "average" recoveries obtained for other negative-strand RNA viruses. By increasing transfection efficiencies and optimizing the ratio of transfected plasmids it might be possible to obtain higher recoveries of virus. Recently, Gómez-Puertas et al. (15) demonstrated that by optimizing plasmid ratios they can significantly increase the formation of influenza virus-like particles from expressed viral proteins. In addition, cell lines expressing essential proteins for encapsidation, transcription, and replication of viral genomic RNA (PB1, PB2, PA, and NP) could help to reduce the number of plasmids needed and thus increase the efficiency of rescue.

In summary, we have rescued a recombinant influenza A virus by cotransfected eight transcription plasmids for the individual vRNA segments and four protein expression plasmids, entirely from cDNA in the absence of any helper virus. The identity of the rescued virus was confirmed by providing evidence for the presence of two genetic tags in two different genome segments. The development of an entirely plasmid-based rescue system for influenza A virus opens the way for the study of different aspects of influenza virus replication and its interactions with the host cell. In addition, it allows full ma-

nipulation of the genome of the virus, which might result in the development of new vaccine strains not only for influenza, but for other infectious agents by introducing specific foreign epitopes into influenza virus proteins. In contrast to the earlier helper virus-based rescue techniques, the plasmid-based system can easily be used for the generation of infectious influenza viruses containing multiple mutations in several different genes at the same time.

We thank Andrew Gannon, Selvon St. Clair, and Stephan Pleschka for constructing several plasmids. We also thank Leo Poon, Jason Paragas, Thomas Zürcher, Masayoshi Enami, and David Pritchard for helpful discussions and Richard Jaskunas for advice.

This work was supported in part by grants from the MRC (programme grant G9523972 to G.G.B.) and the NIH (P.P. and A.G.S.). E.F. was supported by the Max Kade Foundation in New York (January 1997 to February 1998) and by the MRC programme grant to G.G.B. in Oxford (March 1998 to the present).

ADDENDUM IN PROOF

Following submission of this paper, Neumann et al. (G. Neumann, T. Watanabe, H. Ito, S. Watanabe, H. Goto, P. Gao, M. Hughes, D. R. Perez, R. Donis, E. Hoffmann, G. Hobom, and Y. Kawaoka, Proc. Natl. Acad. Sci. USA 96:9345–9350, 1999) provided independent evidence for a plasmid-based rescue of influenza A virus.

REFERENCES

1. Baron, M. D., and T. Barrett. 1997. Rescue of rinderpest virus from cloned cDNA. *J. Virol.* 71:1265–1271.
2. Berg, D. T., D. B. McClure, and B. W. Grinnell. 1993. High-level expression of secreted proteins from cells adapted to serum-free suspension culture. *BioTechniques* 14:972–978.
3. Bridgen, A., and R. Elliott. 1996. Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNAs. *Proc. Natl. Acad. Sci. USA* 93:15400–15404.
4. Buchholz, U. J., S. Finke, and K.-K. Conzelmann. 1999. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. *J. Virol.* 73:251–259.
5. Collins, P. L., M. G. Hill, E. Camargo, H. Grosfeld, R. M. Chanock, and

B. R. Murphy. 1995. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. *Proc. Natl. Acad. Sci. USA* **92**:11563–11567.

6. **Diaz, M. O., S. Ziemin, M. M. Le Beau, P. Pitha, S. D. Smith, R. R. Chilcote, and J. D. Rowley.** 1988. Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. *Proc. Natl. Acad. Sci. USA* **85**:5259–5263.

7. **Durbin, A. P., S. L. Hall, J. W. Siew, S. S. Whitehead, P. L. Collins, and B. R. Murphy.** 1997. Recovery of infectious human parainfluenza virus type 3 from cDNA. *Virology* **235**:323–332.

8. **Enami, M., W. Luytjes, M. Krystal, and P. Palese.** 1990. Introduction of site specific mutations into the genome of influenza virus. *Proc. Natl. Acad. Sci. USA* **87**:3802–3805.

9. **Enami, M., and P. Palese.** 1991. High-efficiency formation of influenza virus transfectants. *J. Virol.* **65**:2711–2713.

10. **Fodor, E., P. Palese, G. G. Brownlee, and A. García-Sastre.** 1998. Attenuation of influenza A virus mRNA levels by promoter mutations. *J. Virol.* **72**:6283–6290.

11. **Fodor, E., L. Devenish, J. W. McCauley, and W. S. Barclay.** Unpublished data.

12. **García-Sastre, A.** 1998. Negative-strand RNA viruses: applications to biotechnology. *Trends Biotechnol.* **16**:230–235.

13. **García-Sastre, A., A. Egorov, D. Matassov, S. Brandt, D. L. Levy, J. E. Durbin, P. Palese, and T. Muster.** 1998. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. *Virology* **252**:324–330.

14. **Garcin, D., T. Pelet, P. Calain, L. Roux, J. Curran, and D. Kolakofsky.** 1995. A highly recombinogenic system for the recovery of infectious Sendai paramyxovirus from cDNA: generation of a novel copy-back non-defective interfering virus. *EMBO J.* **14**:6087–6094.

15. **Gómez-Puertas, P., I. Mena, M. Castillo, A. Vivo, A. Pérez-Pastrana, and A. Portela.** 1999. Efficient formation of influenza virus-like particles: dependence on the expression levels of viral proteins. *J. Gen. Virol.* **80**:1635–1645.

16. **He, B., R. G. Paterson, C. D. Ward, and R. A. Lamb.** 1997. Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. *Virology* **237**:249–260.

17. **Hoffman, M. A., and A. K. Banerjee.** 1997. An infectious clone of human parainfluenza virus type 3. *J. Virol.* **71**:4272–4277.

18. **Huang, T.-S., P. Palese, and M. Krystal.** 1990. Determination of influenza virus proteins required for genome replication. *J. Virol.* **64**:5669–5673.

18a. **Jin, H. D. Clarke, H. Z. Zhou, X. Cheng, K. Coelingh, M. Bryant, and S. Li.** 1998. Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV. *Virology* **251**:206–214.

19. **Jones, M. H., R. M. Learned, and R. Tjian.** 1988. Analysis of clustered point mutations in the human ribosomal RNA gene promoter by transient expression in vivo. *Proc. Natl. Acad. Sci. USA* **85**:6669–673.

20. **Kato, A., Y. Sakai, T. Shioda, T. Kondo, M. Nakanishi, and Y. Nagai.** 1996. Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. *Genes Cells* **1**:569–579.

21. **Lawson, N. D., E. A. Stillman, M. A. Whitt, and J. K. Rose.** 1995. Recombinant vesicular stomatitis virus from DNA. *Proc. Natl. Acad. Sci. USA* **92**:4477–4481.

22. **Luytjes, W., M. Krystal, M. Enami, J. D. Parvin, and P. Palese.** 1989. Amplification, expression, and packaging of a foreign gene by influenza virus. *Cell* **59**:1107–1113.

23. **Neumann, G., and G. Hobom.** 1995. Mutational analysis of influenza virus promoter elements *in vivo*. *J. Gen. Virol.* **76**:1709–1717.

24. **Neumann, G., A. Zobel, and G. Hobom.** 1994. RNA polymerase I-mediated expression of influenza viral RNA molecules. *Virology* **202**:477–479.

25. **Palese, P.** 1977. The genes of influenza virus. *Cell* **10**:1–10.

26. **Palese, P., H. Zheng, O. G. Engelhardt, S. Pleschka, and A. García-Sastre.** 1996. Negative-strand RNA viruses: genetic engineering and applications. *Proc. Natl. Acad. Sci. USA* **93**:11354–11358.

27. **Peeters, B. P. H., O. S. de Leeuw, G. Koch, and A. L. J. Gielkens.** 1999. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. *J. Virol.* **73**:5001–5009.

28. **Pleschka, S., S. R. Jaskunas, O. G. Engelhardt, T. Zürcher, P. Palese, and A. García-Sastre.** 1996. A plasmid-based reverse genetics system for influenza A virus. *J. Virol.* **70**:4188–4192.

29. **Radecke, F., P. Spielhofer, H. Schneider, K. Kaelin, M. Huber, C. Dötsch, G. Christiansen, and M. A. Billeter.** 1995. Rescue of measles virus from cloned DNA. *EMBO J.* **14**:5773–5784.

29a. **Roberts, A., and J. K. Rose.** 1998. Recovery of negative-strand RNA viruses from plasmid DNAs: a positive approach revitalizes a negative field. *Virology* **247**:1–6.

30. **Schnell, M. J., T. Mebatson, and K. K. Conzelmann.** 1994. Infectious rabies viruses from cloned cDNA. *EMBO J.* **13**:4195–4203.

31. **Seong, B. L., and G. G. Brownlee.** 1992. A new method for reconstituting influenza polymerase and RNA *in vitro*: a study of the promoter elements for cRNA and vRNA synthesis *in vitro* and viral rescue *in vivo*. *Virology* **186**:247–260.

32. **Whelan, S. P. J., L. A. Ball, J. N. Barr, and G. T. W. Wertz.** 1995. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. *Proc. Natl. Acad. Sci. USA* **92**:8388–8392.

33. **Zhang, H., and G. M. Air.** 1994. Expression of functional influenza virus A polymerase proteins and template from cloned cDNAs in recombinant vaccinia infected cells. *Biochem. Biophys. Res. Commun.* **200**:95–101.

Available online at www.sciencedirect.com

SCIENCE @ DIRECT®

Virus Research 103 (2004) 155–161

**Virus
Research**

www.elsevier.com/locate/virusres

Efficient generation and growth of influenza virus A/PR/8/34 from eight cDNA fragments

Emmie de Wit, Monique I.J. Spronken, Theo M. Bestebroer, Guus F. Rimmelzwaan,
Albert D.M.E. Osterhaus, Ron A.M. Fouchier*

National Influenza Center and Department of Virology, Erasmus MC, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands

Available online 22 April 2004

Abstract

A reverse genetics system for the generation of influenza virus A/PR/8/34 (NIBSC vaccine strain) from plasmid DNA was developed. Upon transfection of eight bidirectional transcription plasmids encoding the gene segments of A/PR/8/34 into 293T cells, virus titers in the supernatant were about 10^4 TCID₅₀/ml. The production of A/PR/8/34 in 293T cells was compared to that of A/WSN/33, for which virus titers in the supernatant were 10^7 – 10^8 TCID₅₀/ml. Time-course analysis of virus production indicated that the differences in virus titers were due to reinfection of 293T cells by A/WSN/33 but not A/PR/8/34. Indeed, virus titers of A/PR/8/34 comparable to those of A/WSN/33 were achieved upon addition of trypsin to the culture medium of transfected cells. The production of chimeric viruses revealed that the difference in virus titers between A/PR/8/34 and A/WSN/33 are determined primarily by differences in the surface glycoproteins hemagglutinin and neuraminidase and the polymerase protein PB1. In conclusion, high-titer virus stocks of recombinant influenza A/PR/8/34 virus can be produced as well as virus stocks with much lower titers, but without the requirement of virus amplification through replication.

© 2004 Elsevier B.V. All rights reserved.

Keywords: Influenza A/PR/8/34; Reverse genetics; Chimeric viruses; Fourth 3' nucleotide

1. Introduction

For a long time the fundamental research of influenza A viruses has been hampered by the lack of availability of efficient reverse genetics systems. Although the earliest reverse genetics techniques for negative stranded RNA viruses were in fact developed for influenza A virus (Enami et al., 1990; Luytjes et al., 1989), the rescue of this virus exclusively from recombinant DNA was achieved only recently (Fodor et al., 1999; Neumann et al., 1999). Recombinant influenza virus was produced upon transfection of eukaryotic cells with a set of eight plasmids from which each of the genomic viral RNA (vRNA) segments was transcribed by RNA polymerase I and a set of four additional plasmids expressing the nucleoprotein (NP) and the polymerase proteins PB1, PB2, and PA. The reported efficiencies of virus production using these 12-plasmid systems were relatively low with less than 10^4 plaque-forming units (pfu) of

influenza virus A/WSN/33 per ml of transfected cell supernatant. Neumann et al. reported that upon co-expression of five additional plasmids encoding the hemagglutinin (HA), neuraminidase (NA), matrix proteins 1 and 2 (M1 and M2) and non-structural protein 2 (NS2), virus titers in the supernatants could be increased up to 5×10^7 pfu/ml. An elegant modification of these 12 and 17-plasmid systems came from Hoffmann et al. who implemented bidirectional vectors to reduce the number of transfected plasmids to eight. With this system, the negative-stranded vRNA and the positive-stranded mRNA can be synthesized from the same plasmid and virus titers up to 2×10^7 were reported (Hoffmann et al., 2000). The ability to produce recombinant influenza A virus rapidly and at such high titers will greatly facilitate future influenza virus research. Indeed, several influenza virus strains have now been produced from recombinant DNA to address a number of fundamental research questions in the influenza virus field (Hatta et al., 2001, 2002). In addition, these techniques may be used to produce "conventional" vaccine viruses and to design live attenuated vaccines through genetic engineering. Finally, the use of influenza A viruses as gene delivery vectors and

* Corresponding author. Tel.: +31-10-4088066; fax: +31-10-4089485.
E-mail address: r.fouchier@erasmusmc.nl (R.A.M. Fouchier).

to express foreign proteins of interest may now be employed.

It is important to note that the reverse genetics systems described above are all based on influenza virus A/WSN/33 (H1N1). Although influenza virus A/WSN/33 has been used successfully to address many research questions, the surface glycoproteins of this virus have properties that may be undesirable for certain purposes. The NA of A/WSN/33 can bind plasminogen that upon conversion to plasmin can cleave the HA to yield functional HA₁ and HA₂ subunits (Goto and Kawaoka, 1998). As a result, the virus can replicate without trypsin in *in vitro* cell cultures. For certain purposes, such as mutagenesis studies, virus replication in the transfected producer cells may be undesirable since reverse mutations and second-site mutations may occur. Moreover, for the generation of reassortant viruses to be used as vaccines, influenza virus A/PR/8/34 has been the strain of choice for many years. Therefore, we have designed a reverse genetics system to produce recombinant influenza virus A/PR/8/34. We have used both the 12-plasmid and 8-plasmid systems and compared the virus production of A/PR/8/34 with A/WSN/33. We conclude that virus titers of ~10⁴ can be obtained without virus replication in the transfected cell culture which can be boosted to >10⁷ when the virus is allowed to replicate. This reverse genetics system may thus be useful for research purposes as well as for the production of vaccine virus.

2. Materials and methods

2.1. Cells and viruses

Madin–Darby Canine kidney (MDCK) cells were cultured in EMEM (BioWhittaker) supplemented with 10% FCS, 100 IU/ml penicillin, 100 µg/ml streptomycin, 2 mM glutamine, 1.5 mg/ml sodium bicarbonate, 10 mM Hepes and non-essential amino acids. 293T cells were cultured in DMEM (BioWhittaker) supplemented with 10% FCS, 100 IU/ml penicillin, 100 µg/ml streptomycin, 2 mM glutamine, 1 mM sodium pyruvate, and non-essential amino acids.

Influenza virus A/PR/8/34 was kindly provided by Dr. Wood, the National Institute for Biological Standards and Control, Potters Bar, United Kingdom. Because this strain is adapted for replication in embryonated chicken eggs and may not replicate optimally in mammalian cell cultures, this virus was passaged seven times at a low multiplicity of infection in MDCK cells grown in Episert media (Gibco BRL) supplemented with 10 IU/ml penicillin and 10 µg/ml streptomycin. After the seventh passage virus titers of 10⁸ TCID₅₀/ml were obtained routinely.

2.2. Transfection of 293T cells

Transient calcium phosphate-mediated transfections of 293T cells were performed essentially as described (Pear-

et al., 1993). Cells were plated the day before transfection in gelatinized 100 mm diameter culture dishes to obtain 50% confluent monolayers. After overnight transfection with 25–50 µg plasmid DNA, the transfection medium was replaced with fresh medium supplemented with 2% FCS for virus production or 10% FCS for all other transfections. Cells were incubated for 30–72 h, after which supernatants were harvested and cells were analyzed for fluorescence if appropriate. Plasmid pEGFP-N1 (Clontech, BD Biosciences, Amsterdam, The Netherlands) was transfected in parallel in all experiments and the percentage of fluorescent cells was measured in a FACScan, confirming that the transfection efficiency ranged from 95 to 100%. Virus-containing supernatants were cleared by centrifugation for 10 min at 300 × g. Virus titers in the supernatant were determined either directly or upon storage at 4 °C for less than 1 week, or at –80 °C for longer than 1 week.

2.3. Plasmids

Plasmids pPOLI-CAT-RT, pHMG-PB1, pHMG-PB2, pHMG-PA and pHMG-NP were a kind gift from Drs. Garcia-Sastre and Palese (Mount Sinai School of Medicine, New York, USA), plasmids pH1863 and pH2428 from Dr. Hobom (University of Giessen, Germany) and plasmids pHW2000, and pHW181 through pHW188 from Dr. Webster (St. Jude Children's Research Hospital, Memphis, TN, USA).

The human RNA polymerase I promoter (Phu) was amplified by PCR using plasmid pH1863 as template and cloned in plasmid pSP72 (Promega Biotech, Leiden, The Netherlands) using XbaI and XbaI sites included in the primers. The murine RNA polymerase I terminator or the hepatitis delta ribozyme sequence were amplified by PCR using plasmids pH2428 or pPOLI-CAT-RT as templates and cloned in pSP72-Phu using XbaI and BamHI sites present in the primers to give plasmids pSP72-PhuTmu and pSP72-PhuThep, respectively. Flanking the XbaI site between the Phu and Tmu or Thep sequences we included BpuAI sites to enable the forced directional cloning of influenza A virus cDNAs in these vectors. The eight genomic segments from influenza virus A/PR/8/34 were amplified by RT-PCR and cloned in pSP72-PhuThep (segments 2 and 6) or pSP72-PhuTmu (all other segments). Vector pSP72-PhuThep was used for segments 2 and 6 because pSP72-PhuTmu did not yield the desired recombinant plasmids for unknown reasons. Of note, vectors pSP72-PhuTmu and pSP72-PhuThep work equally well in transient assays in 293T cells (data not shown). To generate bidirectional expression vectors, plasmid pHW2000 was modified so that the BsmBI sites were at the same positions relative to the RNA polymerase I promoter and terminator sequences as the BpuAI sites in our own constructs. The eight genomic segments from influenza virus A/PR/8/34 were subsequently amplified by PCR and cloned in this modified pHW2000 vector. All plasmids were sequenced using a Dye-terminator ET

terminator sequencing kit (Amersham Pharmacia Biotech, Roosendaal, The Netherlands) and an ABI 373 automatic DNA sequencer (PE Biosystems), according to the instructions of the manufacturer. All PCR primer sequences and plasmid maps are available on request.

2.4. Virus titration

Virus titrations were performed as described previously (Rimmelzwaan et al., 1998). Briefly, 10-fold serial dilutions of the transfected cell supernatants were prepared in infection medium. Infection medium consisted of EMEM (BioWhittaker) supplemented with 4% bovine serum albumine (fraction V, GibcoBRL), 100 IU/ml penicillin, 100 µg/ml streptomycin, 2 mM glutamine, 1.5 mg/ml sodium bicarbonate, 10 mM Hepes, non-essential amino acids, and 25 µg/ml trypsin. Prior to inoculation, the cells were washed twice with PBS. One hundred milliliter of the diluted culture supernatants was used to inoculate a confluent monolayer of MDCK cells in 96 wells plates. After 1 h at 37 °C the cells were washed again with PBS and 200 µl fresh infection medium was added to each well. At 3 days post infection, the supernatants of these cultures were tested for HA activity as an indicator for infection of the cells in individual wells. The titers of infectivity were calculated from 10 replicates according to the method of Spearman–Karber.

3. Results

3.1. A reverse genetics system for influenza virus A/PR/8/34

Influenza virus A/PR/8/34, obtained from the National Institute for Biological Standards and Control, United Kingdom, was passaged seven times in MDCK cells in the presence of trypsin. This virus was found to replicate

to high titers in embryonated eggs and MDCK cell cultures (data not shown). The eight genomic segments of this virus were amplified by PCR and cloned into plasmids pSP72-PhuTmu or pSP72-PhuThep. Each of the eight plasmids was sequenced and the sequences were compared with those of A/PR/8/34 and other influenza A virus sequences available from the Influenza Sequence Database (<http://www.flu.lanl.gov>) (Table 1). For the total genome of A/PR/8/34 which is 13 588 nucleotides in length, we found 111 nucleotide substitutions as compared to sequences of A/PR/8/34 available from the database, resulting in 39 amino acid substitutions. This is not surprising since the passage history of the two A/PR/8/34 strains may be quite different. Analysis of all the sequences available from the Influenza Sequence Database revealed that of these 39 amino acid substitutions only one was unique to A/PR/8/34.

The eight constructs encoding the gene segments of A/PR/8/34 were transfected into 293T cells together with expression plasmids for the polymerase proteins and nucleoprotein of influenza virus A/PR/8/34: HMG-PB2, HMG-PB1, HMG-PA, and HMG-NP (Pleschka et al., 1996). At 72 h after transfection, an infectious virus titer of 1×10^3 TCID₅₀/ml of influenza virus A/PR/8/34 was detected in the culture supernatant. However, when this experiment was subsequently repeated five times, virus could be produced only once more with equally low virus titers (data not shown). The inability to generate recombinant virus reproducibly was not due to low transfection efficiencies, since transfections with pEGFP-N1 performed in parallel with these experiments revealed >99% fluorescent cells in these cultures as measured in a FACScan.

In the meantime, a bidirectional 8-plasmid reverse genetics system was described by Hoffmann et al. that we compared with our own 12-plasmid system. To this end, cDNAs encoding the gene segments of influenza virus A/PR/8/34 were cloned into plasmid pHW2000 (Hoffmann et al., 2000).

Table 1
Comparison of nucleotide and amino acid sequences of the genome of MDCK-adapted A/PR/8/34* with those of A/PR/8/34 and A/WSN/33 from the Influenza Sequence Database

Gene segment	Encoded protein	A/PR/8/34			A/WSN/33		
		Accession number	Nucleotide substitutions	Amino acid substitutions	Accession number	Nucleotide substitutions	Amino acid substitutions
1	PB2	NC002023	19	7	J02179	89	26
2	PB1	NC002021	18	8	J02178	62	22
	PB1F2		3	3		10†	8†
3	PA	NC002022	20	1	X17336	65	17
4	HA	NC002017	13	9	J02176	105	54
5	NP	NC002019	15	4	M30746	56	15
6	NA	NC002018	9	5	J02177	82	38
7	M1	NC002016	6	0	L25818	34	5
	M2			2			9
8	NS1	NC002020	11	2	M12597	32	8
	NS2			1			6

* These sequences are available from the Influenza Sequence Database under accession numbers ISDN13419-13426.

† Total insertion counted as a single substitution.

Of note, the sequence of each of the A/PR/8/34 gene segments was identical to that in the 12-plasmid system. Transfection of the eight plasmids encoding the gene segments of influenza virus A/PR/8/34 resulted in a virus titer in the supernatant of $\sim 10^4$ TCID₅₀/ml 30 h post transfection. More importantly, the virus titers obtained in these transfection experiments were highly reproducible. The titers that we obtained upon transfection of constructs encoding the eight gene segments of influenza virus A/WSN/33 into 293T cells were much higher, however, ranging from 10^7 – 10^8 TCID₅₀/ml.

3.2. Effect of mutations at position 4 of the 3' terminus

The eight genomic cDNAs inserted in both the 12-plasmid system and the 8-plasmid system were generated using primers specific for the 12 conserved nucleotides (nt) at the 3' terminus and 13 nt at the 5' terminus. The virus-specific sequence at the 3' terminus was UCGUUUUUCGUCC, despite the fact that for A/PR/8/34 gene segments 1, 2, 3, 6, and 7 the fourth nucleotide position was reported to be C rather than U (according to the Influenza Sequence Database; <http://www.flu.lanl.gov>). To test the effect of mutations at the position 4 nt in the 3' terminus, we generated a set of 8 plasmids containing the eight gene segments of A/PR/8/34 with a C at position 4. The nucleotide sequence of each of these gene segments was identical to the sequence of the original constructs except for this fourth nucleotide. Upon transfection of 8 plasmids with a C at position 4, virus titers were 5.2×10^3 TCID₅₀/ml, which is slightly higher than upon transfection of 8 plasmids with a U at position 4 (mean virus titer of 3.3×10^3 TCID₅₀/ml). We next generated sets of recombinant viruses in which each of the genomic segments was replaced with a segment containing C at position 4. These viruses were all produced at comparable levels. The virus titers obtained upon transfection of plasmids representing "wild type" A/PR/8/34 according to the Influenza Sequence Database, with a U in segments 4, 5, and 8 and a C in segments 1, 2, 3, 6, and 7 resulted in a virus titer of 1.1×10^4 TCID₅₀/ml. From these data we concluded that the low virus titers obtained with A/PR/8/34 were not due to mutations at position 4 in our set of plasmids.

3.3. Increased virus titers due to reinfection

The HA precursor protein (HA₀) of influenza A viruses is cleaved by cellular proteases into HA₁ and HA₂ subunits to yield membrane fusion-competent virus particles. For many *in vitro* cell cultures infected with influenza A virus, trypsin is added to the culture medium to enable cleavage of HA. Influenza virus A/WSN/33 can replicate in cell cultures without the addition of trypsin to the culture medium. The NA of A/WSN/33 can bind plasminogen that is converted to plasmin, which can subsequently cleave the HA₀ into functional HA₁ and HA₂ subunits (Goto and Kawaoka, 1998). We therefore wished to test if the differences in virus titers




Fig. 1. Virus production in the presence and absence of trypsin. Supernatant of 293T cells transfected with constructs encoding A/WSN/33 (○) or A/PR/8/34 (▲) was harvested at different time points after transfection and titrated on MDCK cells (panel A). Average and standard deviation calculated from two independent experiments are shown. After transfection, trypsin was added to the supernatant of 293T cells transfected with constructs encoding A/PR/8/34 or A/WSN/33 (B). Supernatants were harvested 72 h after transfection and titrated on MDCK cells. (White bars) no trypsin and (black bars) with trypsin. Average and standard deviation calculated from three independent experiments are shown.

between influenza viruses A/WSN/33 and A/PR/8/34 could be explained by trypsin-independent replication in the 293T cells by A/WSN/33 but not by A/PR/8/34.

To this end, we first performed time-course analyses of virus production from 293T cells transfected with constructs encoding either influenza virus A/PR/8/34 or A/WSN/33. Influenza viruses A/PR/8/34 and A/WSN/33 were produced at the same rate during the first 24 h of virus production after transfection. However, from 24 h post transfection onwards, virus production from cells transfected with constructs encoding A/PR/8/34 hardly increased, while virus production from cells transfected with constructs encoding A/WSN/33 continued to increase logarithmically until 36 h post infection (Fig. 1A). The A/WSN/33 virus particles produced late after transfection could well be derived from 293T cells infected with virus produced in the early phase.

To gain further evidence that the high influenza virus A/WSN/33 titer could indeed be caused by the trypsin-independent infection of 293T cells by influenza virus A/WSN/33 but not by A/PR/8/34, we next added trypsin to the culture medium after transfection of 293T cells to a concentration of 0.25 mg/ml. Indeed, upon the addition of trypsin, the virus titers of influenza virus A/PR/8/34 were at the same level as those of influenza virus A/WSN/33 (Fig. 1B). These data indicate that the inability of influenza virus A/PR/8/34 to infect 293T cells without the addition

of trypsin to the culture medium can explain relatively low virus titers of recombinant virus produced from 293T cells. By adding trypsin to the culture medium of transfected 293T cells it is possible to produce high titers of influenza virus A/PR/8/34.

3.4. Analysis of A/WSN/33-A/PR/8/34 chimeric viruses

We next wished to address the question whether NA was the sole determinant of the difference in virus titers obtained with influenza virus A/PR/8/34 and A/WSN/33 due to trypsin-independent replication of the latter virus. To this end, chimeric influenza viruses were produced consisting of seven gene segments of influenza virus A/WSN/33 and one of influenza virus A/PR/8/34 and vice versa and virus titers were determined in MDCK cells. Virus titers obtained upon transfection of 293T cells with constructs encoding seven influenza virus A/PR/8/34 gene segments and one influenza virus A/WSN/33 gene segment were lower than those of wild type influenza virus A/PR/8/34, except when segments 2 (PB1) or 7 (M) of A/WSN/33 were used (Fig. 2A). Although PB1 and M could be partially responsible for low A/PR/8/34 virus titers, the titers obtained with A/PR/8/34 and WSN-PB1 or WSN-M were not nearly as high as wild type A/WSN/33. Therefore, it appeared that none of the gene segments of influenza virus A/PR/8/34 were solely respons-

sible for the low virus titers of influenza virus A/PR/8/34 compared to A/WSN/33.

Viruses with seven influenza virus A/WSN/33 gene segments and one gene segment derived from A/PR/8/34 all yielded titers below wild type A/WSN/33 titers. Upon exchange of gene segments 1, 3, 5, 7, and 8 virus titers were reduced by less than one order of magnitude. The exchange of HA and NA gene segments resulted in a 97-fold and 75-fold reduction in virus production, respectively. Influenza virus A/WSN/33 with PB1 of A/PR/8/34 produced a virus titer that was four orders of magnitude lower than that of wild type A/WSN/33 (Fig. 2B).

Since the receptor-binding activity of HA needs to be balanced by the receptor-removing activity of NA, we generated chimeric virus in which the HA and NA genes of influenza viruses A/PR/8/34 and A/WSN/33 were exchanged simultaneously. Supernatants were harvested 72 h after transfection of 293T cells and titrated on MDCK cells. Compared to 293T cells transfected with constructs encoding all eight influenza virus A/WSN/33 gene segments, cells transfected with constructs encoding six influenza virus A/WSN/33 gene segments and HA and NA of influenza virus A/PR/8/34 produced 141-fold less virus. The 293T cells transfected with six influenza virus A/PR/8/34 gene segments and HA and NA of influenza virus A/WSN/33 produced 224-fold more virus than cells transfected with eight constructs encoding influenza virus A/PR/8/34 (Fig. 3). These chimeric viruses thus demonstrated that the viral surface glycoproteins play a significant role in determining the virus titers produced from 293T cells. Since we already showed that PB1 had a significant influence on virus titers produced in 293T cells (Fig. 2), we next exchanged PB1 together with HA and NA. Recombinant influenza virus A/WSN/33 with segments 2, 4 and 6 of A/PR/8/34 yielded extremely low (34.1 TCID₅₀/ml) virus titers from transfected 293T cells. The reciprocal exchange of A/PR/8/34 with segment 2, 4, and 6 of A/WSN/33 yielded virus titers of 3.3×10^6 TCID₅₀/ml, which is in the same range as virus titers obtained with wild type influenza virus A/WSN/33. These data suggest that the differences in virus titers between recombinant influenza virus A/WSN/33




Fig. 2. Production of chimeric influenza viruses from transfected 293T cells. Cells were transfected with seven constructs encoding the gene segments of A/PR/8/34 and one derived from A/WSN/33 as indicated (panel A) or seven gene segments encoding the gene segments of A/WSN/33 and one derived from A/PR/8/34 as indicated (panel B). The first bar in the panel represents wild type A/PR/8/34 (A) or wild type A/WSN/33 (B). Supernatants of transfected cells were harvested 30 h after transfection and titrated on MDCK cells to determine virus titers. Error bars indicate the standard deviation from three independent experiments.




Fig. 3. Virus production upon exchange of HA, NA, and PB1 between A/PR/8/34 and A/WSN/33. Transfected 293T supernatants were harvested at 72 h post transfection and titrated on MDCK cells to determine virus titers. (White bars) wild type virus, (grey bars) exchange of HA and NA, (black bars) exchange of HA, NA, and PB1. Average and standard deviation calculated from four independent experiments are shown.

and A/PR/8/34 are determined primarily by the viral surface glycoproteins and PB1.

4. Discussion

Here, we describe a reverse genetics system for the NIBSC vaccine strain influenza virus A/PR/8/34 adapted to MDCK cells. A bidirectional 8-plasmid transcription system that was first described for influenza virus A/WSN/33 (Hoffmann et al., 2000) was found to be superior to our in-house unidirectional 12-plasmid transcription system. A large difference was observed in the amount of virus produced from 293T cells transfected with constructs encoding influenza virus A/PR/8/34 and A/WSN/33 and the molecular basis for this difference was investigated. The production of A/PR/8/34 could be increased slightly by changing the 3' position 4 nucleotide from a U to a C in the non-coding region (NCR) of gene segments 1, 2, 3, 6, and 7. The NCRs contain the promoter region for transcription and replication, bind the polymerase proteins and are involved in influenza virus packaging. Lee and Seong showed that the 3' position 4 nucleotide in the NCR of NA is involved in the temporal regulation of transcription and replication of NA (Lee and Seong, 1998). If this is true for all gene segments, this could explain the fact that the right combination of Us and Cs in all gene segments can lead to a higher virus yield. It should be noted, however, that the differences in virus titers for our mutant viruses were much smaller than expected from these studies on the NA gene segment.

Our time-course analyses showed that despite similar rates of virus production during the early phase after transfection, virus production of A/PR/8/34 and A/WSN/33 was different after >24 h post transfection. Whereas the amount of virus produced by cells transfected with constructs encoding influenza virus A/PR/8/34 hardly increased from 24 h after transfection onwards, the virus titers in the supernatant of cells transfected with constructs encoding influenza virus A/WSN/33 continued to increase logarithmically (Fig. 1A). Presumably, viruses produced relatively early after transfection were the direct result of transfection of the 293T cells whereas the late production of virus may be explained by the amplification of influenza virus A/WSN/33 by infection of 293T cells.

Indeed, the low titers of influenza virus A/PR/8/34 could be explained by the trypsin-dependent replication of this virus in 293T cells. The addition of trypsin to the culture medium of 293T cells transfected with the constructs encoding influenza virus A/PR/8/34 resulted in virus titers in the supernatant similar to those of cells transfected with constructs encoding influenza virus A/WSN/33 (Fig. 1B).

The construction of PB1 chimeric viruses indicated that this gene has a major influence on the amount of virus produced from 293T cells (Fig. 2). The amino acid sequences of PB1 of influenza viruses A/PR/8/34 and A/WSN/33 are 97.0% identical (Table 1). All but one of the amino acid

residues that are different between PB1 of A/PR/8/34 and A/WSN/33 are found in other strains for which sequences are available from the Influenza Sequence Database, and it is therefore unlikely that these differences have detrimental effects on virus replication. However, A/PR/8/34 has a unique serine residue at position 394 of PB1, which is in the region of PB1 that is involved in binding to cRNA (Gonzalez and Ortín, 1999). Theoretically, this substitution could be (partially) responsible for the low virus titers obtained with A/PR/8/34. However, mutagenesis of this residue in PB1 of A/PR/8/34 did not result in differences in virus titers (data not shown).

PB1 has polymerase activity and binds to PB2 and PA (Gonzalez et al., 1996), vRNA and cRNA (González and Ortín, 1999). One of the possible explanations for the effect of PB1 on virus production is that one of these functions is performed better by PB1 of A/WSN/33 as compared to that of influenza virus A/PR/8/34. Another possibility is that the recently discovered peptide PB1F2, encoded by an alternative open reading frame of PB1 is responsible for differences in virus titers. For influenza virus A/PR/8/34 the PB1F2 open reading frame encodes a 87-residue peptide that causes apoptosis (Chen et al., 2001). In A/WSN/33 this open reading frame is also present but is 3 amino acid residues longer than PB1F2 of A/PR/8/34 and different at seven amino acid positions (Table 1). These differences may affect the function of the protein and thereby have an effect on the amount of virus that is produced. However, this is not very likely since Chen et al. could not detect obvious differences in growth ability in eggs, MDCK or MBDK cells between wild type and PB1F2-deficient viruses.

Upon exchange of the HA and NA of A/PR/8/34 with those of A/WSN/33, virus titers in the 293T supernatant were almost as high as those of wild type influenza virus A/WSN/33. When A/WSN/33 had the HA and NA of influenza virus A/PR/8/34 inserted, virus titers dropped but were not as low as those of wild type A/PR/8/34. Upon exchange of PB1 in addition to HA and NA, virus titers were similar to those of wild type viruses. The effect of HA and NA on virus titers is not determined by WSN-NA alone, since WSN-NA in the context of A/PR/8/34 virus did not result in virus titers similar to A/WSN/33 wild type virus. It was shown by Kawaoka et al. that in the 1957 and 1968 pandemic viruses besides HA and NA, PB1 originated from an avian influenza strain (Kawaoka et al., 1989). Also, Hatta et al. were not able to generate reassortant viruses consisting of seven gene segments of A/Mallard/New York/6750/78 and either PB1, PA, HA or NA of A/Memphis/8/88 (Hatta et al., 2002). These data may suggest that PB1, HA and NA can not be easily exchanged between different influenza virus strains.

Our observation that influenza virus A/WSN/33 replicates in cell culture after transfection indicates that care must be taken if this strain is used for mutagenesis studies. Although high virus yields are beneficial for such experiments, undesired mutations may be acquired during these limited

rounds of virus replication. Similarly, cocultivation of transfected 293T cells with MDCK cells or the addition of trypsin to the culture medium may result in increased virus titers, but could also result in reverse mutations and second-site mutations which are undesirable in many studies. Influenza viruses A/Teal/HK/W312/97 (Hoffmann et al., 2000), A/Hong Kong/483/97, and A/HK/486/97 (Hatta et al., 2001), A/Mallard/NY/6750/78 A/Memphis/8/88 (Hatta et al., 2002) were also generated using a 8-plasmid or 12-plasmid reverse genetics system. For efficient generation of high virus stocks of these viruses, however, it was necessary to amplify these viruses in either MDCK cells or embryonated chicken eggs. Recently Schickli et al. and Hoffmann et al. also produced A/PR/8/34 from recombinant DNA using a 12-plasmid and a 8-plasmid system, respectively. Influenza virus A/PR/8/34 reassortant viruses were produced with HA and NA of different influenza A virus subtypes in 293T cells cocultured with MDCK cells (Hoffmann et al., 2002; Schickli et al., 2001). Using a similar approach we have generated A/PR/8/34(NIBSC)-H3N2 reassortant viruses (data not shown), that could be used to generate vaccine strains in the future.

In the reverse genetics system shown here for the NIBSC vaccine strain of influenza virus A/PR/8/34, replication does not appear to occur in 293T cells and it may therefore be the system of choice for some research projects despite the lower virus titers. When needed, e.g. for vaccine virus production, high virus titers of influenza virus A/PR/8/34 can be achieved by adding trypsin to the culture medium of transfected cells, or cocultivation of transfected 293T cells with cells that are more susceptible to virus replication as was also done by Schickli et al. and Hoffmann et al. (Hoffmann et al., 2002).

Acknowledgements

We wish to thank S. Herfst for excellent technical assistance, J. Wood for providing influenza virus A/PR/8/34, A. Garcia-Sastre and P. Palese for plasmids pPOLI-CAT-RT, pHMG-PB1, pHMG-PB2, pHMG-PA and pHMG-NP, G. Hobom for plasmids pH1863 and pH2428, and R. Webster for plasmids pHW2000 and pHW181 through pHW188. Part of this work was supported by Solvay Pharmaceuticals B.V., Weesp, The Netherlands and the Foundation for Respiratory Virus Infections. R.F. is a fellow of the Royal Dutch Academy of Arts and Sciences.

References

- Chen, W., Calvo, P.A., Malide, D., Gibbs, J., Schubert, U., Bacik, I., Basta, S., O'Neill, R., Schickli, J., Palese, P., Henklein, P., Bennink, J.R., Yewdell, J.W., 2001. A novel influenza A virus mitochondrial protein that induces cell death. *Nat. Med.* 7 (12), 1306–1312.
- Enami, M., Luytje, W., Krystal, M., Palese, P., 1990. Introduction of site-specific mutations into the genome of influenza virus. *Proc. Natl. Acad. Sci. USA* 87 (10), 3802–3805.
- Fodor, E., Devonish, L., Engelhardt, O.G., Palese, P., Brownlee, G.G., Garcia-Sastre, A., 1999. Rescue of influenza A virus from recombinant DNA. *J. Virol.* 73 (11), 9679–9682.
- Gonzalez, S., Ortín, J., 1999. Distinct regions of influenza virus PB1 polymerase subunit recognize vRNA and cRNA templates. *EMBO J.* 18 (13), 3767–3775.
- Gonzalez, S., Zurcher, T., Ortín, J., 1996. Identification of two separate domains in the influenza virus PB1 protein involved in the interaction with the PB2 and PA subunits: a model for the viral RNA polymerase structure. *Nucleic Acids Res.* 24 (22), 4456–4463.
- Goto, H., Kawakita, Y., 1998. A novel mechanism for the acquisition of virulence by a human influenza A virus. *Proc. Natl. Acad. Sci. USA* 95 (17), 10224–10228.
- Hatta, M., Gao, P., Halfmann, P., Kawakita, Y., 2001. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. *Science* 293 (5536), 1840–1842.
- Hatta, M., Halfmann, P., Wells, K., Kawakita, Y., 2002. Human influenza A viral genes responsible for the restriction of its replication in duck intestine. *Virology* 295 (2), 250–255.
- Hoffmann, E., Krauss, S., Perez, D., Webby, R., Webster, R., 2002. Eight-plasmid system for rapid generation of influenza virus vaccines. *Vaccine* 20 (23–26), 3165.
- Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G., Webster, R.G., 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. *Proc. Natl. Acad. Sci. USA* 97 (11), 6108–6113.
- Kawaoka, Y., Krauss, S., Webster, R.G., 1989. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. *J. Virol.* 63 (11), 4603–4608.
- Lee, K.H., Seo, B.L., 1998. The position 4 nucleotide at the 3' end of the influenza virus neuraminidase vRNA is involved in temporal regulation of transcription and replication of neuraminidase RNAs and affects the repertoire of influenza virus surface antigens. *J. Gen. Virol.* 79 (Pt 8), 1923–1934.
- Luytje, W., Krystal, M., Enami, M., Pavlin, J.D., Palese, P., 1989. Amplification, expression, and packaging of foreign gene by influenza virus. *Cell* 59 (6), 1107–1113.
- Neumann, G., Watanabe, T., Ito, H., Watanabe, S., Goto, H., Gao, P., Hughes, M., Perez, D.R., Donia, R., Hoffmann, E., Hobom, G., Kawaoka, Y., 1999. Generation of influenza A viruses entirely from cloned cDNAs. *Proc. Natl. Acad. Sci. USA* 96 (16), 9345–9350.
- Pear, W.S., Nolan, G.P., Scott, M.L., Baltimore, D., 1993. Production of high-titer helper-free retroviruses by transient transfection. *Proc. Natl. Acad. Sci. USA* 90 (18), 8392–8396.
- Pleschka, S., Jaskunas, R., Engelhardt, O.G., Zurcher, T., Palese, P., Garcia-Sastre, A., 1996. A plasmid-based reverse genetics system for influenza A virus. *J. Virol.* 70 (6), 4188–4192.
- Rimmelzwaan, G.F., Baars, M., Claas, E.C., Osterhaus, A.D., 1998. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. *J. Virol. Methods* 74 (1), 57–66.
- Schickli, J.H., Flandorfer, A., Nakaya, T., Martinez-Sobrido, L., Garcia-Sastre, A., Palese, P., 2001. Plasmid-only rescue of influenza A virus vaccine candidates. *Philos. Trans. R. Soc. London B: Biol. Sci.* 356 (1416), 1965–1973.



ELSEVIER

Vaccine

Vaccine 20 (2002) 3165–3170

www.elsevier.com/locate/vaccine

Eight-plasmid system for rapid generation of influenza virus vaccines

Erich Hoffmann^{a,1}, Scott Krauss^a, Daniel Perez^a, Richard Webby^a, Robert G. Webster^{a,b,*}

^a Department of Virology and Molecular Biology, St. Jude Children's Research Hospital, 332 North Lauderdale, Memphis, TN 38105-2794, USA

^b Department of Pathology, University of Tennessee, Memphis, TN 38105-2794, USA

Received 9 January 2002; received in revised form 28 March 2002; accepted 9 May 2002

Abstract

The antigenic variation of influenza A virus hemagglutinin (HA) and neuraminidase (NA) glycoproteins requires frequent changes in vaccine formulation. The classical method of creating influenza virus seed strains for vaccine production is to generate 6 + 2 reassortants that contain six genes from a high-yield virus, such as A/PR/8/34 (H1N1) and the HA and NA genes of the circulating strains. The techniques currently used are time-consuming because of the selection process required to isolate the reassortant virus. We generated the high-yield virus A/PR/8/34 (H1N1) entirely from eight plasmids. Its growth phenotype in embryonated chicken eggs was equivalent to that of the wild-type virus. By using this DNA-based cotransfection technique, we generated 6 + 2 reassortants that had the antigenic determinants of the influenza virus strains A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), A/teal/HK/W312 (H6N1), and A/quail/HK/G1/97 (H9N2). Our findings demonstrate that the eight-plasmid system allows the rapid and reproducible generation of reassortant influenza A viruses for use in the manufacture of vaccines.

© 2002 Elsevier Science Ltd. All rights reserved.

Keywords: Influenza; Vaccines; Reverse genetics

1. Introduction

During the 20th century, influenza A viruses of the H1N1, H2N2, and H3N2 antigenic subtypes have caused epidemics of respiratory disease in humans. In 1997, H5N1 viruses of avian origin caused human illness and death in China [1,2]. In 1998 and 1999, H9N2 viruses circulating in poultry caused disease in humans [3]. Sequence analysis of the HA gene of the human isolate A/HK/1073/99 (H9N2) revealed the virus to be closely related to a virus isolated from quail, A/quail/HK/G1/97 (H9N2) [4]. These influenza outbreaks raised concerns about newly emerging influenza A viruses and the possibility of a new pandemic [5]. At the time of the outbreaks, no vaccines were available for protection against the H5 subtype.

The licensed influenza vaccines in current use are inactivated virus vaccines created by growing virus in embryonated chicken eggs and subsequently purifying and inactivating them by chemical means. Each year, the World Health Organization selects subtypes that are representative of strains currently circulating in humans. The efficacy of

vaccines requires that the selected vaccine strains be sufficiently closely related to the circulating strains to ensure the induction of effective neutralizing antibodies. However, not all viruses that are closely related are suitable for vaccine production; some grow poorly in eggs. Therefore, the current practice is to generate a high-growth reassortant that combines the high virus yield of the laboratory strain A/PR/8/34 (H1N1) with expression of the glycoproteins of the currently circulating strain [6].

Coinfection with two influenza viruses containing eight segments can theoretically result in the generation of $2^8 - 2 = 254$ different progeny viruses. The selection procedure required to obtain the desired reassortant virus and to verify its gene constellation is cumbersome and time-consuming [7]. Although the reverse genetics method in which cells are transfected with in vitro-generated ribonucleoproteins, reduces the possible number of progeny viruses, a more efficient selection method is needed [8]. Plasmid-driven synthesis of viral RNA and proteins allows the recovery of infectious influenza virus without the need for helper virus infection [9–11]. Therefore, we investigated whether the eight-plasmid system which we established [11] allows the generation of 6 + 2 reassortant viruses. Here, we demonstrate the utility of this approach for the generation of high-yield reassortants. Our findings suggest that vaccine manufacturers can apply this DNA transfection method to cell lines

* Corresponding author. Tel.: +1-901-495-3400; fax: +1-901-523-2622.
E-mail address: robert.webster@stjude.org (R.G. Webster).

¹ Present address: Medimmune, 297 North Bernardo Avenue, Mountain View, CA 94043, USA.

Table 1
Generation of 6 + 2 reassortant influenza A viruses

HA/NA-subtype	Parent virus	HA plasmid	NA plasmid	Recombinant virus ^a
H1N1	A/New Caledonia/20/99 (H1N1)	pHW454-HA	pHW456-NA	rgPR8-H1N1
H3N2	A/Panama/2007/99 (H3N2)	pHW444-HA	pHW446-NA	rgPR8-H3N2
H5N1	A/Goose/HK/437-4/99 (H5N1)	pHW251-HA	pHW246-NA	rgPR8-H5ΔN1 ^b
H6N1	A/teal/HK/W312/97 (H6N1)	pHW244-HA	pHW246-NA	rgPR8-H6N1
H9N2	A/quail/HK/G1/97 (H9N2)	pHW409-HA	pHW422-NA	rgPR8-H9N2

^a Viruses were generated by transfecting cocultured 293T–MDCK cells with six plasmids carrying the six internal genes of the virus strain A/PR/8/34 (H1N1) and two plasmids encoding the desired HA and NA subtypes.

^b The N1 neuraminidase was derived from A/teal/HK/W312/97 (H6N1).

which are approved for vaccine production for rapid and reproducible generation of influenza virus vaccines.

2. Materials and methods

2.1. Virus strains

The influenza A viruses used in this study (Table 1) were obtained from the repository of St. Jude Children's Research Hospital and were propagated in embryonated chicken eggs.

2.2. RT-PCR and construction of plasmids

RT-PCR was performed with segment-specific primers as described elsewhere [12]. Briefly, RNA was isolated by using the RNeasy kit (Qiagen). RNA was transcribed to cDNA by using Uni12-primer (AGC AAA AGC AGG) and the cDNA was then amplified by using segment-specific primers. The *HA*, *NP*, *NA*, *M*, and *NS* genes of A/PR/8/34 (H1N1) (PR8 virus) were cloned by digesting the PCR fragments with *Bsm*BI or *Bsa*I and ligating them into the cloning vector pHW2000. The *P* genes were cloned by isolating two (PB2, PA) or three (PB1) fragments, digesting them, and ligating them into pHW2000-*Bsm*BI. To ensure that the genes were free of unwanted mutations, the inserted viral cDNAs were sequenced. The eight plasmids containing the full-length cDNA of PR8 virus were designated pHW191-PB2, pHW192-PB1, pHW193-PA, pHW194-HA, pHW195-NP, pHW196-NA, pHW197-M, and pHW198-NS. PCR with the primer pair Bm-HA1 (TAT TCG TCT CAG GGAGCA AAA GCA GGG G) and Bm-NS-890R (ATA TCG TCT CGT ATT AGT AGA AAC AAG GGT GTT TT) was used to clone *HA* genes of several subtypes (nucleotides representing the influenza A virus non-coding regions are underlined). Those primers were also used to characterize the recombinant viruses by RT-PCR. The plasmid pHW251-HA encoding a deletion mutant of the A/Goose/HK/437-4/99 (H5N1) hemagglutinin was derived by PCR amplification of two fragments of the plasmid pHW250-HA encoding the full-length H5. The fragments were digested with *Bsm*BI and inserted into pHW2000-*Bsm*BI. For cloning of pHW409-HA, the H9-PCR fragment was first inserted into the pCR2.1 vector

(Invitrogen); the resultant plasmid containing the *H9* gene was used to subclone the *H9* gene into pHW2000-*Bsm*BI. The construction of the plasmids pHW244-HA and pHW246-NA representing the *HA* and *NA* genes from A/teal/HK/W312 (H6N1) has been described elsewhere [11]. The Center for Biotechnology at St. Jude Children's Research Hospital determined the sequence of template DNA by using Rhodamine or dRhodamine dye-terminator cycle sequencing ready reaction kits with AmpliTaq[®] DNA polymerase FS (Perkin-Elmer Applied Biosystems Inc., Foster City, CA) and synthetic oligonucleotides. Samples were separated by electrophoresis and analyzed on PE/ABI model 373, model 373 Stretch, or model 377 DNA sequencers.

2.3. Generation of recombinant viruses

Recombinant viruses were generated by DNA transfection as described previously [11]. Briefly, the day before transfection 293T and MDCK cells were trypsinized, (0.2–1) × 10⁶ of each cell line were used for the transfection experiments. Different dilutions (1:10³–1:10⁵) of virus stocks containing 320–5120 hemagglutination units (HAU) per ml were used to infect the allantoic cavity of 10-day-old embryonated chicken eggs. The data in Table 2 represent results from two or three experiments.

After 48 h, the allantoic fluid was harvested for analysis. H5N1, H6N1, and H9N2 viruses were grown in BL3 facilities at St. Jude Children's Research Hospital.

2.4. Hemagglutination (HA) and hemagglutination inhibition (HI) assays

Fifty microliters of 0.5% chicken red blood cell suspension in PBS was added to 50 µl of two-fold dilutions of virus in phosphate buffered saline (PBS), and the mixture was incubated at room temperature for 30 min. The HA titre was calculated as the reciprocal value of the highest virus dilution that caused complete hemagglutination.

For HI assays, 50 µl of receptor destroying enzyme treated antiserum was titrated, and 25 µl of an equivalent amount of virus (four hemagglutinating doses) was added to each well. After incubation at room temperature for 30 min, 50 µl of a

Table 2
Growth of 6 + 2 reassortant influenza A viruses

Virus	HA titre ^a										Mean
	1	2	3	4	5	6	7	8	9	10	
wtPR8	10240	5120	10240	5120	10240	Dead	10240	10240	5120	10240	8533
rgPR8	10240	20480	320	10240	5120	640	5120	5120	2560	5120	6496
rgPR8-H1N1	2560	1280	1280	2560	2560	640	2560	5120	1280	1280	2112
rgPR8-H3N2	1280	1280	1280	1280	640	2560	2560	2560	1280	640	1536
rgPR8-H5ΔN1	160	320	160	160	320	160	160	320	320	160	224
rgPR8-H6N1	2560	5120	2560	1280	1280	1280	1280	1280	2560	2560	2048
rgPR8-H9N2	5120	5120	10240	5120	5120	5120	10240	5120	5120	5120	6144

^a The HA titre of the allantoic fluid was determined 48 h after infection of 10-day-old embryonated chicken eggs. Assays were performed with 0.5% chicken red blood cells. Values represent the titres after infection of 10 different eggs.

0.5% suspension of chicken red blood cells was added. The HI titre was determined after 30 min as the reciprocal of the serum dilution that inhibited hemagglutination.

3. Results

3.1. Generation of A/PR/8/34 (H1N1) from eight plasmids

The influenza A virus A/PR/8/34 (H1N1) is well adapted to growth in embryonated chicken eggs and is currently used as the master strain for the production of inactivated vaccines. To generate A/PR/8/34 (H1N1) virus from plasmids, we amplified the eight viral RNA segments by RT-PCR and cloned the fragments into the plasmid pHW2000 [11]. Recombinant viruses were generated by transfection of cocultured 293T-MDCK cells with the resultant eight plasmids (pHW191-PB2, pHW192-PB1, pHW193-PA, pHW194-HA, pHW195-NP, pHW196-NA, pHW197-M, and pHW198-NS). The yield of virus recovered after 72 h was determined to be 2×10^6 pfu/ml by titration of the cell culture supernatant in MDCK cells. The supernatant of cocultured Vero-MDCK cells contained 1×10^4 pfu/ml.

To compare the growth of the wild-type virus (wtPR8) with that of the recombinant virus (rgPR8) generated by reverse genetics, we infected embryonated chicken eggs with wild-type or recombinant virus. The allantoic fluid of 10 infected eggs was harvested 48 h after infection. The virus yield was determined by HA assay. Although the HA titres differed among individual eggs, both viruses had HA titres between 5120 and 10,240 in most of the eggs and were therefore high-yielding isolates (Table 2). These results show that the A/PR/8/34 (H1N1) rgPR8 virus is generated efficiently and reliably from eight plasmids and that the plasmid-derived recombinant virus has the same high-yield phenotype as the wild-type virus.

3.2. Generation of the H3N2 and H1N1 6 + 2 reassortants recommended for human vaccine strains

The A/Panama/2007/99 (H3N2) and A/New Caledonia/20/99 (H1N1) virus strains were recommended by World

Health Organization for use in influenza vaccine in the year 2001/2002. To test the utility of the eight-plasmid system to generate reassortants representing these strains, we cotransfected 293T-MDCK cells with plasmids encoding the glycoproteins of A/Panama/2007/99 (H3N2) or A/New Caledonia/20/99 (H1N1) and with the six plasmids encoding the internal genes of A/PR/8/34 (Fig. 1). We found the HA titres in the majority of infected eggs to be 1280–2560 (Table 2). The recombinant rgPR8-H1N1 and rgPR8-H3N2 viruses were shown by HI assay (Table 3) to be antigenically identical to the parental viruses A/Panama/2007/99 (H3N2) and A/New Caledonia/20/99 (H1N1).

3.3. Generation of 6 + 2 reassortants from viruses circulating in Southeast China

The pathogenic H5N1 viruses isolated in 1997 in Hong Kong were hypothesized to have been generated by reassort-

Table 3
Antigenic characterization of wild-type and recombinant viruses by hemagglutination inhibition (HI) assay

Virus	Antiserum	
	Specific ^a	α-H7 ^b
wtPR8	2560	< ^c
rgPR8	640	<
A/New Caledonia/20/99 (H1N1)	>5120	80
rgPR8-H1N1	>5120	160
A/Panama/2007/99 (H3N2)	>5120	<
rgPR8-H3N2	>5120	<
A/Goose/HK/437-4/99 (H5N1)	2560	<
rgPR8-H5ΔN1	>5120	<
A/teal/HK/W312/97 (H6N1)	320	<
rgPR8-H6N1	80	<
A/quail/HK/G1/97 (H9N2)	1280	<
rgPR8-H9N2	1280	<
A/Eq/Prague	<	640

^a Specific antiserum against wild-type virus was used for each subtype.

^b A/equine/Prague/1/56 (H7N7)-specific antiserum was used as a control.

^c <: No detectable inhibition of hemagglutination.




Fig. 1. Eight-plasmid system for rapid generation of reassortant influenza A virus. To test the utility of the eight-plasmid system for generation of reassortant viruses, 293T-MDCK cells were cotransfected with six plasmids representing the A/PR/8/34 (H1N1) master strain and two plasmids representing the desired HA and/or NA subtypes. Influenza viruses were generated within 2–3 days after transfection. Because the viruses were derived entirely from DNA, no selection system was needed to isolate the desired reassortant. The rescued viruses can be used as seed viruses for growth in embryonated chicken eggs.

ment of a Goose-H5 precursor virus [13]. The high homology of six segments of A/quail/HK/G1/97 (H9N2) and seven segments of A/teal/HK/W312/97 (H6N1) to those of the H5N1 viruses suggested that the H5N1 viruses were derived from H9N2 or H6N1 viruses circulating in Asia [4,14,15]. The close relationship of those viruses to the pathogenic H5N1 viruses which caused disease in humans indicates that those viruses could be transmitted to mammalian species. Indeed, H9N2 viruses closely related to the G1 lineage have been isolated from humans [3,16].

To evaluate whether 6 + 2 reassortants could be derived from currently circulating H6N1 and H9N2 subtypes, we cotransfected 293T-MDCK cells with plasmids containing the hemagglutinin and neuraminidase genes from A/teal/HK/W312/97 (H6N1) or A/quail/HK/G1/97

(H9N2) and with the six plasmids representing the internal genes of the PR8 virus. The HA titres of the reassortants were 5120–10,240 for rgPR8-H9N2 and 1280–5120 for rgPR8-H6N1 (Table 2). Antigenic analysis (Table 3) confirmed that the rgPR8-H6N1 and rgPR8-H9N2 viruses were of the same subtype as A/teal/HK/W312/97 (H6N1) and A/quail/HK/G1/97 (H9N2).

Preparation of high-growth reassortants for the production of H5N1 vaccine strains is difficult, because the infected chicken embryos die within 1 day after infection. The high lethality of H5N1 strains in chickens is associated with the basic amino acids of the connecting peptide between the HA1 and HA2 subunits. Therefore, we constructed a plasmid in which the region encoding the connecting peptide (PQRERRRKKR ↓ G) of the H5

from A/Goose/HK/437-4/99 (H5N1) was replaced with a sequence found in the H6 of A/teal/HK/W312 (H6N1) (PQIETR ↓ G). This plasmid and the plasmid encoding N1 neuraminidase from A/teal/HK/W312/97 (H6N1) (closely related to the neuraminidase of the pathogenic H5N1 viruses from 1997) together with the six PR8-plasmids were cotransfected into 293T-MDCK cells resulting in the generation of rgPR8-H5ΔN1 virus. This reassortant virus yielded an HA titre of 160–320, 48 h after infection (Table 2).

3.4. Characterization of the reassortant viruses by RT-PCR

Although controls were included in the experiments and no wild-type viruses were used during the DNA transfection experiments to minimize the possibility of laboratory contaminations, RT-PCR was performed to confirm that the recovered influenza viruses were reassortants with the PR8 backbone. The *NS* and *HA* genes of the 6 + 2 reassortants were amplified by RT-PCR with the primer pair Bm-HA1 and Bm-NS-890R, which were previously shown to amplify these genes [12]. Partial sequencing of the PCR products with segment-specific primers confirmed that the *HA* genes were derived from the designated subtypes and that all of the *NS* genes were derived from PR8 virus. These results show that reassortant influenza A viruses of the H1N1, H3N2, H5N1, H6N1, and H9N2 subtypes can be generated rapidly and reproducibly.

4. Discussion

The eight-plasmid virus generation system that uses the human RNA polymerase-I promoter requires the use of cell lines derived from humans or monkeys because of the species specificity of pol I-mediated transcription [17]. In this study, we used 293T cells for virus generation because those cells have high transfection efficiency resulting in high virus yield. To ensure the safety of a vaccine, cell lines approved for influenza virus vaccines, such as Vero monkey kidney cells can be employed for primary virus generation by DNA transfection. In addition to the use of approved cell lines certified cell culture media and transfection reagents approved for vaccine production have to be used. It is anticipated that the resultant 6 + 2 reassortant viruses after those technical modifications will have the same high-growth phenotype as those generated in this study. For the subsequent production of vaccines, embryonated chicken eggs or continuous cell lines can be used. Because of the limited availability of eggs for the production of virus, continuous cell lines are considered an attractive alternative. There is evidence that human viruses propagated in cell lines are more likely than those propagated in eggs to have an HA that resembles the HA of the original human isolate [18–20]. For the production of vaccines, any cell line which allows the efficient replication of influenza virus, such as Vero cells or St. Jude porcine lung (SJPL) cells, can be used [20–22].

We have demonstrated that H3N2 and H1N1 reassortants generated by DNA transfection grow to moderate to high titres in eggs—a growth level equivalent to that observed in classical reassortment techniques. The H6N1 and H9N2 reassortants from subtypes currently circulating in Southeast China grew to high titres in eggs, indicating that our 6 + 2 approach can generate high-yield reassortants of these subtypes. Our findings support the view that the six internal genes of the PR8 virus are important for the high-yield phenotype. Because rgPR8-H5ΔN1 and rgPR8-H6N1 viruses differed only in the *HA* gene, the lower yield of rgPR8-H5ΔN1 virus was caused by the H5Δ hemagglutinin. These results show that not only the internal genes but also the hemagglutinin gene are determinants of the virus yield in eggs. Deletion of basic amino acids (PQRERRKKR ↓ G → PQRETR ↓ G) of A/Hong Kong/483/97 (H5N1) resulted in a variant that was attenuated in mice [23]. Possibly, the genetic alteration of the H5 molecule reduces the replication efficiency of a virus in mice and in eggs. Further studies using the eight-plasmid system allows to elucidate whether the yield of H5N1 viruses can be increased by genetic manipulation of the H5 (e.g. the addition of amino acids to the connecting peptide) or the *PR8*-genes.

The use of 6 + 2 plasmids to generate 6 + 2 reassortant influenza A viruses eliminates the need for a selection system, thus simplifying the creation of viruses of the desired subtypes. The rapid generation of reassortants and the improved full-length amplification of influenza gene segments by RT-PCR [12] suggest that plasmid collections representing different subtypes of circulating strains, including those isolated from humans and animals, should be created in concert with surveillance studies. We have rescued reassortant PR8 viruses representing 15 HA and nine NA subtypes (data not shown) by using the same technique; therefore, this method is applicable to all influenza virus subtypes. If new pathogenic viruses should emerge, plasmids representing the closest antigenic subtype can be used to produce virus seed suitable for manufacturing a vaccine.

The classical reassortment method currently in use requires lengthy screening and selection procedures that create a 2–3-month lag time between identification of a new strain and the start of vaccine production. If plasmid collections were available, only 1–3 weeks would be needed to generate reassortants by the DNA transfection method. The vaccines could then enter production and become available within about 4–5 months. This 2-month reduction in lag time could be crucial in reducing the spread of a newly emerging pathogenic virus. Further, generation of 6 + 2 viruses by the PR8-plasmid method does not require multiple passages in eggs, as does the classical reassortment method. Viral adaptation to growth in eggs can alter the HA antigens, thereby compromising the protective effect of the vaccine product [24]. Therefore, the *de novo* generation of reassortant influenza viruses by DNA transfection would produce virus seed more quickly, and the product would be more

reproducible and more likely to closely match the circulating strain antigenically.

Acknowledgements

These studies were supported by Public Health Research Grants AI08831, AI95357 and AI29680 from the National Institute of Allergy and Infectious Diseases, by Cancer Center Support CORE Grant CA-21765, and by the American Lebanese Syrian Associated Charities. We thank Alan Hay for providing the influenza viruses A/Panama/2007/99 (H3N2) and A/New Caledonia/20/99 (H1N1). The excellent technical assistance of Ashley Baker, David Walker, and Nannan Zhou is gratefully acknowledged. We thank Sharon Naron for scientific editing.

References

- [1] Subbarao K, Klimov A, Katz J, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. *Science* 1998;279:393–6.
- [2] Claas EC, Osterhaus AD, van Beek R, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. *Lancet* 1998;351:472–7.
- [3] Peiris M, Yuen KY, Leung CW, et al. Human infection with influenza H9N2. *Lancet* 1999;354:916–7.
- [4] Guan Y, Shortridge KF, Krauss S, Webster RG. Molecular characterization of H9N2 influenza viruses: were they the donors of the internal genes of H5N1 viruses in Hong Kong? *Proc Natl Acad Sci USA* 1999;96:9363–7.
- [5] de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL. A pandemic warning? *Nature* 1997;389:554.
- [6] Kilbourne ED. Future influenza vaccines and the use of genetic recombinants. *Bull World Health Organ* 1969;41:643–5.
- [7] Voeten JT, Brands R, Palache AM, et al. Characterization of high-growth reassortant influenza A viruses generated in MDCK cells cultured in serum-free medium. *Vaccine* 1999;17(15/16):1942–50.
- [8] Li S, Liu C, Klimov A, et al. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. *J Infect Dis* 1999;179:1132–8.
- [9] Neumann G, Watanabe T, Ito H, et al. Generation of influenza A viruses entirely from cloned cDNAs. *Proc Natl Acad Sci USA* 1999;96:9345–50.
- [10] Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, García-Sastre A. Rescue of influenza A virus from recombinant DNA. *J Virol* 1999;73:9679–82.
- [11] Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. *Proc Natl Acad Sci USA* 2000;97:6108–13.
- [12] Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. Universal primer set for the full-length amplification of all influenza A viruses. *Arch Virol* 2001;146:2275–89.
- [13] Xu X, Subbarao K, Cox NJ, Guo Y. Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. *Virology* 1999;261:15–9.
- [14] Hoffmann E, Stech J, Leneva I, et al. Characterization of the influenza A gene pool in avian species in Southern China: was H6N1 a derivative or a precursor of H5N1? *J Virol* 2000;74:6309–15.
- [15] Webster RG, Guan Y, Peiris M, et al. Characterization of H5N1 influenza viruses that continue to circulate in Geese in Southeastern China. *J Virol* 2002;76(1):118–26.
- [16] Lin YP, Shaw M, Gregory V, et al. Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. *Proc Natl Acad Sci USA* 2000;97(17):9654–8.
- [17] Comai L, Tanese N, Tjian R. The TATA-binding protein and associated factors are integral components of the RNA polymerase-I transcription factor SL1. *Cell* 1992;68:965–76.
- [18] Schild GC, Oxford JS, de Jong JC, Webster RG. Evidence for host-cell selection of influenza virus antigenic variants. *Nature* 1983;303:706–9.
- [19] Robertson JS, Bootman JS, Newman R, et al. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. *Virology* 1987;160:31–7.
- [20] Seo SH, Golubeva O, Webby R, Webster RG. Characterization of a porcine lung epithelial cell line suitable for influenza virus studies. *J Virol* 2001;75(19):9517–25.
- [21] Govorkova EA, Murti G, Meignier B, de Taisne C, Webster RG. African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. *J Virol* 1996;70(8):5519–24.
- [22] Kistner O, Barrett PN, Mundt W, et al. Development of a Vero cell-derived influenza whole virus vaccine. *Dev Biol Stand* 1999;98:101–10.
- [23] Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong influenza A viruses. *Science* 2001;293(5536):1840–2.
- [24] Kodihalli S, Justewicz DM, Gubareva LV, Webster RG. Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective. *J Virol* 1995;69:4888–97.

Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines

R J Webby, D R Perez, J S Coleman, Y Guan, J H Knight, E A Govorkova, L R McClain-Moss, J S Peiris, J E Rehg, E I Tuomanen, R G Webster

Summary

Background In response to the emergence of severe infection capable of rapid global spread, WHO will issue a pandemic alert. Such alerts are rare; however, on Feb 19, 2003, a pandemic alert was issued in response to human infections caused by an avian H5N1 influenza virus, A/Hong Kong/213/03. H5N1 had been noted once before in human beings in 1997 and killed a third (6/18) of infected people.^{1,2} The 2003 variant seemed to have been transmitted directly from birds to human beings and caused fatal pneumonia in one of two infected individuals. Candidate vaccines were sought, but no avirulent viruses antigenically similar to the pathogen were available, and the isolate killed embryonated chicken eggs. Since traditional strategies of vaccine production were not viable, we sought to produce a candidate reference virus using reverse genetics.

Methods We removed the polybasic aminoacids that are associated with high virulence from the haemagglutinin cleavage site of A/Hong Kong/213/03 using influenza reverse genetics techniques. A reference vaccine virus was then produced on an A/Puerto Rico/8/34 (PR8) backbone on WHO-approved Vero cells. We assessed this reference virus for pathogenicity in in-vivo and in-vitro assays.

Findings A reference vaccine virus was produced in Good Manufacturing Practice (GMP)-grade facilities in less than 4 weeks from the time of virus isolation. This virus proved to be non-pathogenic in chickens and ferrets and was shown to be stable after multiple passages in embryonated chicken eggs.

Interpretation The ability to produce a candidate reference virus in such a short period of time sets a new standard for rapid response to emerging infectious disease threats and clearly shows the usefulness of reverse genetics for influenza vaccine development. The same technologies and procedures are currently being used to create reference vaccine viruses against the 2004 H5N1 viruses circulating in Asia.

Lancet 2004; **363:** 1099–103

Departments of Infectious Diseases (R J Webby PhD, E I Tuomanen MD, E A Govorkova PhD, R G Webster PhD), **Therapeutics Production and Quality** (J S Coleman Msc, J H Knight Msc, L R McClain-Moss Bsc), and **Pathology** (J E Rehg DVM) **St Jude Children's Research Hospital, Memphis, TN, USA;** **Department of Veterinary Medicine, University of Maryland, College Park, MD, USA** (D R Perez PhD); **Department of Microbiology and Pathology, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, People's Republic of China** (Y Guan PhD, J S Peiris MD)

Correspondence to: Richard Webby, Division of Virology, MS#330, Department of Infectious Diseases, St Jude Children's Research Hospital, 332 N Lauderdale Street, Memphis, TN 38105, USA (e-mail: richard.webby@stjude.org)

Introduction

In February, 2003, two family members were admitted to intensive care wards in Hong Kong Special Administrative Region with influenza-like respiratory illness. Avian-like H5N1 influenza viruses were isolated from both patients, one of whom succumbed to infection. This was the first time since 1997 that H5N1 viruses had been identified in human beings, and WHO responded by issuing a pandemic alert. Candidate vaccines were immediately sought. The recent outbreak of severe acute respiratory syndrome (SARS) had been a striking example of the rapid and global spread of an emerging infectious disease. However, even the effects of SARS could be dwarfed by those that could arise with the emergence of an influenza pandemic.

Infection caused by the influenza A virus is a zoonosis, and the animal reservoir of this virus is the aquatic bird populations of the world. The compelling epidemiological link between the presence of the virus in poultry in live-bird markets and the appearance of H5N1 in human beings in 1997 suggested that influenza A viruses can be transmitted directly from avian species to man and can cause severe respiratory disease.^{1–3} Although control of the 1997 outbreak was achieved by culling millions of birds in the Hong Kong markets,⁴ this episode demonstrated that the capability for an effective global response to emerging influenza threats was poor because of technical, legislative, and infrastructural limitations. A disturbing finding that emerged from this event was that the scientific community was unable to produce an effective vaccine even after several years.

The inactivated human influenza vaccines in use today are derived from essentially modified viruses. By exploiting the segmented nature of the influenza A genome, vaccine manufacturers and the laboratories of the WHO influenza network have produced a reassortant virus carrying the circulating virus's gene segments that encode haemagglutinin and neuraminidase, the major targets of neutralising antibodies. The remaining six-gene segments are supplied from PR8, a laboratory-adapted avirulent H1N1 strain.⁵ The resulting reassortant virus has the antigenic properties of the circulating strain and the safety and high-yield properties of PR8.

The first batch of inactivated material against the 1997 H5N1 virus was not ready for clinical trial until 7 months after the second case of human infection arose, and even today the effectiveness of vaccine against this virus has not been proven.⁶ A key reason for this delay in the production of an H5N1-specific vaccine was the nature of the virus itself. The H5N1 virus is highly pathogenic in human beings and poultry. The agent must be handled only under conditions of at least biosafety level 3 (BSL3), and it can kill fertilised chicken eggs, the standard medium for the reassortment and

propagation of influenza virus before its inactivation and formulation for use in vaccines. These same traits are present in the 2003 H5N1 virus.

The pathogenic nature of these H5N1 viruses is linked to the presence of additional basic residues in haemagglutinin at the site of cleavage, a step required for haemagglutinin activation and, thus, for virus entry into cells.^{7–9} To overcome the high pathogenicity of the virus, polybasic aminoacids have to be eliminated. A rapid, reproducible system to achieve these modifications—ie, plasmid-based reverse genetics—has been developed only in the past 4–5 years.^{10–12} The potential benefits of reverse genetics for the generation and attenuation of vaccine candidates against highly pathogenic and low pathogenic influenza viruses are enormous.^{13–15} However, the host specificity of the RNA polymerase I promoter used in the influenza reverse-genetics systems and the required use of an approved cell line limits the practical options for the system's use in the manufacture of human vaccines. The vaccine-candidate reference virus stock described in this report has been produced entirely on a cell substrate licensed for the manufacture of human vaccine, and as such, is—to our knowledge—the first reverse genetically derived influenza vaccine suitable for testing in clinical trials. We describe the construction of a vaccine reference virus in Good Manufacturing Practice (GMP)-grade facilities in less than 4 weeks from the time of virus isolation. Our findings highlight the speed with which new technologies can be implemented in response to influenza pandemic alerts.

Methods

Cells and A/Puerto Rico/8/34 plasmids

We obtained WHO-approved Vero cells (WHO-Vero, X38, p134) from the American Type Culture Collection (Manassas, Virginia, USA). Passage-142 cells (five passages since their removal from a working cell bank) were used for the rescue of the vaccine-candidate virus. The plasmids containing the genes from PR8 have been described elsewhere.¹³

Virus propagation, RNA extraction, PCR amplification, and haemagglutinin and neuraminidase gene cloning

We obtained A/Hong Kong/213/03 (H5N1) that had been passaged in eggs from the WHO influenza network. The virus was isolated and propagated in 10-day-old embryonated chicken eggs. Total RNA was extracted from infected allantoic fluid with use of the RNeasy kit (Qiagen, Valencia, CA, USA) in accordance with manufacturer's instructions. Reverse transcription was carried out with the uni12 primer (5'-AGCA AAAGCAGG-3') and AMV reverse transcriptase (Roche, Indiana Biochemicals Indianapolis, USA). The removal of the connecting peptide of the haemagglutinin was done with use of PCR with the following primer sets: (1) Bm-HA-1 (5'-TATTCGTCAGGGAGCAA AAGCAGGG-3') and 739ΔR (5'-TAATCGTC TCGTTCAATTGAGGGCTATTCTGAGCC-3'); and (2) 739ΔF (5'-TAATCGTCAGGAA CTAGAGGATTATTGGAGCTATAGC-3') and Bm-NS-890r (5'-ATATCGTCAGGTATTAGTAG AAACAAGGGTGT-3'). We amplified the neuraminidase gene of A/Hong Kong/213/03 using the primer pair Ba-NA-1 (5'-TATTGGTCTC AGGGAGCAAAAGCAGGAGT-3') and Ba-NA-1413r (5'-ATATGGTCTCGTATTAGTAGAACAG GAGTTTTT-3'). PCR products were purified and cloned into the vector pHW2000 as described previously.¹¹

Rescue of virus from Vero cells

The rescue of infectious virus from cloned cDNA was done under GMP conditions. Vero cells were grown to 70% confluence in a 75 cm² flask, trypsinised (with trypsin-versene), and resuspended in 10 mL of Opti-MEM I (Invitrogen, Carlsbad CA, USA). To 2 mL of cell suspension we added 20 mL of fresh Opti-MEM I; then, we added 3 mL of this diluted suspension to each well of a six-well tissue culture plate (about 1×10⁶ cells per well). The plates were incubated at 37°C overnight. The next day, 1 µg of each plasmid and 16 µL of Transit LT-1 transfection reagent (Panvera, Madison, WI, USA) were added to Opti-MEM I to a final volume of 200 µL and the mixture incubated at room temperature for 45 min. After incubation, the medium was removed from one well of the six-well plate, 800 µL of Opti-MEM I added to the transfection mix, and this mixture added dropwise to the cells. 6 h later, the DNA-transfection mixture was replaced by Opti-MEM I. 24 h after transfection, 1 mL of Opti-MEM I that contained 1 µg/mL L-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK)-treated trypsin (Worthington Biochemicals, Lakewood, NJ, USA) was added to the cells. About 72 h after the addition of TPCK-trypsin, the culture supernatants were harvested and clarified by low-speed centrifugation; we then injected 100 µL of the clarified supernatant into the allantoic cavity of individual 10-day-old pathogen-free embryonated research grade eggs (Charles River SPAFAS, North Franklin, CT, USA).

Pathogenicity testing in chickens

Ten 4-week-old chickens received intravenous injections of 0·1 mL diluted virus (dilution ratio, 1/10). We monitored chickens for signs of disease for 10 days using the Intravenous Pathogenic Index, approved by the Office of International Epizootics (OIE). Additionally, we took tracheal and cloacal swabs (in 1 mL of media) 3 days and 5 days after infection, and we did assays for the presence of virus by injection of 0·1 mL into all of three 10-day-old embryonated chicken eggs. Haemagglutination activity in the allantoic fluid of these eggs was assessed after incubation at 35°C for 2 days.

Pathogenicity testing in ferrets

We tested pathogenicity of the vaccine in five young adult male ferrets (Marshall's Farms, North Rose, NY, USA) aged 4–8 months (weight about 1·5 kg) that were shown by haemagglutination inhibition assays to be seronegative for currently circulating human influenza A viruses (H3N2, H1N1) and H5N1 viruses. We anaesthetised the ferrets with inhaled isoflurane, and they were then infected intranasally with 10⁶–50% egg infectious dose (EID₅₀)/mL of vaccine reassortant virus or wildtype virus. We monitored the ferrets once per day for signs of sneezing, inappetence, and inactivity, and we recorded rectal temperatures and bodyweights. 3, 5, and 7 days after infection, the ferrets were anaesthetised with ketamine (25 mg/kg), and we collected nasal washes using 1 mL of sterile phosphate-buffered saline (PBS) containing antibiotics. We measured titres of virus in these washes with EID₅₀ assays.

To further assess the pathogenicity of the viruses, we collected tissue samples from lungs, brain, olfactory bulb, spleen, and intestine for virus isolation and histopathological analysis at the time of death or in the case of three ferrets, after euthanasia at day 3 after infection. The tissues were fixed in 10% neutral buffer formalin, processed and embedded in paraffin, sectioned at 5 µm, stained with haematoxylin and eosin and examined by light microscopy in a blinded fashion.

Stability testing in eggs

To test the stability of the vaccine virus on propagation, we made 16 consecutive passages of the virus in embryonated chicken eggs. A 10^4 dilution of the virus was made in PBS, and 0.1 mL of the solution was injected into the allantoic cavities of all of four 10-day-old embryonated chicken eggs. Eggs were incubated at 35°C for 1.5–2 days. After incubation, each egg was candled to determine embryo viability before chilling at 4°C. We harvested 2 mL of allantoic fluid from each egg harvested, and samples were pooled together, tested for haemagglutination activity, and then reinjected into another four eggs.

Role of the funding source

The sponsor had no role in study design, in the collection, analysis, and interpretation of data, in the writing of the report or decision to submit this manuscript for publication.

Results

Alteration of haemagglutinin cleavage site and virus rescue

The first challenge we faced in producing a vaccine against A/Hong Kong/213/03 (H5N1) was to attenuate the virus in preparation for mass production. Previous experiences have shown that removal of the basic aminoacids at the haemagglutinin cleavage site substantially attenuates pathogenic influenza viruses.^{15–17} Using a PCR-based mutagenesis approach, we replaced the cleavage site encoded by the haemagglutinin gene of A/Hong Kong/213/03 (H5N1) with that of the avirulent A/teal/Hong Kong/W312/97 (H6N1) (figure 1); this modified haemagglutinin gene and the neuraminidase gene of A/Hong Kong/213/03 (H5N1) were cloned individually into the vector pHW2000.¹¹ The two resulting plasmids and the six plasmids encoding the remaining proteins of PR8¹³ were transfected into WHO-approved Vero cells under GMP conditions to rescue the vaccine seed virus, Δ213/PR8. 36–48 h after transfection, isolated areas of cytopathic effect could be seen on the Vero monolayers. Although addition of further 1 µg aliquots of TPCK-treated trypsin every 24 h led to a proportional increase in the cytopathic effect, it was not required for successful virus rescue. The candidate vaccine strain grew to high titres on subsequent amplification in eggs (haemagglutination titres of 1024–2048) and did not cause embryo death. The vaccine seed virus was unable to form plaques on Madin-Darby

A/teal/HK/W312/97 (H6N1)




Figure 1: Creation of haemagglutinin protein of candidate vaccine seed

Haemagglutinin protein of the candidate vaccine seed (Δ213/PR8) was produced by replacing the connecting peptide of the A/Hong Kong/213/03 haemagglutinin gene with that of the A/Teal/Hong Kong/W312/97 gene.




Figure 2: Weight changes of ferrets Infected with wildtype A/Hong Kong/213/03 or Δ213/PR8
Vertical bars show SD.

canine kidney (MDCK) cells in the absence of trypsin, a trait consistent with that of influenza viruses that lack the polybasic cleavage site, and was antigenically indistinguishable from the parental H5N1 virus in haemagglutination inhibition assays. The rescued virus was fully sequenced and was identical to the plasmids used in its creation.

Pathogenicity testing of the candidate reference virus

To assess the pathogenicity of the H5N1 vaccine seed virus, we compared the properties of this virus with those of the wildtype A/Hong Kong/213/03 (H5N1) in ferrets and in chickens. By stark contrast with the wildtype virus, which was lethal to all chickens within 48 h of infection, intravenous administration of a 1/10 dilution of Δ213/PR8 did not result in any signs of infection in chickens, and we were unable to detect any virus in swabs of cloacae or tracheae from inoculated birds. Compared with A/Hong Kong/213/03 (H5N1), Δ213/PR8 was attenuated in ferrets that had been inoculated intranasally with 10^6 EID₅₀ of virus. Ferrets infected with A/Hong Kong/213/03 had inappetence and weight loss (figure 2), with one infected animal dying 6 days after infection and a second killed 10 days after infection because of hind-limb paralysis. Infection in these animals was characterised by viral shedding until 7 days after infection and replication of virus in the lower respiratory tract and olfactory bulb (as determined by virus isolation). In the A/Hong Kong/213/03 infected animals, there was a mild mononuclear cell infiltrate in the meninges and tracheal submucosal mucous glands and an extensive bronchopneumonia. The pneumatic infiltrate progressed in severity from the bronchi to the pleura. The bronchi and bronchioles contained sloughed necrotic epithelial cells, numerous mononuclear cells, and a few neutrophils. The alveoli were consolidated with inflammatory cells and fibrin (figure 3). By contrast, those ferrets infected with Δ213/PR8 did not lose weight (figure 2) and seemed to remain healthy during the study (14 days) (figure 3). Virus was detected in the nasal washes of these animals at 5 days but not 7 days after infection, and virus was recovered from the upper respiratory tract only. By light microscopy, the meninges and trachea of the Δ213/PR8 infected ferrets did not have an inflammatory infiltrate and only a few neutrophils were noted occasionally in pulmonary bronchi. Our results clearly show that




Figure 3: Ferret lung 3 days after infection with wildtype virus (A) and the reverse genetic virus $\Delta 213/\text{PR}8$ (B)

(A) Alveoli are filled with inflammatory cells and the bronchiolar submucosa is oedematous. (B) Alveoli are free of inflammatory cells and there are a few neutrophils on the surface of the bronchiolar epithelium. Magnification $\times 20$.

$\Delta 213/\text{PR}8$ was attenuated. In view of our findings, this virus can be safely handled with standard precautions in BSL2 containment facilities.

Stability of non-pathogenic phenotype

Because the mechanisms and requirements for the accumulation of basic aminoacids at the haemagglutinin cleavage site are not entirely understood, we wanted to confirm that the altered cleavage site remained stable on multiple passages in embryonated chicken eggs. Such passaging in eggs would occur in transition and amplification of the reference virus to vaccine stock. The rescued virus was stable on continued serial passage in embryonated eggs, and we did not detect any change in nucleotide sequence of the haemagglutinin cleavage site after 16 passages. There was no evidence of changing pathogenicity of the virus and we noted only one dead embryo at passage 15. No haemagglutination activity was evident in this egg and no embryo death was seen in passage 16, which strongly suggests that the death was not related to virus replication. Haemagglutination titres at each passage ranged from 512 to 2048 with no apparent trend of increasing or decreasing titres in subsequent passages.

Discussion

The rapid response in terms of potential vaccine reference virus production to the 2003 H5N1 outbreak differs strikingly from the response to the 1997 episode. This difference is attributable to the new scientific technology available in 2003 and, just as importantly, to the infrastructure for virus surveillance in Hong Kong developed since 1997. The first case of H5N1 influenza in Hong Kong was in May, 1997; yet several months elapsed before this virus was finally characterised as an H5N1 virus. In 2003, the causative agent was identified only hours after admission of the patients to the hospital. The increased awareness, surveillance, and availability of reagents to identify influenza viruses of all subtypes bode well for the rapid identification of viruses that arise from future interspecies transfer events and for the coordination of international vaccine development by WHO. The timely distribution of candidate viruses is a very important step in the development of vaccines for pandemic emergencies. Despite the heightened security and documentation requirements for shipping and receiving potential bioterrorism agents, the H5N1 and SARS outbreaks have shown that in true emergencies, global distribution is feasible.

Although it is pertinent to prepare for future pandemics by stockpiling potential vaccine strains, the H5N1 situation in 2003—and the ongoing H5N1 outbreaks throughout Asia in 2004 (<http://www.who.int>)—have highlighted the fact that some of the focus of pandemic planning must go into the implementation of technology to rapidly produce vaccines from field isolates. Although viruses similar to A/Hong Kong/213/03 (H5N1) had been circulating in bird populations, these viruses were antigenically distinct, despite high genetic similarities (Guan Y and Peiris JS, unpublished data). That the aminoacid differences are on the globular head of haemagglutinin and seem to be responsible for much of the antigenic difference means that even a vaccine previously prepared from genetically similar precursor viruses might not provide adequate protection. We may well be faced with potential pandemic situations in the future and the rapid production of a matched vaccine will be needed—a point again highlighted by H5N1 outbreaks in 2004. Although the reference virus described in this report was prepared from a virus isolated in a similar geographic region and only a year earlier, it shares only limited antigenic cross-reactivity to the 2004 H5N1 viruses. Hyperimmune sheep serum samples produced against the purified haemagglutinin of $\Delta 213/\text{PR}8$ has at least a six-fold reduced haemagglutination inhibitory activity against A/Vietnam/1203/04 as compared with A/Hong Kong/213/03. As our findings show, we have the technical capabilities to respond rapidly to outbreaks with a safe and stable reference virus, but there is still much to be accomplished before such viruses can be fully used in pandemic and interpandemic influenza vaccine production.

The use of reverse genetics introduces a number of new processes into influenza vaccine manufacture that are not encountered with standard reassortment methods. One of the most obvious is the need for cultured cells. Although both Vero¹⁸ and MDCK^{19,20} cells are in development as substrates for the growth of influenza vaccine, there are additional requirements for the use of cells in reverse genetics. Unfortunately, the number of suitable cell lines is very small. In addition to the regulatory requirements, the choice of cell is also limited by the technology. The plasmid based reverse-genetics systems^{10–12} use the species-specific human RNA polymerase I promoter, which

necessitates the use of cells from primate origin. The Vero cell line is probably the only option currently able to meet both regulatory and technical demands. We have shown that Vero cells can be used to successfully rescue H1N1, H3N2, H6N1, and H9N2 viruses on the PR8 backbone using the 8-plasmid system.²¹ Others have demonstrated the suitability of Vero cells for alternative influenza virus reverse-genetics systems.¹⁰ Although cultures of Vero cells are easily obtained, only cells from fully tested and licensed cell banks are likely to be acceptable for vaccine manufacture. This issue must be acknowledged and access to such cells must be incorporated as part of future pandemic plans.

That future threats of influenza pandemics will be addressed by the use of the technology described in this report seems inevitable. Despite the presence of low pathogenic surrogate strains, the recent human death from influenza-like illness caused by highly pathogenic H7N7 virus in the Netherlands²² reinforces the fact that future outbreaks will probably occur in which this reverse-genetics technology provides the logical—and, possibly, the only—way to respond rapidly and effectively. Although our response to the outbreak of H5N1 influenza in 2003 has shown that current scientific capabilities are sufficient to respond to the threat, there are still legal and infrastructural barriers to be overcome.²³ These barriers include licensing and intellectual property issues surrounding what is, essentially, a genetically modified organism. Yet, these difficulties are not insurmountable and pandemic scares such as the 2003 and ongoing 2004 H5N1 outbreaks are forcing commercial and regulatory parties to address these issues with some urgency. With the development of the 2003 H5N1 vaccine reference virus, and ongoing attempts to create the same for the 2004 virus, the challenge in responding to a threat of an influenza pandemic must now be supported by the large-scale manufacture of the vaccine and by clinical trials of a new vaccine manipulated by reverse genetics.

Contributors

R J Webby, D R Perez, J S Coleman, J H Knight, E I Tuomanen, R G Webster designed the study; R J Webby did much of the construction of the vaccine seed virus; D R Perez developed and constructed plasmid templates; Y Guan and J S Peiris characterised and isolated the initial H5N1 virus; J E Rehg participated in the design and analysis of animal safety testing of the candidate H5N1 vaccine seed virus; E A Govorkova participated in the safety testing of the candidate H5N1 vaccine seed virus; L R McClain-Moss participated in the preparation of GMP documentation of the process and was involved in the reconstitution of the vaccine seed virus.

Conflict of interest statement

None declared. The corresponding author has had full access to all the data in the study and has had the final responsibility for the decision to submit this manuscript for publication.

Acknowledgments

We thank Todd Hatchette, Katherine Sturm-Ramirez, and Scott Krauss for expert advice; Ashley Baker, Christie Johnson, Yolanda Sims, Patrick Seiler, Jennifer Humberd, and Kelly Jones for excellent technical assistance; Julia Hurwitz for access to the Vero-cell banks. Editorial assistance was provided by Julia Cay Jones. These studies were supported by grant AI95357 from the National Institute of Allergy and Infectious Disease, by Cancer Center Support (CORE) grant CA21765 from the National Institutes of Health, and by the American Lebanese Syrian Associated Charities (ALSAC).

References

- de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL. A pandemic warning? *Nature* 1997; 389: 554.
- Subbarao K, Klimov A, Katz J, et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. *Science* 1998; 279: 393–96.
- Shortridge KF, Zhou NN, Guan Y, et al. Characterization of avian H5N1 influenza viruses from poultry in Hong Kong. *Virology* 1998; 252: 331–42.
- Shortridge KF, Gao P, Guan Y, et al. Interspecies transmission of influenza viruses: H5N1 virus and a Hong Kong SAR perspective. *Vet Microbiol* 2000; 74: 141–47.
- Kilbourne ED. Future influenza vaccines and the use of genetic recombinants. *Bull World Health Organ* 1969; 41: 643–45.
- Wood JM. Developing vaccines against pandemic influenza. *Philos Trans R Soc Lond B Biol Sci* 2001; 356: 1953–60.
- Bosch FX, Orlich M, Klenk HD, Rott R. The structure of the hemagglutinin, a determinant for the pathogenicity of influenza viruses. *Virology* 1979; 95: 197–207.
- Bosch FX, Garten W, Klenk HD, Rott R. Proteolytic cleavage of influenza virus hemagglutinins: primary structure of the connecting peptide between HA1 and HA2 determines proteolytic cleavability and pathogenicity of Avian influenza viruses. *Virology* 1981; 113: 725–35.
- Kawaoka Y, Nestorowicz A, Alexander DJ, Webster RG. Molecular analyses of the hemagglutinin genes of H5 influenza viruses: origin of a virulent turkey strain. *Virology* 1987; 158: 218–27.
- Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. *J Virol* 1999; 73: 9679–82.
- Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. *Proc Natl Acad Sci USA* 2000; 97: 6108–13.
- Neumann G, Watanabe T, Ito H, et al. Generation of influenza A viruses entirely from cloned cDNAs. *Proc Natl Acad Sci USA* 1999; 96: 9345–50.
- Hoffmann E, Krauss S, Perez D, Webby R, Webster R. Eight-plasmid system for rapid generation of influenza virus vaccines. *Vaccine* 2002; 20: 3165–70.
- Schickli JH, Flandorfer A, Nakaya T, Martinez-Sobrido L, Garcia-Sastre A, Palese P. Plasmid-only rescue of influenza A virus vaccine candidates. *Philos Trans R Soc Lond B Biol Sci* 2001; 356: 1965–73.
- Subbarao K, Chen H, Swayne D, et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. *Virology* 2003; 305: 192–200.
- Li S, Liu C, Klimov A, et al. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. *J Infect Dis* 1999; 179: 1132–38.
- Liu M, Wood JM, Ellis T, et al. Preparation of a standardized, efficacious agricultural H5N3 vaccine by reverse genetics. *Virology* 2003; 314: 580–90.
- Kistner O, Barrett PN, Mundt W, et al. Development of a Vero cell-derived influenza whole virus vaccine. *Dev Biol Stand* 1999; 98: 101–10.
- Brands R, Visser J, Medema J, Palache AM, van Scherpenburg GJ. Influvac: a safe Madin Darby Canine Kidney (MDCK) cell culture-based influenza vaccine. *Dev Biol Stand* 1999; 98: 93–100.
- Halperin SA, Smith B, Mabrouk T, et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. *Vaccine* 2002; 20: 1240–47.
- Ozaki H, Govorkova EA, Li C, Xiong X, Webster RG, Webby RJ. Generation of High-Yielding Influenza A Viruses in African Green Monkey Kidney (Vero) Cells by reverse genetics. *J Virol* 2003; 78: 1851–57.
- Fouchier RA, Schneeberger PM, Rozendaal FW, et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. *Proc Natl Acad Sci USA* 2004; 101: 1356–61.
- Fedson DS. Pandemic influenza and the global vaccine supply. *Clin Infect Dis* 2003; 36: 1552–61.

“Ambisense” Approach for the Generation of Influenza A Virus: vRNA and mRNA Synthesis from One Template

Erich Hoffmann,* Gabriele Neumann,† Gerd Hobom,‡ Robert G. Webster,* and Yoshihiro Kawaoka*

^{*}Department of Virology and Molecular Biology, St. Jude Children’s Research Hospital, 332 North Lauderdale, Memphis, Tennessee 38105-2794;

[†]Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 2015 Linden Drive West, Madison, Wisconsin 53706; and [‡]Institut für Mikro- und Molekulbiologie, Frankfurter Straße 107, 36392 Giessen, Germany

Received September 27, 1999; returned to author for revision December 2, 1999; received December 13, 1999

We present a system for creating influenza virus by generating viral RNA (vRNA) and mRNA from one template. Recently, a system for the generation of influenza A virus entirely from cloned cDNAs was established (Neumann et al., 1999, Proc. Natl. Acad. Sci. USA 96, 9345–9350). Cells were transfected with plasmids for RNA polymerase I-driven intracellular synthesis of all eight viral RNAs, and with protein expression plasmids for the synthesis of viral structural proteins. Although this system is highly efficient in virus generation, the construction and cotransfection of 17 plasmids is cumbersome and may limit the use of this system to cell lines that can be transfected with high efficiencies. Synthesizing both vRNA and mRNA from one template would reduce the number of plasmids required for virus generation. Therefore, we generated a bidirectional transcription construct that contains cDNA encoding PB1 flanked by an RNA polymerase I (pol I) promoter for vRNA synthesis and an RNA polymerase II (pol II) promoter for mRNA synthesis. The utility of this approach is proved by the generation of virus after transfecting the pol I/pol II-promoter-PB1 construct together with vRNA- and protein-expression constructs for the remaining seven segments. Because this approach reduces the number of plasmids required for virus generation, it also reduces the work necessary for cloning, probably enhances the efficiency of virus generation, and expands the use of the reverse-genetics system to cell lines for which efficient cotransfection of 17 plasmids cannot be achieved.

© 2000 Academic Press

INTRODUCTION

Influenza A virus is a negative-strand RNA virus with a segmented genome consisting of eight viral RNA segments. The genomic RNAs contain one or more open reading frames that are flanked by noncoding sequences at the 5' and 3' ends of the RNA molecules (Desselberger et al., 1980). The viral RNAs are associated with viral NP and polymerase proteins (PB1, PB2, and PA) in virions and in infected cells to form ribonucleoprotein (RNP) complexes (Hsu et al., 1987). After the RNP complexes enter the nucleus, the RNA segments are replicated and transcribed to yield three types of RNA molecules. The vRNA is transcribed into cRNA, which is copied into vRNA. The vRNA serves as template for the synthesis of mRNA, from which viral proteins are translated. Late in the life cycle, the genomic RNAs and proteins are packaged into new progeny virus particles that can start a new replication cycle.

Several methods have been developed for genetic engineering of influenza A viruses (Luytjes et al., 1989; Zobel et al., 1993). The ribonucleoprotein (RNP) transfec-

tion system developed by Palese and coworkers (Luytjes et al., 1989; Enami et al., 1990) is based on the *in vitro* transcription reaction for synthesis of RNA molecules. RNP complexes are made by incubating the RNA transcripts with purified nucleoprotein and the three polymerase subunits (PB1, PB2, PA). After the reconstituted RNP complexes are transfected into eukaryotic cells, a helper virus is used as the source of the proteins needed for replication of the recombinant RNP molecules.

Hobom and coworkers (Zobel et al., 1993; Neumann et al., 1994) developed a system based on the precise transcription of an influenza virus cDNA template by the cellular RNA polymerase I (pol I) complex. In this system, the viral cDNA is inserted between a pol I-promoter and terminator sequence. After *in vivo* synthesis of genomic influenza-like RNA molecules, the nucleoprotein and polymerase proteins are delivered by infection with helper virus, thus forming functional RNPs in mouse or primate cells (Neumann et al., 1994; Hoffmann, 1997). Pleschka and colleagues (1996) also used a pol I-promoter for the transcription of viral cDNA, but the 3' end of the viral RNA was generated by the autocatalytic cleavage of a hepatitis delta ribozyme sequence. However, the potential use of the RNP- and the DNA-transfection methods is limited, because of the use of a helper virus,

*To whom correspondence and reprint requests should be addressed. E-mail: robert.webster@stjude.org.



GENERATION OF INFLUENZA A VIRUS

which requires a strong selection system to obtain the desired virus from a vast background of helper virus.

In a previous study, a plasmid-based system was used to provide both viral RNA and viral proteins for the generation of influenza A viruses without helper virus infection (Neumann *et al.*, 1999). This reverse-genetics system proved to be highly efficient for the generation of the A/WSN/33 (H1N1) virus in 293T cells. However, this system, which contains the pol I- and pol II-promoters with the influenza virus cDNAs on different plasmids, requires the construction of at least 12 plasmids for efficient virus recovery. Transfection of cells with this many plasmids may limit the use of this system to cell lines which have a high transfection efficiency. To be able to rescue virus from different cell types may increase the virus yield by enhancing the replication of influenza A virus in these cells and increase the range of cells suitable for the production of vaccines (Govorkova *et al.*, 1996). As a first step in reducing the number of plasmids, we report here the construction and transfection of plasmids containing both the pol I- and pol II-promoter on the same plasmid and present evidence that this system allows the expression of vRNA and protein from one template.

RESULTS AND DISCUSSION

Design and features of the cloning vector pHW12 containing two eukaryotic promoters

Influenza A viruses are segmented viruses that contain RNA molecules with negative-sense polarity. During the replication cycle, recognition of the 5'- and 3'-structures of the eight vRNA segments by the ribonucleoprotein complex proteins (PB2, PB1, PA, NP) results in the replication and transcription of the influenza virus genes. The fact that the terminal sequence elements are highly conserved indicates that a transcribed artificial RNA should have sequences that are the same as those of the 5' and 3' ends (Luo *et al.*, 1991; Flick *et al.*, 1996). The cloning vector pHW12 was constructed, allowing the insertion of sequences of interest between the pol I-promoter and terminator by using the restriction endonuclease *Bsm*BI (see Fig. 1A). The pol I-transcription unit is flanked by the pol II-promoter from the cytomegalovirus (CMV) and by the polyadenylation signal of the gene encoding bovine growth hormone. The CMV-promoter, the poly A site, and the backbone of the plasmid, are derived from the cloning vector pcDNA3.

PB1 protein expression in the pol I/pol II bidirectional transcription system

To test the pol I/pol II one-plasmid transcription system, we inserted the cDNA of the PB1 gene of A/WSN/33 virus into the cloning vector pHW12 to yield the plasmid pHW52-PB1 (Fig. 1B). *Hind*III and *Xba*I restriction sites

were inserted into the 5' and 3' noncoding regions of the gene. These genetic tags were included to ensure that the generated recombinant virus could be identified by RT-PCR. We expected that human cells transfected with this plasmid would yield two types of RNA (Fig. 1B): PB1-vRNA, synthesized by cellular pol I; and an mRNA with a 5'-cap structure, synthesized by the pol II. Translation of the mRNA should result in the synthesis of PB1-protein.

To examine whether the PB1-protein is produced by this construct, we tested replication and transcription of an artificial vRNA by constructing the expression plasmids pHW21-PB2, pHW23-PA, and pHW25-NP. All contain cDNAs encoding PB2, PA, and NP proteins of A/WSN/33 under the control of the CMV-promoter. For the *in vivo* synthesis of an artificial vRNA, we constructed the reporter plasmid pHW72-EGFP (Fig. 2A), containing the EGFP cDNA flanked by the noncoding region of the M-segment and the human pol I-promoter and the TATA terminators sequence. Five plasmids (2 µg pHW21-PB2, 2 µg pHW52-PB1 [pol I/pol II-promoter construct], 2 µg pHW23-PA, 2 µg pHW25-NP, and 1 µg pHW72-EGFP) were transfected into 293T cells. Twenty-four hours after transfection, the cells were analyzed by fluorescence microscopy. After 24 h, fluorescent cells were observed (data not shown). This result shows that after 24 h the polymerase proteins are synthesized in a concentration sufficient to allow recognition of the internal virus-specific ends of the EGFP-vRNA. These proteins synthesize mRNA, which is translated into EGFP.

To evaluate the efficiency of this system, we performed flow cytometric analysis to count the number of fluorescent cells (Fig. 2B). Forty-eight hours after transfection with the five plasmids, 18.72% of the cell population show fluorescence. Only a background level of fluorescence (0.06%) was observed when pHW52-PB1 plasmid was not added; this finding is consistent with those earlier studies, which showed that all four RNP-complex proteins are necessary for the amplification of the virus (Huang *et al.*, 1990). The results indicate that the cDNA transcription and the resulting concentration of PB1 protein together with the other RNP complex proteins is sufficient to initiate a viral transcription/replication process.

Generation of recombinant influenza A virus

For the generation of infectious influenza A virus it is necessary that the plasmid pHW52-PB1 provides only PB1 mRNA and protein but also sufficient amounts of PB1-vRNA, which can be packaged into progeny virus (Fig. 1B). For the remaining seven vRNAs, we used plasmids that contain the cDNAs for the full-length RNA of the A/WSN/33 virus, flanked by the human pol I-promoter and the murine terminator. Transfection of these plas-






FIG. 1. The pol I/pol II bidirectional transcription system. (A) The cloning vector pHW12. The plasmid contains the RNA polymerase II promoter (p_{II} CMV) of the human cytomegalovirus and the polyadenylation signal (a_{II} BGH) of the gene encoding bovine growth hormone. Inserted between these elements is a murine terminator (t_I) and the sequence of the human RNA polymerase I promoter (p_{Ib}). For insertion of arbitrary sequences between the pol I promoter and terminator, two *Bsm*BI restriction sites were introduced. After digestion with *Bsm*BI, a vector fragment (bold type) with sticky but noncomplementary 5' protruding ends is generated. For propagation in *E. coli*, the plasmid contains an origin of replication (ori) and a beta lactamase gene (bla) for selection in ampicillin-containing medium. (B) The expression plasmid pHW52-PB1 and proposed transcription products after transfection. The plasmid is derived from pHW12; cDNA of the PB1 segment is inserted between the pol I promoter (p_{II}) and terminator (t_I). The arrow represents the sequence for the ORF of the PB1 gene. Between the influenza virus-specific noncoding region (NCR) and the coding region for the PB1 gene, sequences containing *Hind*III and *Xba* restriction sites have been inserted. After transfection of this expression plasmid, two types of molecules are expected to be synthesized. From the human pol I promoter, RNA with the 5' and 3' noncoding region is transcribed by cellular RNA polymerase I, and this transcription results in an influenza-like vRNA molecule with recognition elements for the viral polymerase proteins at both ends. Transcription by RNA polymerase II is expected to result in an mRNA with a 5' cap structure and a 3' poly A tail; this mRNA expresses PB1 protein after translation.

mids should result in the synthesis of all eight viral RNAs that are replicated and transcribed by the polymerase proteins, forming new vRNPs. After synthesis of the

structural proteins, the RNP would be packaged into new virus particles.

We transfected 293T cells (Table 1) with different




FIG. 2. Flow cytometric evaluation of the efficiency of the plasmid-based pol I/pol II transcription system. (A) Schematic representation of the reporter plasmid pHW72-EGFP with a pol I-transcription unit containing the sequences of the noncoding region of the M segment and the cDNA encoding EGFP. (B) We transfected 293T cells with the indicated plasmids; 48 h later, we used flow cytometric analysis to determine the number of fluorescent cells. Upper panel: flow cytometric analysis after transfection of pHW21-PB2, pHW23-PA, pHW25-NP, and pHW72-EGFP without pHW52-PB1; lower panel: analysis after transfection with pHW52-PB1. The bar M1 represents the region used to determine the percentage of fluorescent cells.

amounts of pHW52-PB1 plasmid (0, 2, and 4 μ g) together with the plasmids pPolI-WSN-PB2, pPolI-WSN-PA, pPolI-WSN-HA, pPolI-WSN-NP, pPolI-WSN-NA, pHW127-M, and pHW128-NS (1 μ g each). The protein-expression plasmids pHW21-PB2 (1 μ g), pHW23-PA (0.1 μ g), pHW25-NP (1 μ g), pEWSN-HA (1 μ g), and pCAGGS-WNA15 (1 μ g) were cotransfected. The expression plasmids for the hemagglutinin (HA) and the neuraminidase (NA) were included to increase the yield of transfectant virus.

Forty-eight hours after transfection, the supernatant of the primary transfected 293T cells was transferred to MDCK cells. In all transfection experiments in which pHW52-PB1 plasmid was added, 24 h after the passage we observed a virus-induced cytopathic effect. No cytopathic effect was visible if no PB1-expressing plasmid was included in the transfection reaction. The virus titer

was determined by titrating the supernatant of the transfected cells on MDCK cells; the supernatant was found to contain 2×10^4 – 2×10^6 pfu/ml. This finding shows that, after transfection of the PB1-pol I/pol II-promoter plasmid (together with the expression plasmids), PB1 vRNA and PB1 protein are synthesized in the human cell line 293T at a level sufficient for the generation of infectious influenza A viruses. In the cotransfection experiments (Table 1) with plasmids containing the PB1-cDNA separated on two plasmids (pHW82-PB1 and pHW22-PB1), a virus titer of 2×10^4 pfu/ml was found; the analogous experiment using the plasmids with wild-type PB1 sequences (pPolI-WSN-PB1 and pHW22-PB1) resulted in a virus titer of 3×10^6 pfu/ml.

Unlike the expression construct with a pol II-promoter used in a previous study (Neumann et al., 1999), we used

TABLE 1
Plasmid Sets Used for Recovery of Recombinant Influenza A Virus

Plasmid	Promoter	cDNA	μg -Transfected plasmid DNA				
			1	1	1	1	1
pHW21-PB2	pol II	PB2	1	1	1	1	1
pHW22-PB1	pol II	PB1	—	—	—	1	1
pHW23-PA	pol II	PA	0.1	0.1	0.1	0.1	0.1
pHW25-NP	pol II	NP	1	1	1	1	1
pEWSNHA	pol II	HA	1	1	1	1	1
pCAGGS-WNA15	pol II	NA	1	1	1	1	1
pPolI-WSN-PB2	pol I	PB2	1	1	1	1	1
pHWB2-PB1	pol I	PB1*	—	—	—	1	—
pPolI-WSN-PB1	pol I	PB1	—	—	—	—	1
pPolI-WSN-PA	pol I	PA	1	1	1	1	1
pPolI-WSN-NP	pol I	NP	1	1	1	1	1
pPolI-WSN-HA	pol I	HA	1	1	1	1	1
pPolI-WSN-NA	pol I	NA	1	1	1	1	1
pHW127-M	pol I	M	1	1	1	1	1
pHW128-NS	pol I	NS	1	1	1	1	1
pHW52-PB1	pol I + pol II	PB1*	0	2	4	—	—
Virus titer (pfu/ml)			0	2×10^4	2×10^5	2×10^6	3×10^6

Note: 293T cells were transfected with the indicated plasmids; the virus titer in the cell culture supernatants was determined in MDCK cells.

*The cDNA contains additional noninfluenza A virus sequences in the noncoding region of the PB1 segment.

the plasmid pHW52-PB1 (Fig. 1B) that contains sequences derived from the pol I-transcription unit that are inserted between the CMV-promoter and the polyadenylation site. The expression of the EGFP reporter gene demonstrates that the overall expression of PB1-protein in this system is sufficient for formation of EGFP-RNP complexes. Although the pol I-promoter/terminator region contains recognition sequences for pol I-specific transcription and termination factors (Bell *et al.*, 1988; Kuhn *et al.*, 1994; Beckmann *et al.*, 1995), these DNA-binding proteins do not seem to inhibit pol II-mediated transcription. These findings are consistent with the finding that the pol I-specific DNA-binding proteins are more abundant in the nucleolus, the compartment in which the cellular rRNA-transcription takes place (Evers *et al.*, 1995). These results indicate that after transfection of the pol I/pol II-promoter construct into the cell, some of the plasmids are delivered to the nucleolus, where the pol I-mediated transcription occurs, and some are retained in the nucleus, where they are transcribed by RNA polymerase II.

Because the reporter construct pHW52-PB1 contained additional noninfluenza virus sequences (restriction sites) in the noncoding region before the start codon and after the stop codon, we were interested as to whether these sequences were stably maintained in the viral PB1 RNA segment (Fig. 3A). Therefore, we isolated vRNA after the second passage of transfectant virus on MDCK cells and performed reverse-transcription PCR analysis. As shown in Fig. 3B, the amplification of vRNA with PB1-specific primers resulted in the generation of cDNA

fragments of the expected sizes. With the same viral RNA and primers, but without the addition of reverse-transcriptase, no amplification product was obtained, showing that the cDNA originated from viral RNA and not from plasmid DNA carried over from the supernatant of transfected cells. Sequencing of the PCR products revealed that both restriction site sequences were present in the RNA molecule. The results show that the pol I/pol II-transcription system allows recovery of infectious recombinant virus and that virus with foreign sequences in the noncoding region of the PB1 gene is viable. This modified-PB1 segment is still replicated, transcribed, and packaged into virus particles. Previously, by using the RNP-transfection system, the noncoding regions of influenza A virus segments were changed. By substituting the noncoding region of the NA gene with the corresponding sequence of the NS segment of influenza B, transfectant influenza viruses were obtained (Muster *et al.*, 1991; Bergmann and Muster, 1995). This type of virus with a chimeric NA segment showed an attenuated phenotype in mice and protected mice inoculated with a nonlethal dose against infection of the wild-type influenza virus infection. These results showed that the genetic alteration of the noncoding region of an RNA segment can change the biological property of a transfectant virus. Here, we report for the first time that even noninfluenza virus sequences can be inserted into the noncoding region of the PB1 segment. With the pol I/pol II-transcription system, it is now possible to systematically modify these sequence elements in the noncoding region of the PB1 segment and to evaluate whether these genetic




FIG. 3. Detection of recombinant influenza A virus by RT-PCR. (A) Schematic representation of the recombinant PB1 RNA segment and the location of primers used for RT-PCR. The sequences (shown in cRNA orientation) above the RNA segment represent the introduced noninfluenza virus sequences before the start codon (AAGCUU) and after the stop codon (CUCGAG). The primers used in the RT-PCR reaction are represented by arrows. The expected sizes of the fragments at the 5' and 3' parts are shown in brackets. (B) RT-PCR reaction was performed with primers specific for the PB1 gene segment and with vRNA extracted from virions. The reaction products were subjected to electrophoresis on a 2% agarose gel. To ensure that the amplified DNA fragments were derived from vRNA, and not from plasmid DNA carried over from transfected cells, one reaction was performed without the addition of reverse-transcriptase (−). Lanes 1 and 2: reactions using the primers Bm-PB1#1 and Seq-PB1#1; lanes 3 and 4: reactions using Seq-PB1#2 and Bm-PB1-2341R; M: 100-bp ladder (Promega). The presence of the inserted sequences was verified by sequencing the amplified DNA fragments.

manipulations result in changes in the biological properties of the recombinant viruses. Indeed, the lower yield of the viruses with the mutated PB1 segment compared to the wild-type virus indicates that the inserted sequences negatively influence the virus growth.

Although the plasmid-based system developed recently (Neumann *et al.*, 1999) is highly efficient in generating Influenza virus, it involves cloning of 14 to 17 plasmids. In this study, we reduced the number of plasmids

to 13, which are needed for the efficient recovery of influenza A/WSN/33 virus strain. The reduction in the number of plasmids achieved by this approach promises to increase the efficiency of transfection for cell lines other than 293T cells, thus allowing the delivery of genes to cell lines for which the efficient delivery of 14 plasmids is difficult to achieve. Fodor *et al.* (1999) were able to rescue influenza virus after transfecting 12 plasmids; the virus yield in this study was 1–2 infectious virus particles per 10⁶ transfected Vero cells. It would be interesting to investigate whether the pol I/pol II-transcription system, in addition to the transcription of PB1-cDNA, can also be used for the remaining seven RNA segments. Such investigations could test whether the pol I/pol II bidirectional transcription system allows the development of a plasmid-based system that contains eight plasmids for the production of influenza A viruses, thus improving this reverse-genetics system by decreasing the time and cost required for genetic engineering of influenza A viruses. It would also be interesting to investigate whether the transfection system containing a pol I- and pol II-promoter on the same plasmid is applicable for the generation of other orthomyxoviruses (i.e., influenza B, thogotovirus).

MATERIALS AND METHODS

Cloning of plasmids

All cloning and PCR reactions were performed according to standard protocols. Briefly, the expression plasmids for the polymerase-complex genes of A/WSN/33 were derived from pcDNA3 (Invitrogen, La Jolla, CA) containing the immediate early promoter of the human cytomegalovirus (CMV) and the poly A site of the gene encoding bovine growth hormone (BGH). The viral cDNAs were derived from the plasmids pWNP143, pWS-NP3, pWSNPB2-14, and pGW-PB1 (kindly provided by D. Nayak) to yield the expression constructs pHW26-NP, pHW23-PA, pHW21-PB2, and pHW22-PB1, respectively. pHW12 was generated by inserting human pol I-promoter and terminator sequences between the pol II-promoter and the polyA-site (Fig. 1A). The plasmid pHW52 was derived from pHW12 by first inserting oligonucleotides containing the noncoding region of PB1 extended by *Hind*III and *Xba*I sites and then inserting the PB1-coding region from pHW22-PB1 into these sites (Fig. 1B). The plasmid pHW82-PB1 was derived from pHW52-PB1 by deletion of the CMV-promoter sequences. The coding region for the enhanced green fluorescent protein (EGFP) in the reporter construct pHW72-EGFP was obtained after PCR-amplification using pEGFP-N1 (Clontech, Palo Alto, CA) as template and inserting the cDNA after *Sac*II/*Xba*I digestion into the plasmid pHW72 (E. Hoffmann, unpublished) containing the human pol I-promoter and murine terminator and the noncoding region

of the M-segment separated by SacII/Xhol sites (Fig. 2A). pHW127-M and pHW128-NS were constructed by RT-PCR amplification of viral RNA with the primers containing segment-specific sequences and *Bsm*BI sites for insertion into the *Bsm*BI-digested vector pHW21 (Hoffmann, 1997; Neumann et al., 1999). All sequences of the oligonucleotides for PCR amplification or cloning are available on request. The construction of the plasmids pPolI-WSN-PB1, pPolI-WSN-PB2, pPolI-WSN-PA, pPolI-WSN-NP, pPolI-WSN-HA, pPolI-WSN-NA, pEWSN-HA, and pCAGGS-WNA15 has been described elsewhere (Neumann et al., 1999).

Cell culture and transfection

Madin-Darby canine kidney (MDCK) cells were maintained in modified Eagle medium (MEM) containing 10% fetal bovine serum (FBS); 293T human embryonic kidney cells were cultured in Dulbecco's modified Eagle medium (DMEM) containing 10% FBS. TransIT LT-1 (Panvera, Madison, WI) was used according to the manufacturer's instructions to transfet 1×10^6 293T cells. Different amounts of plasmids (Table 1) were mixed with TransIT LT-1 (2 μ l TransIT LT-1 per 1 μ g of DNA), incubated at room temperature for 45 min and added to the cells. After 6 h, the DNA-transfection mixture was replaced by Opti-MEM (Gibco/BRL, Gaithersburg, MD), containing 0.3% bovine serum albumin (BSA) and 0.01% FBS. Forty-eight hours after transfection, supernatants containing virus were titrated in MDCK cells.

RNA isolation and RT-PCR

Viral RNA was isolated from virus particles with the use of the RNeasy-Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. For characterization of recombinant influenza viruses, the Access RT-PCR kit (Promega, Madison, WI) was used according to the protocol provided. The following primers were used in the RT-PCR experiments: Seq-PB1#1: 5'-AGG ATG GGA TTC CTC AAG G-3'; Seq-PB1#2: 5'-GCT ATG GTT TCC AGA GCC CG-3'; Bm-PB1-1: 5'-TAT TCG TCT CAG GGA GCG AAA GCA GGC A-3'; Bm-PB1-2341R: 5'-ATA TCG TCT CGT ATT AGT AGA AAC AAG GCA-TTT-3'. RT-PCR experiments were performed by using the PTC-200 DNA engine (MJ Research, Watertown, MA). The amplification program started with one cycle at 48°C for 45 min (first-strand cDNA synthesis) and one cycle at 94°C for 2 min (inactivation of the AMV reverse-transcriptase and cDNA denaturation). These cycles were followed by 40 cycles at 94°C for 20 s, 52°C for 30 s, and 72°C for 30 s (PCR amplification); the program ended with one cycle at 72°C for 5 min. The PCR products were analyzed by agarose gel electrophoresis and sequenced with the primer Seq-PB1#1 or Seq-PB1#2 (Fig. 3).

Flow cytometry

Forty-eight hours after transfection, 293T cells were washed with phosphate-buffered saline (PBS), pelleted, and resuspended in PBS plus 5% FBS. Flow cytometric analysis was performed by using a FACSCalibur flow cytometer (Becton-Dickinson) and the data were analyzed by using the CellQuest software package. For EGFP expression analysis, we used the emission wavelength of 530 nm (FL1) to achieve a high sensitivity for EGFP-mediated fluorescence detection.

ACKNOWLEDGMENTS

These studies were supported by Public Health Research Grants AI29680, AI08831, AI29599, and AI44388 from the National Institute of Allergy and Infectious Diseases; by Cancer Center Support CORE Grant CA-21766; and by the American Lebanese Syrian Associated Charities. We thank S. Krauss, D. Walker, and D. Todd for excellent technical support and Dr. R. Cross for performing the flow cytometry. We also thank Julia Gay Jones and Flo Witte for scientific editing.

REFERENCES

- Beckmann, H., Chen, J. L., O'Brien, T., and Tjian, R. (1995). Coactivator and promoter-selective properties of RNA polymerase I TAFs. *Science* 270, 1606-1609.
- Bell, S. P., Learned, R. M., Jantzen, H. M., and Tjian, R. (1988). Functional cooperativity between transcription factors UBF1 and SL1 mediates human ribosomal RNA synthesis. *Science* 241, 1192-1197.
- Bergmann, M., and Muster, T. (1995). The relative amount of an influenza A virus segment present in the viral particle is not affected by a reduction in replication of that segment. *J. Gen. Virol.* 76, 3211-3216.
- Desselberger, U., Racaniello, V. R., Zazra, J. J., and Palese, P. (1980). The 3' and 5'-terminal sequences of influenza A, B and C virus RNA segments are highly conserved and show partial inverted complementary. *Gene* 8, 315-328.
- Enami, M., Luytjes, W., Krystal, M., and Palese, P. (1990). Introduction of site-specific mutations into the genome of influenza virus. *Proc. Natl. Acad. Sci. USA* 87, 3802-3806.
- Evers, R., Smid, A., Rudloff, U., Lottaepich, F., and Grummt, I. (1995). Different domains of the murine RNA polymerase I-specific termination factor mTF-I serve distinct functions in transcription termination. *EMBO J.* 14, 1248-1258.
- Filick, R., Neumann, G., Hoffmann, E., Neumeier, E., and Hobom, G. (1996). Promoter elements in the influenza vRNA terminal structure. *RNA* 2, 1046-1057.
- Fodor, E., Devenish, L., Engelhardt, O. G., Palese, P., Brownlee, G. G., and Garcia-Sastre, A. (1999). Rescue of influenza A virus from recombinant DNA. *J. Virol.* 73, 9879-9882.
- Govorkova, E. A., Murti, G., Meignier, B., de Taiana, C., and Webster, R. G. (1996). African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. *J. Virol.* 70, 5519-5524.
- Hoffmann, E. (1997). Ph.D. thesis, Justus Liebig University, Giessen, Germany.
- Heu, M. T., Pervin, J. D., Gupta, S., Krystal, M., and Palese, P. (1987). Genomic RNAs of influenza viruses are held in a circular conformation in virions and in infected cells by a terminal panhandle. *Proc. Natl. Acad. Sci. USA* 84, 8140-8144.
- Huang, T. S., Palese, P., and Krystal, M. (1990). Determination of influenza virus proteins required for genome replication. *J. Virol.* 64, 6669-6673.

GENERATION OF INFLUENZA A VIRUS

Kuhn, A., Voit, R., Stefanovsky, V., Evers, R., Bianchi, M., and Grummt, I. (1994). Functional differences between the two splice variants of the nucleolar transcription factor UBF: The second HMG box determines specificity of DNA binding and transcriptional activity. *EMBO J.* 13, 416-424.

Luo, G. X., Luytjes, W., Enami, M., and Palese, P. (1991). The polyadenylation signal of influenza virus RNA involves a stretch of uridines followed by the RNA duplex of the panhandle structure. *J. Virol.* 65, 2861-2867.

Luytjes, W., Krystal, M., Enami, M., Pavin, J. D., and Palese, P. (1989). Amplification, expression, and packaging of a foreign gene by influenza virus. *Cell* 59, 1107-1113.

Muster, T., Subbarao, E. K., Enami, M., Murphy, B. R., and Palese, P. (1991). An influenza A virus containing influenza B virus 5' and 3' noncoding regions on the neuraminidase gene is attenuated in mice. *Proc. Natl. Acad. Sci. USA* 88, 5177-5181.

Neumann, G., Zobel, A., and Hobom, G. (1994). RNA polymerase-mediated expression of influenza viral RNA molecules. *Virology* 204, 477-479.

Neumann, G., Watanabe, T., Ito, H., Watanabe, S., Goto, H., Saito, H., Hughes, M., Perez, D. R., Donis, R., Hoffmann, E., Hobom, G., and Kawaoka, Y. (1999). Generation of influenza A viruses entirely from cloned cDNAs. *Proc. Natl. Acad. Sci. USA* 96, 9346-9350.

Pleschka, S., Jaskunas, R., Engelhardt, O. G., Zurcher, T., Palese, P., and Garcia-Sastre, A. (1996). A plasmid-based reverse genetics system for influenza A virus. *J. Virol.* 70, 4188-4192.

Zobel, A., Neumann, G., and Hobom, G. (1993). RNA polymerase-catalyzed transcription of intact viral cDNA. *Nucleic Acids Res.* 21, 3607-3614.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.